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GENERAL INTRODUCTION
C H A P T E R  1

General introduction | 11
1
Cystic fibrosis
Cystic fibrosis (CF) is the most common life limiting autosomal recessive disorder 
in Caucasians. Genetic mutations can cause dysfunctional or absent cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. The CFTR protein is present in 
many organs, so a dysfunctional or absent CFTR can impact many organ systems. One 
of the major systems affected are the lungs.1 When the CFTR is defective or absent, the 
chloride secretion is reduced or absent causing a hyperabsorption of sodium and water 
across the airway epithelial cells. This imbalance leads to reduced airway surface liquid 
and more viscous mucous, impairing mucociliary clearance.2 This results in chronic 
bacterial infections and inflammation of the airways. Chronic respiratory disease is the 
leading cause of mortality and morbidity in patients with CF.3
Monitoring early CF lung disease with chest computed tomography
CF lung disease and progressive structural lung changes starts early in life. Lung 
function and symptom based parameters have mostly been used as outcome measures 
for intervention studies in CF. Unfortunately in the children with CF aged of 5 and 
younger, lung function outcome measures are cumbersome to execute and to date 
not sensitive enough to quantify structural lung disease.4 The most sensitive modality 
to detect and monitor structural lung changes in the younger children is computed 
tomography (CT). CT can visualize the lung parenchyma and airways in more detail 
than conventional chest X-ray and magnetic resonance imaging.5 Structural changes 
on chest CT can be detected as early as three months and can be present in children 
without any symptoms.6,7 Due to the silently progressive nature of CF lung disease it 
is essential to intervene at a young age, before any permanent and irreversible lung 
changes have established.4 
To evaluate the effectiveness of early CF treatment there is a need for sensitive CT 
image analysis methods to quantify structural lung disease in young children. In 
order to sensitively monitor early CF lung disease with the aid of CT, radiation risk and 
standardization have to be addressed. 
Radiation risk of routine chest CT
Chest CT became an essential imaging technique in clinical practice for the detection 
and monitoring of CF lung disease in children since the nineties. 8,9 The use of chest 
CT has increased over the past years among pediatric CF patients. A downside of CT 
scanning, however, is the exposure to ionizing radiation. This is especially important 
for children as they are more sensitive to radiation and generally have longer life 
expectancies to develop radiation induced cancer.10 The potential risks associated with 
12 | CHAPTER 1
radiation exposure have for long been a hurdle for implementation of routine chest CT 
in clinical practice and for clinical studies.11 Routine chest CT introduces accumulative 
radiation exposure and should only be applied if the benefits are greater than the risks. 
The risks of routine chest CT have been estimated previously, 12 but these estimates 
were highly conservative and are now outdated thanks to the lower radiation output of 
modern CT scanners. Additionally, to fully comprehend the risk to benefit ratio, there is 
a need to put potential radiation risk estimates into perspective of daily life risks. 
Chest CT in clinical trials
The improved sensitivity of chest CT for the detection of structural lung disease in CF has 
opened up the possibility of its use as an outcome measure in clinical trials.13 Traditional 
functional outcome measures for clinical trials in CF lung disease are relatively insensitive 
to measure progression of CF lung disease, particularly in children. The need for more 
sensitive outcome measures became more urgent as promising but very expensive 
disease modifying agents were developed recently.1 Functional outcome measures 
require a large number of study subjects to demonstrate an effect, causing the clinical 
trials to be very expensive. More multi-center clinical trials are needed to test all the 
different new compounds developed, leading to an increased challenge to enroll large 
numbers of patients. 
The use of chest CTs in clinical trials is a promising outcome measure for children with 
CF, but standardization of CT protocols across CF centers is needed before such trials 
can be executed. Large differences in CT protocols and CT scanners used across centers 
are present. This leads to variability in image quality, radiation dose, and lung volume 
levels. 14 As with any other outcome measure, detailed standardization is needed across 
centers and across CT vendors to allow for the use of chest CT in multicenter clinical trials.
Image analysis
The most important structural changes related to CF lung disease that can be detected 
on chest CTs are bronchiectasis, airway wall thickening, mucous plugging and 
hypoperfusion. Bronchiectasis is defined as an abnormal widening of the airways in 
combination with a lack of tapering. In adults an airway to artery ratio larger than 1 is 
classified as bronchiectasis.15 The inner airway diameter is mostly used nowadays for 
comparison with the accompanying artery.16–18 There is however no clear consensus 
based on objective quantification on whether the inner or outer airway diameter 
should be used for the diagnosis of bronchiectasis. Additionally, the definition of 
bronchiectasis has not well been investigated in children. In healthy subjects, the airway 
to artery ratio is thought to increase with age and a smaller ratio has been suggested 
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in children.19,20 Lack of tapering is present if the airway diameter remains unchanged 
for at least 2 cm after branching,15 but has not previously been quantified objectively. 
Tapering could also be quantified by comparing the airway diameter before branching 
to the airway diameter after branching and has been objectified previously as the 
homothety ratio. 21,22 Airway wall thickening is present when the airway wall diameter 
occupies more than 20% of the total outer airway diameter.23 To date, the presence of 
CF related bronchiectasis and airway wall thickening are primarily determined visually 
by radiologists without measuring tools. For detection of more subtle lung changes in 
children an objective quantification of airway dimensions was considered necessary to 
allow unbiased assessment of bronchiectasis and airway wall thickening. 
Several semi-quantitative scoring techniques were developed to assess structural CF 
lung disease on chest CT more objectively. Most scoring techniques were developed to 
quantify moderate to severe lung disease in adults with CF.24,25 These scoring systems 
were however not sensitive for young children with CF. For this reason a scoring 
technique was recently developed specifically for young children with early CF lung 
disease.26 These scoring techniques measure disease severity in a semi quantitative 
subjective way, and have not been compared to objective dimensions of the airways. 
More objective quantitative methods to assess airway dimensions were first proposed 
10 years ago27 and repeated in children with volumetric CT recently.7 These methods 
assessed the airway and artery dimensions on a limited number of axial CT slices 
using digital calipers. A disadvantage of this approach is that it causes inaccuracy due 
to projection error, 28 i.e. the airway and artery dimensions can be perceived larger or 
smaller depending on the plane in which the airway is visualized, causing an incorrect 
measurement. In addition, relatively few airway artery pairs can be detected on these 
axial slices. Ideally, airway and artery dimensions should be measured perpendicular to 
the longitudinal airway axis. Nowadays, anatomical sizes of the airways can be assessed 
by reformatting and three-dimensional (3D) rendering the airways with advanced CT 
image analysis software. Cross-sectional areas of the central and peripheral airways can 
be visualized. Using the 3D segmented bronchial tree, all visible airway artery pairs can 
be measured. Such systems have the potential to detect more subtle changes and may 
be more sensitive to detect early lung disease. A disadvantage of such system is that 
the manual quantification of a large number of airway and artery dimensions is very 
time consuming. However, in the current era such measurements can potentially be 
automated offering fast, inexpensive and sensitive analysis.29 In addition, automatic 
quantification would eliminate intra- and inter-observer variability related to manual 
scoring. Lastly, automated analysis can objectively assess tapering and define the 
objective dimensions of the airway along the entire airway branch without extremely 
tedious and time-consuming manual labour.  
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Reference values
Chest CT is widely used in the pediatric population to diagnose chest disorders and to 
monitor progression of thoracic abnormalities. To determine pulmonary abnormalities 
it is essential to have pediatric reference values for thoracic structures. The size and 
orientation of thoracic structures are known to be dependent on age and gender in 
the pediatric population.30,31 A known limitation for the establishment of pediatric CT 
reference values is that it is not justified to acquire chest CTs in a healthy population and 
expose healthy children to ionizing radiation to establish reference values.32 Therefore 
the availability of CT reference values in the pediatric population is scarce. Normative 
dimensions of the trachea are currently based on studies with small sample sizes,33 
studies in adults34 or on studies more than 30 years old using older generation CT 
scanners.30,35  Normative data of the airway and artery dimensions are currently based on 
studies with small sample sizes 19,21 or values  determined in adults.36 Evidently, attempts 
should be made to obtain pediatric reference values based on larger sample sizes than 
currently available. This could be based for instance on patients in need for a CT scan 
due to several clinical indications, but afterwards assessed as normal by the radiologist. 
Objectives and outline of this thesis
The following objectives in this thesis have been established to address the issues 
introduced above: 
•	 To estimate the risks of radiation exposure due to CT scanning and to put these risks 
into perspective in relation to other risks
•	 To characterize and standardize pediatric chest CT across CF centers
•	 To develop an objective method for quantification of airway abnormalities in infants, 
children and adolescents with CF
•	 To compare CF scoring methods with objectively quantified airway and artery 
dimensions
•	 To provide reference values for key thoracic structures on chest CT of children
The studies addressing these objectives are outlined in this thesis as follows: 
Part 1 is about the safety and standardization of pediatric chest CT. 
Chapter 2 describes the fundamentals related to CT radiation and estimates the lifetime 
risk of cancer mortality due to CT related radiation exposure. In addition it puts the risks 
of radiation exposure in perspective by comparing them with other medical and non-
medical risks. 
Chapter 3 describes the approach to standardize pediatric chest CT across 16 centers 
participating in an international network. CT scanners are characterized and the 
performances of these scanners are compared. 
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Part 2 focusses on the assessment of CF lung disease on chest CT of pediatric patients 
with CF. 
Chapter 4 describes a sensitive quantitative method for the assessment of airway and 
artery dimensions to quantify structural lung disease in children and adolescents with 
CF and the comparison with airway and artery dimensions of control patients. 
Chapter 5 entails the same objective airway and artery quantification applied in a 
longitudinal CT dataset of younger children with early CF lung disease and the cross-
sectional comparison with an age matched control patient cohort. 
Chapter 6 compares two semi quantitative CF scoring systems with the objective 
airway and artery quantification method in children and adolescents with CF. 
Chapter 7 investigates automated quantification of airway and artery dimensions and 
validates tapering as a sensitive biomarker for bronchiectasis. In addition, reference 
tapering values are provided for a control group with and without lung volume control. 
Part 3 describes the CT reference values in control pediatric patients. 
Chapter 8 presents the normative CT defined central airways. 
Chapter 9 presents the normative CT defined airway and artery dimensions.
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ABSTRACT
Computed tomography (CT) is a sensitive technique to monitor structural changes 
related to cystic fibrosis (CF) lung disease. It detects structural pulmonary abnormalities 
such as bronchiectasis and trapped air, in an early stage, before they become apparent 
with other diagnostic tests. Clinical decisions may be influenced by knowledge of 
these abnormalities. CT imaging, however, comes with risk related to ionizing radiation 
exposure. 
The aim of this review is to discuss the risk of routine CT imaging in CF patients using 
current models of radiation-induced cancer and to put this risk into perspective with 
other medical and non-medical risks. The magnitude of the risk is a complex, controversial 
matter. Risk analyses have largely been based on a linear no-threshold model and excess 
relative and excess absolute risk estimates mainly derived from atomic bomb survivors. 
The estimates have large confidence intervals. Our risk estimates are in concordance 
with previously reported estimates. A large proportion of radiation, to which humans 
are exposed to, is from natural background sources and varies widely depending on 
geographical location. The risk differences due to variation in background radiation can 
be larger than the risks associated with CF lung disease monitoring using CT.
We conclude that the risk related to routine usage of CT in clinical care is small. In 
addition, a life limiting disease, such as CF lowers the risk of radiation-induced cancer. 
Nonetheless, the use of CT should always be justified and the radiation dose should be 
kept as low as reasonably achievable.
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INTRODUCTION
The number of computed tomography (CT) scans performed in the USA increased by 
600% over the past 20 years.1-3 In 2007, nearly 70 million CT procedures were performed 
in the USA, of which 7 million were performed in the pediatric population.4  Since 2007, 
CT usage in pediatrics has plateaued or even declined in some locales, likely related to 
multiple factors including economic cost constraints and increased awareness of cancer 
risks in the pediatric population, but the technique is still in frequent use.5,6
A downside of CT imaging is that it involves exposure to ionizing radiation. Even 
though CT imaging represents only 17% of radiological examinations, it accounts for 
half of the collective dose from medical sources in some countries. As a consequence 
of the increased use of CT, the overall radiation exposure from medical procedures 
has increased as well.7 Recent studies have shown a small but statistically significant 
association between pediatric CT scanning and cancer incidence.1,8 Every CT procedure 
should be justified by weighing the perceived benefits against the potential risks.9,10 CT 
imaging has multiple roles, such as diagnosing disease, monitoring disease progression, 
assessing response to therapy, detecting complications of therapy, and detecting 
disease recurrence. It provides detailed anatomic information from multiple organ 
systems simultaneously.3,11 These benefits improve health care and can be lifesaving in 
certain conditions.12 
Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disorder in the 
white population.  Chronic respiratory disease accounts for more than 80% of mortality 
in CF patients.13 Chest CT imaging is increasingly used both for patient management 
and clinical trials in CF, since chest CT is the most sensitive modality to assess and 
monitor CF-related changes in lung structure.14 Chest CT can detect changes in lung 
structure before they become apparent by pulmonary function testing15 or other 
imaging techniques such as MRI and chest radiography.14,16,17 Pulmonary abnormalities, 
such as bronchiectasis, air trapping, bronchial wall thickening and mucous plugging 
can be observed with chest CT imaging.18,19 Importantly, bronchiectasis and trapped 
air, defined by CT, are well-validated outcome measures.20 These abnormalities can be 
identified by CT in early infancy.21-23 The diagnosis of bronchiectasis can be delayed by 
three years in CF patients without CT scans.13 Early detection of lung abnormalities is 
essential, because further irreversible lung damage may be prevented by treatment. 
Additionally, as a secondary benefit, patients and parents could have better compliance 
to their medication, when shown the results of their lung images.24 Hence, the ability 
and benefits of chest CT to detect and monitor CF lung disease are clear. 
However, the enthusiasm for the routine use of CT is tempered by the ongoing debate 
over carcinogenic risks.1,25 This is especially important for patients with chronic diseases 
like CF, where the cumulative radiation risks of repetitive CT scans must be taken into 
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consideration. On one hand there is the risk of radiation exposure that may increase the 
likelihood of developing malignancies. On the other hand there is the risk of undetected 
progression of CF lung disease eventually leading to severe lung disease and reduced 
life expectancy. 
For the optimal and safe use of chest CT, an understanding of the basic concepts related 
to diagnostic use of ionizing radiation is important for CF care givers. Our aim is to 
provide a better understanding of the factors related to monitoring CF lung disease 
with chest CT scans. We will discuss what is known about the possible risks of ionizing 
radiation, the radiation dose, and the risks associated with chest CT in CF patients. 
Furthermore, we will put these risks into perspective by comparisons with other medical 
and non-medical risks.
General introduction to effects of radiation 
The adverse effects of ionizing radiation can be regarded as either deterministic or 
stochastic. Table 1 provides a brief overview of the terminology used in radiology and 
radiation protection.  A deterministic effect is the direct consequence of tissue damage 
due to radiation. Such effects include epilation and skin erythema. Deterministic effects 
are highly dose dependent and only occur after exceeding a threshold dose.3 The 
threshold values are high and beyond the range typically associated with CT imaging 
used for monitoring CF-related lung disease. 
A stochastic effect is a random, probabilistic effect due to genomic damage. Stochastic 
effects include carcinogenesis and mutagenesis, and lack an obvious threshold. 
Stochastic genomic damage by radiation can increase the risk for developing cancer, 
but not the cancer’s severity.26
An important risk modifier is the age at the time of radiation exposure. Pediatric 
patients are more sensitive to radiation-induced cancer than adult patients.27 The 
estimated additional lifetime cancer mortality risk due to radiation increases steeply 
with younger ages at exposure.28 This is presumed to be related to the larger proportion 
of proliferative tissue stem cells and the longer time for a potential cancer to develop in 
children compared to adults.11,15
Terminology for CT radiation dose
Several terms define the radiation dose related to the CT scan. The absorbed dose 
describes how much energy from ionizing radiation has been absorbed per unit 
mass and is expressed in units of Grays (Gy), with 1 Gy equal to 1 Joule/kilogram. 
To express the absorbed dose in relation to a specific CT protocol, the most commonly 
used descriptors are the Computed Tomography Dose Index (CTDI) and the dose-
length-product (DLP).29 
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TABLE 1. Definitions of radiology dose and risk terms
Term Definition
Absorbed dose Amount of ionizing radiation energy absorbed in per unit mass
CTDI  
(Computed Tomography Dose Index)
A CT  radiation dose descriptor used to characterize exposure 
to standardized reference phantoms for acceptance testing, 
quality control and protocol comparisons
CTDIvol A CTDI measure that approximates the average dose to a slice 
of the reference phantom, taking the helical pitch into account
Deterministic effect Tissue damage due to exceeding a threshold dose of radiation, 
with the severity proportionate to dose
DLP  
(Dose Length Product)
A CT radiation dose descriptor that consists of the product of 
the  CTDIvol  and scan length, and measures the total radiation 
exposure for the whole series of images
EAR (Excess Absolute Risk) model A risk model that expresses the excess risk as the difference 
between the total risk and the background risk
Effective dose Weighted sum of doses to irradiated tissues used to describe 
total risk of stochastic effects for radiation protection purposes
ERR (Excess Relative Risk) model A risk model that expresses the excess risk as a ratio relative to 
the background risk 
LNT (Linear No Threshold) model A risk model in which any radiation dose is potentially harmful 
and the probability of cancer is linearly related to dose
Organ dose Radiation absorbed dose for a specific organ
Stochastic effect An event such as carcinogenesis or mutagenesis  that occurs 
by chance depending on the radiation dose without an 
obvious threshold
The CTDI is a descriptor of the energy absorbed within a dose profile deposited within 
the nominal collimated beam width and is used for quality control and comparison of 
the radiation dose of various CT protocols. To calculate the CTDI the radiation output of 
the CT scanner is measured with an ionization chamber using either a 16 cm diameter 
head phantom or a 32 cm body phantom.30 The volumetric CTDI (CTDIvol) expressed 
in milligrays (mGy), is the most commonly used descriptor and represents the average 
dose over the scanned volume. A product of the CTDIvol and the scan length is known as 
the DLP which is reported in units of milligray times cm (mGy·cm).31
Changes of scanning protocol parameters on a CT scanner (e.g. tube voltage, tube 
current, pitch, bowtie filter, scan length) are reflected by changes in the CTDIvol and/
or the DLP value. Every CT scanner provides the CTDIvol and DLP to the user for each 
scanning procedure, a feature that facilitates comparison of different CT scanners 
and scanning protocols. However, the CTDIvol and the DLP only provide information 
regarding CT scanner radiation output and absorbed dose in standardized phantoms. 
These measures neither take the size of the patient into consideration, nor do they 
describe the radiation dose absorbed by any individual patient. This is an important 
aspect to keep in mind, especially in the pediatric population. To conclude, the CTDI 
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value is important for comparison of different CT scanners and scanning protocols but 
is not an accurate measure of the absorbed radiation dose for the individual pediatric 
patient32 and should not be directly used to calculate the accompanying radiation risk.3
Effective dose
The effective dose, measured in units of Sievert (Sv), was developed as a quantity for 
radiation protection purposes.33,34 The effective dose takes into account where the 
radiation dose is being absorbed, as well as the relative radiosensitivity of different 
tissues.11 It is calculated by summing the weighted dose to exposed tissues using sex- 
and age- averaged tissue weighting factors derived from estimates of risk and lethality 
of cancer and effect on quality of life. Thus the effective dose characterizes the radiation 
burden to a sex- and age-averaged “reference person” from a given radiation exposure, 
but it does not provide the dose specific to a patient from an individual study. Therefore, 
the effective dose should not be calculated or used for risk assessment of an individual 
patient, especially children who may differ greatly from the “reference person”.30,34 
From CT dose to organ dose
The organ dose is defined as the average radiation energy absorbed in an individual 
organ, usually expressed in mGy units in diagnostic CT.11 The size specific dose estimate 
(SSDE) is a measure that approximates the dose that the individual patient absorbs from 
the CT scan, by using the CTDIvol multiplied by a conversion factor based on patient 
cross-sectional size.35 The SSDE may be useful as a first approximation of some organ 
doses, depending on organ location and size.  However, organ doses can be estimated 
more accurately for specific CT scanners and scanning protocols using specialized Monte 
Carlo dose calculation software.36,37 These estimates become more accurate when more 
information, such as the energy spectra, x-ray beam or the type of filter used to shape 
the x-ray beam, are incorporated. Monte Carlo organ dose estimates can be expressed 
per unit CTDIvol or DLP.
38 
From organ dose to cancer risk in patients with CF 
As discussed previously, the effective dose is not appropriate for estimations of radiation 
risk in individual patients. For a given dose, there is a discrepancy in cancer risk from 
radiation exposure between children and adults.11 Therefore, it is recommended to use 
the organ absorbed dose to estimate radiation risk.34 Organ dose in combination with 
age- and sex-specific risk coefficients provided by the BEIR VII report can be used to 
estimate lifetime attributable risks of cancer incidence and mortality.39 
As an example, consider a CF chest CT protocol without contrast for a 5-year-old 
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consisting of inspiratory and expiratory series on a Philips Brilliance 64 CT scanner with a 
total radiation output corresponding to a CTDIvol32 cm of 2.1 mGy. The total dose of 2.1 mGy 
for the two series is very similar to a single volumetric chest CT dose recommendation 
at the age of 5 years by Nievelstein and colleagues,40 and compared to several European 
surveys, the total dose is up to four times lower.41 During a chest CT scan, several organs 
(including the thyroid, breasts, esophagus, lungs, thymus, and portions of the upper 
abdominal viscera) are irradiated. Thus to determine cancer risk, multiple organ doses 
have to be taken into consideration. Organ doses can be estimated with CT-Expo, a dose 
calculation software.36,37 Each organ dose is multiplied with the corresponding lifetime 
attributable risk of cancer mortality for an exposure at the age of 5 as described in the 
BEIR VII report.39 In our example, we estimate a sex-averaged lifetime cancer mortality 
risk of 0.023% attributable to the radiation output associated with a CTDIvol32 cm of 2.1 
mGy. Note that for our CF chest CT protocol, the organ doses and thus the corresponding 
risk estimates are much lower than the doses and corresponding risks for a typical non-
CF chest CT scan. For example, our lung dose estimate of 4 mGy compares to a lung 
dose of 10-15 mGy for a chest CT scan previously reported in the literature.6
If a patient with CF is routinely monitored for progression of structural lung disease 
with biennial CT scans, from birth till the age of 17, they will typically undergo 9 chest 
CT scans. The radiation dose used for CT at relatively older ages is typically higher than 
the 2.1 mGy in our previous example, because the x-ray beam is attenuated more by 
the thicker tissues of larger children.42 At younger ages the dose is less than 2.1 mGy. 
The total CTDIvol32 cm for these 9 scans combined is calculated to be approximately 20 
mGy. Organ doses at various ages were estimated by estimating organ doses for the 
baby, child and adult phantom with CT Expo. The values for the intermediary ages were 
estimated with linear interpolation. Lifetime attributable risks at various ages were 
estimated by linear interpolation of the tabulated risk values in the BEIR VII report.39 
This results into a cancer mortality risk of 0.2% for a radiation output of 20 mGy in total. 
Meaning that for every 1000 people exposed to 9 chest CT scans during childhood, two 
will possibly die of cancer due to these CT scans. 
It should be noted that for this risk estimate it is assumed that radiation dose for each 
scan will not change over the coming 17 years period. Advances in CT dose reduction 
technology would likely result in lower radiation doses and correspondingly lower 
estimated risks.43
Complexities of estimating radiation risk 
To estimate radiation risks, models are needed. A model is by definition a simplification 
of reality and always comes with limitations. Calculating radiation risk is complex and 
comes with large uncertainties.  
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Often overlooked is the fact that estimations of radiation-induced cancer from CT 
have largely been theoretical calculations extrapolated from findings in subjects who 
received radiation doses many times greater than what is currently used in diagnostic 
CT.25 Radiation risk estimates are mainly derived from longitudinal cohort studies 
of populations exposed to moderate to high doses of radiation, including Japanese 
survivors of the atomic bombs and radiotherapy patients. It is unsure how applicable 
the findings from these groups are to the relatively low doses of radiation exposure 
from CT scans in a mainly white group of children and adolescents with CF.1 
Most radiation risk analyses are based on excess relative risk (ERR) and excess absolute risk 
(EAR) values applied to a linear no-threshold (LNT) dose-response model.  ERR expresses 
the additional risk of radiation exposure relative to the background risk, while EAR 
expresses the additional risk as the difference in the total risk and the background risk.39 
The LNT model assumes that any radiation dose, no matter how small, is potentially 
harmful and that the probability of cancer is linearly related to dose (see Figure 1). The 
LNT model does not take radiation damage repair mechanisms into consideration, 
which exhibit non-linear dose-response properties, and that may even function to 
provide a practical threshold at low dose levels. Compared to the mean exposures of 
the exposed cohort of atomic bomb survivors, the dose of a chest CT scan is relatively 
low. In addition, risk estimates have large confidence intervals.44 Despite its limitations, 
the LNT model is currently dominant in public policy guidelines for risk assessment and 
radiation protection.
Our cancer mortality risk estimate of 0.2% comes with uncertainties as well. The BEIR VII 
committee subjectively provides 95% confidence intervals for lifetime attributable risk of 
solid cancer mortality for persons of mixed ages exposed to radiation. These subjective 
intervals indicate that for lung cancer risk factors may be approximately 2.5 times lower 
or higher. The recent American Association of Physicists in Medicine Position Statement 
also acknowledges these uncertainties stating that: “Risks of medical imaging at effective 
doses below 50 mSv for single procedures and 100 mSv for multiple procedures over 
short time periods are too low to be detectable and may be nonexistent”.45 Despite the 
large and subjective uncertainties, the risk estimate of 0.2% can be of use when putting 
the possible risk of radiation-induced cancer into perspective.
Recent studies of radiation exposure by CT in young populations have shown excess 
cancer rates similar or even higher than those for the atomic bomb survivor cohort. 
In a retrospective study by Pearce and colleagues, a positive association was shown 
between radiation dose from CT scans in childhood and development of leukemia and 
brain tumors.1 In another retrospective study by Mathews and colleagues, the cancer 
incidence rate was found to be elevated within 10 years of follow-up after CT scanning. 
The incidence was greater when exposed at younger ages or in female patients.8 
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Unfortunately, the risk estimates by these two recent retrospective studies1,8 came with 
large uncertainties and any actual risk is too small to estimate with any certainty at the 
level of the individual patient.46
FIGURE 1. The linear no threshold model extrapolated to the lower doses received by chest CT. 
Estimated excess relative risk (±1 SE) of mortality from solid cancers among groups of survivors in 
the Life Span Study cohort of atomic bomb survivors, who were exposed to radiation. The dashed 
straight line represents the results of a linear fit to all the data. The line has been extrapolated to 
include the lower radiation exposure levels of CT scans as well. Adapted from Brenner et al.67
CT radiation risk into perspective
Alarming media reports spread fear and misperception of the true risks posed by 
radiation, while everyday risks from other sources are accepted or disregarded. Many 
in the general and medical field do not understand the concepts of risk or probability.47 
Risks are often overestimated or overweighted when the hazard is sensationalized, 
small, uncertain, delayed in effect, and not under control of the exposed; all of which 
are operative in the setting of medical radiation. Therefore, the risk of radiation must be 
put into proper perspective.
Compared to risks from other CT scan indications
Chest CT scans are used not only for monitoring purposes in CF patients, but also for 
many other clinical indications and diseases. We compared the risk of routine usage of 
CT in CF estimated in this study with the risks from other CT scans for other indications 
and age groups (see Table 2). If not already reported in the article, a sex-averaged, 
lifetime cancer mortality risk was calculated based on the BEIR VII report methodology 
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assuming an otherwise normal life expectancy. Unfortunately, not all studies allowed 
for using organ doses to estimate the risk. Some studies report the effective dose as 
a radiation dose parameter. If only the effective dose was described, it was converted 
to a homogeneous whole body irradiation for the calculations; for example, 1 mSv 
corresponds to an organ dose of 1 mGy for each organ.
TABLE 2. Lifetime cancer mortality risk for various CT scans and age groups
Reference
Age and 
size patient 
group
Indication  
of CT scan
Period that 
data was 
studied
Measure of dose
Sex-
averaged 
lifetime 
cancer 
mortality 
risk based 
on BEIR VII
This review 5 years CF (inspiratory 
and expiratory 
scan) 
2013 CTDIvol,32cm = 2.1 mGy 0.023%
0-17 years CF monitoring 
(9 inspiratory 
and expiratory 
scans) 
2013 Cumulative CTDIvol,32cm=20 
mGy
0.2%
Huda (67) 5 years Routine  Chest Not specified 
Pub year: 2007
Effective dose 2.1 mSv 0.029%*
5 years Low dose CF 
Chest 
Not specified 
Pub year: 2007
Effective dose 0.55 mSv 0.0075%*
Bernier et 
al. (68)
<1 year 
n=11.857
Chest 2000-2006 The reported organ doses. 
Including lung dose of 6 
mGy.
0.038% †
1-5 years 
n=15.505
Chest 2000-2006 The reported organ doses. 
Including lung dose of 5 
mGy.
0.029% ‡
Kharbanda 
et al. (70)
< 19 years 
n=23.148
Trauma 2010 Mean dose= 12.0 mSv 0.11%§
Niemann et 
al. (70)
Adults 20 
years 
n<10
Pulmonary 
embolism
Not specified 
Pub year: 2013
Reported organ doses 
including lung dose of 13 
mGy (sex-averaged).
0.039%*
Adults 60 
years 
n=142
Pulmonary 
embolism
Not specified 
Pub year: 2013
Reported organ doses 
including lung dose of 14 
mGy (sex-averaged).
0.024%*
All calculations are made using the lifetime attributable risk of cancer mortality from the BEIR VII report.39
* Estimations given by the reference. 
† Calculations made with the risk estimates for age at exposure of 0 years.
‡ Calculations made with the average risk estimates for age at exposure of 0 and 5 years. 
§ Calculations made with the risk estimates for age at exposure of 10 years.
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Compared to risks from other radiation sources 
A main source of ionizing radiation is the omnipresent natural background radiation from 
radon, cosmic rays, terrestrial sources and internal sources. Background radiation levels 
vary widely depending on geographic location. The annual global average from natural 
radiation sources for an individual is an effective dose of 2.4 mSv, with a typical range 
of 1 to 10 mSv.48 The Dutch population is exposed to an average background radiation 
of 1.9 mSv per person per year,49 compared to 3.0 mSv per year in the United States.31 
Moving from Nevada to Colorado increases background radiation by 1.5 mSv per year.50 
Across 75 years, this would translate into an additional life-time cancer mortality risk 
of approximately 0.7% based on the lifetime attributable risk estimates of the BEIR VII 
committee. Thus, an additional seven per 1000 people will potentially die from cancer 
when they are lifelong (i.e. 75 years) exposed to an additional annual 1.5 mSv of natural 
background radiation. In comparison, the cancer mortality risk of approximately 0.2% 
as calculated previously for routine chest CT scanning is thus smaller than that from 
geographical higher background radiation (see Figure 2). In certain parts of Brazil, India, 
Iran and China, natural background radiation levels of several times the US average have 
been recorded.48 Despite these higher levels, no increase in the incidence of cancer has 
been documented in the populations residing in these areas.25
FIGURE 2. Causes of death for a group of patients receiving biennial chest CT scans until the 
age of 17 and receiving an additional 1.5 mSv each year during their life due to a relatively high 
natural background radiation level. Only a small fraction (0.2%) dies of cancer induced by the 
chest CT scans. In CF, the excess contribution of radiation-induced cancer mortality is expected to 
be even lower if the shorter life expectancy due to CF is taken into account. 
The Background Equivalent Radiation Time (BERT) describes radiation doses from a 
source, such as from a CT scanner, in relation to the radiation dose of natural background 
radiation. One BERT year in the US corresponds to an effective dose of 3 mSv.51 As 
mentioned previously, the concept of effective dose is not designed to be applied to 
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children undergoing CT scans. Therefore, one cannot easily relate the effective dose of 3 
mSv natural background radiation to the organ doses (in mGy) from pediatric CT scans. 
Alternatively, background radiation and radiation from pediatric CT scans can be related 
to each other through associated risks. The effective dose of 3 mSv can be translated 
into organ doses in mGy assuming uniform irradiation of 3 mGy across the whole body. 
Using the BEIR VII report, the corresponding risk of this whole body irradiation can be 
estimated for various ages and both sexes. Routine biennial CT usage from birth until 
the age of 17 translates into an estimated BERT from birth until the age of 4 years for 
boys and until the age of 6 years for girls. 
Compared to CF related risks
The attributable risks of mortality from (background) radiation-induced cancer as 
calculated above and depicted in Figure 2 are a misleading detriment measurement 
in patients with severe, life-limiting diseases such as CF. A large proportion of patients 
with CF might not survive long enough for the radiation-induced cancer to develop. 
Therefore, a lower lifetime radiation-induced cancer mortality risk in patients with CF 
than calculated above is expected.52 The current median life expectancy of CF patients 
is 40 years of age53 and increasing (see Figure 3), due to improvements in screening, 
treatment and medical care. We assume that life expectancy for CF patients at birth is 
now approximately 50 years. With the use of the previously described organ doses and 
data of the Surveillance, Epidemiology, and End Results (SEER) program of the National 
Cancer institute,54 cancer mortality for a population with lower median survival age 
can be estimated. The radiation-induced cancer mortality for a patient with a median 
survival age of 50 years is calculated to be 0.08%. Taking the different life expectancies 
into account the estimated mortality risk of 0.08% for CF patients is approximately 2.5 
times lower than the estimated mortality risk for a general population. 
de González and colleagues also showed decreased influences of reduced life 
expectancies on risk estimates. Their radiation-induced cancer was approximately 4 
times lower in case of annual CT scanning during lifetime, for a group with a median 
survival age of 36 years compared to a median survival age of 50 years.55 Thus the 
importance of radiation risks in determining optimal imaging use is reduced in patients 
with diminished life expectancies. 
In addition to the reduced life expectancy there is another possible factor affecting the 
validity of our risk estimates in CF patients. The BEIR VII risk factors and therefore our 
estimates do not adjust for the observed change in baseline cancer risk in CF patients 
as described by Maisonneuve and colleagues. The risk of melanoma was decreased in 
patients with CF, whereas the risk of lymphoid leukemia, thyroid, testicular and digestive 
tract cancer was increased especially in transplanted patients. Some increased risks 
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can be explained by genetic mechanisms. The excess in cases of thyroid cancer may 
be explained by the increased surveillance of the CF population.57 Some of the tumors 
found in CF might be associated with excess radiation. As individual radiation exposure 
information is lacking, this hypothesis cannot be further investigated at present. In any 
case, the absolute risk of cancer in CF remains low and will not affect our risk estimates 
significantly. Routine biennial CT imaging seems acceptable based on our risk estimates 
and the known reduced life expectancy in CF.
FIGURE 3. Survival by birth cohort (source: Cystic Fibrosis Foundation (US) patient registry annual 
data report 2011). The graph shows that of patients with CF born between 1987 and 1991 (gray 
line), 94.7 percent were alive at age 14. For children with CF born between 1997 and 2001 (purple 
line), 96.6 percent were alive at age 14. The children with CF born in a more recent cohort have a 
longer life expectancy. 
Compared to other ‘daily’ risks 
The overall probability of death from cancer over a typical person’s lifetime is 23.3%.11,58 
This means that for every 1000 children, 233 will potentially die of cancer even if never 
exposed to medical radiation. Figure 2 shows this baseline cancer mortality risk in relation 
to the additional cancer mortality risk from chest CT scans and excess natural background 
radiation, as discussed previously.  The possible risk of dying from cancer attributable to 
radiation from CT scanning is very small in comparison to the overall risk of dying from 
cancer. In comparison, cigarette smoking confers an 18% risk of developing smoking-
related cancer, and 12% of deaths worldwide are thought to be attributable to tobacco 
use.59 According to the US National Safety Council, there is an approximately 1% lifetime 
risk of dying from a motor vehicle accident and a 0.6% lifetime risk of dying from a fall.60 
The mortality rate in the United States for children between 1 to 19 year olds is 0.4%. 
The primary cause of childhood mortality is unintentional injuries with a mortality rate 
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of 0.15%.61  As calculated in this paper, there is a 0.2% risk estimate of potential mortality 
caused by cancer due to routine biennial chest CT scans performed through childhood 
and adolescence, assuming a LNT model and normal life expectancy. Independent of 
CT scan usage, this possibility is comparable to the 0.18% risk of developing a severe 
reaction to intravenous contrast.62  Lastly, it has been estimated that there is a greater 
than 0.1% risk of death from a medical error per hospitalization.63
CONCLUSIONS
This review describes the radiation risk for routine usage of chest CT scanning in 
pediatric CF patients with a discussion of the level of concern this should generate. 
Our mortality risk estimates for routine biennial pediatric chest CT scanning of 0.2% 
assuming a normal life expectancy, are in concordance with previous risk estimations.6,55 
As discussed by de González and colleagues, and confirmed by the risk estimates made 
in this review, the previous risk estimates by our colleagues, de Jong and colleagues, 
were highly conservative.55,64 The risk is even lower taking into consideration the 
reduced life expectancy of CF patients.
Patients with CF could benefit from routine chest-CT monitoring of the progression 
of their lung disease and their responses to therapy. It is reasonable to believe that 
compensating gains in life expectancy may be expected by sensitively monitoring 
structural lung changes, detecting clinical relevant changes earlier, and more promptly 
instituting treatment and assessing response to therapy.
The additional cancer mortality risk related to the radiation received from routine CT is 
uncertain but small. Considering the small risk and long latency of radiation-induced 
cancer, the benefit-to-risk ratio of CT is very favorable, even if CT scans provide life-
prolonging information in only a tiny fraction of patients with life-limiting severe 
disease such as CF.
Several risk models have been developed to predict the carcinogenic risks of radiation, 
with the LNT model being dominant for radiation protection policies. To quantify overall 
cancer mortality risk from radiation in the dose range of a single CT scan, a cohort of 5 
million people would need to be followed over their lifetime for adequate statistical 
power and precision.25 Hence, in the absence of such dauntingly large studies, risk 
estimates related to low dose radiation exposure remain speculative and uncertain.31 
Undue concern over the potential risks of radiation can cause clinicians or parents to 
forego medically indicated CT scans, thereby imposing the very real risk of missed or 
delayed diagnoses. A patient’s past or future exposure should not factor into current 
imaging decisions. Radiation risk models imply that if a patient without history of 
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irradiation should get a CT scan when clinically indicated, then this same patient 
with history of accumulative radiation exposure should as well.65,66 This will remain 
true provided that for every exposure to diagnostic radiation, the anticipated benefit 
outweighs the potential risk, and assuming that the radiation exposure is kept as low 
as reasonably achievable. It is important to optimize radiation dose and CT protocols, 
especially in the pediatric population, by implementing dose-reducing and dose-
optimizing technology in standard CT scanning protocols and by adopting a radiation 
registry for quality control and staff training. Radiation risk estimation is a complicated 
matter. The risk related to the routine use of CT in clinical care is small but not negligible. 
However, this risk can be outweighed by its benefits, especially in the pediatric patients 
with severe, chronic and life-limiting diseases, such as CF. 
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ABSTRACT 
Progressive cystic fibrosis (CF) lung disease is the main cause of mortality in CF patients. 
CF lung disease starts in early childhood. With current standards-of-care, respiratory 
function remains largely normal in children and more sensitive outcome measures are 
needed to monitor early CF lung disease. Chest CT is currently the most sensitive imaging 
modality to monitor pulmonary structural changes in children and adolescents with 
CF. To quantify structural lung disease reliably among multiple centers, standardization 
of chest CT protocols is needed. The Standardized Chest Imaging Framework for 
Interventions and personalized medicine in CF (SCIFI CF) was founded to characterize 
chest CT image quality and radiation doses among 16 participating European CF 
centers in 10 different countries. We aimed to optimize CT protocols in children and 
adolescents among several CF centers. A large variety was found in CT protocols, image 
quality and radiation dose usage among the centers. However, the performance of all 
CT scanners was found to be very similar, when taking spatial resolution and radiation 
dose into account. We conclude that multicenter standardization of chest CT in children 
and adolescents with CF can be achieved for future clinical trials. 
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INTRODUCTION
Computed tomography (CT) usage has increased over the past two decades to aid with 
diagnostic and monitoring purposes in the pediatric population.1 CT has become an 
important imaging tool for patients with cystic fibrosis (CF), who develop lung disease 
early in life when irreversible pulmonary abnormalities can still be prevented. Some 
centers start monitoring the progression of early CF lung disease with CT at a young 
age,2–4 as this is currently the most sensitive imaging modality to detect and monitor the 
structural changes of early CF lung disease. Chest CT can detect structural abnormalities 
even before symptoms occur in a patient2 and in general before it becomes apparent 
with spirometry5 or any other imaging modality.6–9 Findings on chest CT provide 
important timely information to CF care givers on the presence and progression of 
structural lung abnormalities and guides treatment aimed to prevent progressive 
pulmonary changes.10
The sensitivity of chest CT to detect structural lung changes promptly has also resulted 
in several clinical trials that include chest CT as an outcome measure11–13 and more are 
to be anticipated to evaluate the efficacy of new costly promising disease-modifying 
agents. Chest CT related parameters such as bronchiectasis scores can be of use as 
primary or secondary outcome measures. Smaller sample sizes may suffice in studies 
with more sensitive CT outcome measures.14,15 Chest CT can play an important role 
especially in clinical trials in young children and for children and adolescents with CF as 
well as in other lung diseases when sensitive outcome measures are needed.16
To utilize chest CT in a multi-center clinical trial, it is of great importance to standardize 
image acquisition of chest CT scans. Acquired CT scans require sufficient image quality 
at the lowest possible radiation dose. Currently, technical scanning parameters and 
image reconstruction techniques are chosen by each center individually, affecting 
image acquisition and consistency profoundly.17 Affected image quality could indicate 
false disease progression or treatment effectiveness in patients.  Differences can also be 
found in lung density measurements and airway analyses between scanners, but also 
within a specific CT scanner over time.18 Studies have shown either overestimation or 
underestimation of emphysema and bronchiectasis depending on the reconstruction 
algorithm 17 and the inspiration level during CT acquisition.19 Next to the variety in 
image quality and CT acquisition, a spread in amount of radiation dose used for each 
scanner and protocol can be expected. Radiation exposure comes with potential risks 
and it is therefore important to keep this as low as reasonably achievable, especially in 
young children as they are more sensitive to ionizing radiation 1. The use of a sequential 
technique with gaps, i.e. a non-contiguous scan predates a volumetric or spiral scan. 
Currently sequential chest CT techniques are, however, still used as a strategy to reduce 
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radiation dose by some centers,20–22 even though this strategy comes at the cost of 
losing information and making longitudinal follow up less sensitive.
CT techniques have improved, with the main goal to decrease the radiation exposure 
in patients while maintaining sufficient diagnostic image quality. Techniques such as 
automatic exposure control and the more recent development of iterative reconstruction 
techniques have been effective to lower the radiation exposure in pediatric patients.23,24 
With rapidly improving CT technology and different CT scanners, it can be a challenge 
to quantify and maintain consistent image quality of CT scans during a multi-center 
clinical trial.
The aims of our study was to characterize CT practices and performance of CT scanners 
in different European CF centers involved in CF research and to optimize CT protocols 
for children and adolescents. Standardized chest CT was aimed to be available for future 
clinical trials in the pediatric CF population. For these purposes, the Standardized Chest 
Imaging Framework for Interventions and personalized medicine in CF (SCIFI CF) was 
founded in 2012. Site visits were conducted within European centers, most of them 
being part of the European Cystic Fibrosis Society-Clinical Trial Network (ECFS-CTN). We 
describe the current routine chest CT protocols used for children and the performance 
of the CT scanners using these protocols. Based on these findings, guidelines and 
recommendations are presented for future chest CT protocols.  
MATERIAL AND METHODS
The ECFS-CTN is a European network launched by the European CF society in 2008. It 
was composed of 30 selected CF sites dedicated to CF clinical research in 11 countries in 
2012. All 30 ECFS-CTN centers were invited to participate with the SCIFI CF initiative. In 
addition to the ECFS-CTN centers, 2 other centers requested to participate, as they were 
eager to have their CT scanners characterized for research purposes. A letter was sent to 
each of these centers explaining the background of the SCIFI CF initiative. In addition, 
a questionnaire was sent to acquire general information regarding the pediatric CF 
center and an inventory of the centers’ CT protocols used for CF patients was requested 
(see Appendix for full details). Centers were selected based on the commitment of 
the pediatric pulmonologist and radiologist, availability of the CT scanner, availability 
of the employees and technicians for a site visit, and consent to compensate for the 
costs of the site visit. To ensure the commitment of both the department of pediatric 
pulmonology and the department of radiology, a letter of agreement signed by both a 
pediatric pulmonologist and a radiologist was required. 
All participating centers and their data were anonymized for this manuscript.
Standardization of pediatric chest CT | 49
3
Site visit
The visits to the selected centers were planned and executed over a period of 2 years 
starting from 2013. A SCIFI CF site visit was prepared in close collaboration with the 
CF coordinator of each center. During the two-day visit, a presentation about the SCIFI 
CF initiative was given, phantoms were scanned on the CT scanner, and training was 
provided concerning spirometer guided CT. The feasibilities of standardized inspiration 
levels acquired during CT scanning have been described separately.25 
Evaluation of routine CT protocol
The main CT scanner and the age specific routine chest CT protocols used in clinical 
practice to acquire CT scans in children and adolescents with CF were studied and 
evaluated with three age-specific phantoms (QRM, Quality Assurance in Radiology and 
Medicine, Möhrendorf, Germany). These phantoms were designed to represent the 
average patient size of a newborn, a child (5 years old), and a young adult. The size and 
geometry of the adult phantom was based on measurements in a European young adult 
population.26 The newborn and child phantoms are scaled down versions of this adult 
phantom. Based on the phantom sizes and the information available from the Image 
Gently campaign,27 the newborn, child,  and adult phantom correspond with a patient 
weight of 4, 18, and 58 kg, respectively. The materials used in these anthropomorphic 
phantoms mimic human tissues in the thorax with regards to the characteristics of 
X-ray attenuation. The tissues of the phantom include artificial lung parenchyma, bone, 
and soft tissue-equivalent material. In addition, inserts containing homogeneous solid 
water, iodine or soft tissue-equivalent material can be placed on various positions 
of the phantom. A tungsten wire and golden disk insert were used to determine the 
spatial resolution of the scanner. For the child phantom, the applied x-ray tube voltage 
and rotation time were noted. To assess the applied radiation dose as a function of 
patient size, the newborn, child, and adult phantoms were first scanned according to 
the centers’ current CT protocol for patients with CF in these age groups. The scanner’s 
radiation output was determined by the reported volumetric CT dose index (CTDIvol) 
in the DICOM header or from the accompanying DICOM dose report image. When this 
information was not available, the CTDIvol was determined manually, with the aid of 
tabulated dose values in the software package CT-Expo (version 2.0), using the scanning 
parameters of the protocol. The CTDIvol value of non-contiguous sequential CT protocols 
was extrapolated to the corresponding dose of a continuous volumetric CT scan.
The median dose found in the child phantom in all centers, served as a reference value 
for the absolute dose level. It was assumed that this reference dose level provides images 
with sufficient image quality for diagnosis as it is based on the protocols used by the 
centers for their clinical routine. The dose outliers are assumed to be of too good or too 
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bad diagnostic quality. For each center, the ratio between the newborn and the child 
dose and the ratio between the adult and the child dose were determined. The median 
values of these ratios were multiplied by the reference value for the child phantom to 
obtain reference values for the newborn and young adult.    
CT scanner performance characterization
The performance of each scanner was characterized by assessing the quality of the 
child phantom images reconstructed with the filtered back projection technique. The 
primary measure for image quality QNOISE was solely related to image noise:
with σ as the standard deviation of the image noise. Image noise was determined 
in each slice in a 5 cm2 region of the lung parenchyma. A relatively high QNOISE factor 
corresponds with an image with a relatively low noise level. Thus, for a given level of 
image contrast a relatively high QNOISE factor also corresponds with a better contrast-to-
noise ratio.
It is important to realize that image quality and applied dose are interconnected. 
Moreover, several aspects of image quality, in particular image noise and spatial 
resolution, are closely linked. Therefore, the QNOISE factor was extended accordingly to 
take both spatial resolution and applied dose into account.
In general, a better spatial resolution corresponds with a higher noise level. The spatial 
resolution of an image can be described in-plane and out-of-plane by the pre-sampled 
modulation transfer function (MTF) and slice sensitivity profile (SSP), respectively. The 
measure QNOISE,RES incorporates the previously derived  relationship between image 
noise and spatial resolution28–31:  
with M the reconstruction matrix size, FWHMSSP the full width at half maximum of the 
SSP, and f the spatial frequency. The integral runs from –fN to +fN, with fN the Nyquist 
frequency of the projection data. The SSP was determined by scanning the insert 
containing a 10 μm thick golden disk. The MTF was derived from the point spread 
function (PSF) that was determined from the CT scan of the tungsten wire insert. 
In addition to the spatial resolution, the radiation dose applied during the CT scan 
influences the image noise as well. The measure QNOISE,RES,DOSE incorporates both the 
relationship between image noise and spatial resolution and the relationship between 
image noise and radiation dose:
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QNOISE,RES,DOSE is a figure-of-merit which is similar to the dose efficiency and  imaging 
performance parameter used by another group.32 The higher the Q-factor, the better the 
imaging performance of the CT scanner. A CT scanner with a relatively high QNOISE,RES,DOSE 
produces images with a relatively low noise level at the same dose level and spatial 
resolution as another scanner with a relatively low QNOISE,RES,DOSE factor. CT scanners with 
equal QNOISE,RES,DOSE factors are able to produce images of equal quality with respect to 
noise and resolution at equal dose levels.
The Q values were determined for all axial slices scanned and averaged over all 
slices. Based on these averaged values and corresponding scan parameters, a 
general recommendation was made including the radiation dose to be applied as a 
function of patient age and the scan and reconstruction parameters to be used. These 
recommendations will be discussed in the final section of this guideline.
RESULTS
Study population 
Twenty-three out of the 30 ECFS-CTN centers completed the questionnaires. 19 
centers showed interest in participating in the SCIFI-CF study of which 13 pediatric 
centers fulfilled the requirements to participate. In addition, the CT scanner in our own 
department of radiology at Erasmus MC, Rotterdam, the Netherlands (also ECFS-CTN 
center) was included in this project. Aside from the 14 ECFS-CTN centers two additional 
European non ECFS-CTN centers were included. All 16 centers were visited in 2013 or 
2014. The following manufactures of the CT scanners were involved: 8x Siemens; 5x 
Philips; 2x GE healthcare; 1x Toshiba. 
Evaluation of routine CT protocol
Nine out of the 16 centers routinely monitored CF patients with a chest CT every 
two or three years. Seven centers only acquired chest CT scans on clinical indication. 
Twelve centers acquired volumetric inspiratory chest CTs, of which 9 centers included 
volumetric expiratory CT scans and 3 centers included non-contiguous expiratory CTs. 
Two centers acquired volumetric scans only in the first scan of the patient, followed by 
non-contiguous CT scans for follow-up assessment. Two centers never used volumetric 
CTs in clinical practice for the checkup of CF patients, but only scanned non-contiguously.
Applied x-ray tube voltage for the child phantom varied between centers (range 70-120 
kV, median value 100 kV). X-ray tube rotation time varied as well (range 400-750 ms, 
median value 500 ms).
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Radiation doses applied to the 3 phantoms for each center are presented in Figure 1. On 
average, the applied dose (CTDIvol,32 cm) for the child phantom was 1.8 mGy. The median 
dose was 1.0 mGy (horizontal line in Figure 1a). The applied dose for the newborn and 
adult phantom relative to the dose for the child phantom is shown in Figure 1b.   The 
horizontal lines in Figure 1b correspond to the median relative dose levels of 64% and 
223% for the newborn and adult phantom, respectively. The deviation of the bars from 
these lines indicates how well the dose for a newborn child was reduced and conversely 
increased for an adult relative to the dose for a 5-year old child. For instance, site 10 was 
in agreement with the recommended dose levels for both absolute and relative values.
Young children were scanned while spontaneous breathing in 14 centers and under 
general anesthesia in 2 centers. Starting from the age of 5-6 years old, when children 
can cooperate, inspiration CT’s were scanned with voluntary breath hold in 15 centers 
and with spirometer guidance in 1 center. Expiration CT’s were scanned with voluntary 
breath hold in 15 centers (and in lateral decubitus position in 2 centers) and with 
spirometer guidance in 1 center.
FIGURE 1. Dose levels applied in all centres. a) Volumetric computed tomography dose index 
(CTDIvol) applied in each centre for the child phantom (grey bars) and the median dose value (grey 
line), the adult (black bars) and the newborn phantom (white bars). The smaller bars represent the 
CTDIvol used for the newborn (white) and a young adult (black). b) CTDIvol values relative to the 
dose applied to the child phantom for the phantoms representing a newborn (white bars) and 
young adult (black bars). Grey and black dashed lines correspond to the recommended relative 
dose for a newborn and young adult, respectively. The order of the centres is the same as that in 
in figure 2. #: extrapolated CTDIvol values derived from a sequential computed tomography.
CT scanner performance 
The factors QNOISE, QNOISE,RES, and QNOISE,RES,DOSE for each center are shown in Figure 2 relative 
to the average value for QNOISE, QNOISE,RES, and QNOISE,RES,DOSE, respectively. Large variability 
between scanners can be observed for QNOISE and QNOISE,RES. The large difference seen in 
QNOISE is also seen in the qualities of the phantom scans (Figure 3). The variability found 
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in QNOISE can partly be explained by the variability found in in-plane spatial resolution as 
determined by the MTF. Figure 4 shows the large variation in MTF shapes found across 
the centers. The influence of the MTF can for example be seen in the QNOISE factor of 
center number 9, which is relatively low because of the relatively sharp reconstruction 
kernel used (center number 9 in Figure 2a for QNOISE and the arrow in Figure 4 for MTF). 
After correcting for the negative influence of the sharp kernel on the image noise, the 
Q-factor (QNOISE,RES) increases and is even better than average (Figure 2b). The latter can 
be explained by the relatively high dose level used by this center (Figure 1a). 
FIGURE 2. Q factors for each centre normalised to the average Q factor. a) QNOISE based on image 
noise. b) QNOISE,RES based on image noise and compensated for differences in spatial resolution 
between centres. c) QNOISE,RES,DOSE based on image noise and compensated for differences in spatial 
resolution and radiation dose between centres. Centres are sorted from small to large QNOISE,RES,DOSE.
After compensation for differences in dose, the Figure of merit QNOISE,RES,DOSE  shows less 
variation over all centers. The performances of 10 scanners (40-128 slice scanners) were 
approximately equal. Thus for a given dose level, the image quality can be standardized 
in the majority of the participating centers. A prerequisite is that equal reconstruction 
matrix size, a comparable in-plane spatial resolution and slice sensitivity profile is 
present. 
54 | CHAPTER 3
FIGURE 3. Examples of the child phantom scans made with two different CT scanners. a) The 
highest QNOISE, as seen at site 6, and b) the lowest QNOISE, seen at site 16, are both shown with 
window level −400 Hounsfield units (HU) and window width 1500 HU. Notice the influence of 
the edge enhancing reconstruction kernel in b): the outer edges of the phantom appear brighter 
(arrowhead) and outer edges of the lung equivalent tissue appear darker (arrow).
FIGURE 4. Variety of modulation transfer function (MTF) from all centres. The arrow indicates the 
MTF of site 9, with a relatively sharp reconstruction kernel. The dashed line shows an MTF when 
reconstructing with a kernel for quantitative image analysis. Such an MTF does not have values 
larger than unity. 
Five scanners (16-64 slice scanners) performed below average and one scanner (>128 
slice scanner) performed above average. No relation between applied x-ray tube voltage 
and scanner performance was found. These deviations from the average Q-factor might 
be explained by differences in in-plane sampling frequency. The scanners involved 
show differences in the number of detector elements per detector row and rotation 
time, which is directly related to the number of projection measurements per rotation. 
The number of detector elements per detector row is a hardware property of the 
scanner that cannot be changed by the user. The user can change the rotation time, 
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but options are limited. Longer rotation times do improve the sampling frequency and 
thus the performance of the scanner. This appeared to be the case for center 6 that used 
a rotation time of 750 ms and performed better than similar scanners from the same 
manufacturer at rotation times of 400-500 ms. A disadvantage of long rotation times is 
the correspondingly longer total scan time. Alternatively, a site specific dose level might 
be used at centers with scanners that perform below or above average to achieve an 
equal image noise level at all centers.
DISCUSSION
The SCIFI CF project aimed to compare CT scanners and optimize CT protocols for 
children and adolescents with CF. This study showed considerable differences within CT 
protocols among the 16 participating CF centers. All participating centers have received 
a general report and site-specific report including recommendations to optimize their CT 
protocol for (future) clinical trials. Table 1 shows the general guidelines recommended by 
the SCIFI CF. In addition to standardizing CT image quality, we explored the feasibilities 
of standardized lung volume levels acquired during CT scanning as observed by 
Salamon et al.25
TABLE 1. Summary of the recommended guidelines for CT protocols based on this initiative SCIFI 
CF findings
Data acquisition mode Volumetric, helical scan technique
Patient positioning Supine, with arms above the head
CTDIvol
# for inspiratory scan
1 year old
5 years old 
young adult
0.6 mGy
1.0 mGy
2.2 mGy
Field of view As close as possible to the entirety of the lungs, without cutting of the 
lung borders
CTDIvol for expiratory scan 50% lower than inspiratory scan
Tube voltage Low enough such that the recommended CTDIvol can be reached, e.g. 
80 kV
Tube current Adapt to recommended CTDIvol
Pitch <1; lower limit determined by maximum scan time allowed
Slice thickness Thinnest slice thickness e.g. 1 mm
Reconstruction increment 50% overlap e.g. 0.5 mm with 1 mm slice thickness
Kernel for automated analysis Sharp reconstruction filter without under- or overshoot at edges 
preferably a dedicated kernel for quantitative image analysis
Iterative reconstruction technique If available, iterative reconstruction techniques can be applied in 
addition to the requested filtered back projection techniques
Shielding Breast shielding by bismuth for example is discouraged
SCIFI CF: Standardised Chest Imaging Framework for Interventions and Personalised Medicine in Cystic 
Fibrosis; CTDIvol: volumetric computed tomography dose index expressed in mGy. #: in 32-cm body phantom.
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Standardisation of CT became an important aspect in clinical trials and in clinical practice. 
The Quantitative Imaging Biomarkers Alliance (QIBA) working group was founded 
to standardize CT scanners and techniques for diseases such as chronic obstructive 
pulmonary disease (COPD) and asthma.18 CT standardization has also  been performed 
for a large observational COPD study with assessment of CT lung attenuation variation 
between CT scanners and the determination of longitudinal variation for individual 
scanners.33,34 A custom designed phantom for adult patients was developed to perform 
quality control in CT scanners. Another study by Robinson et al., used a Plexiglas airway 
phantom to standardize CT protocols in children with CF.35 This study, however, did not 
have the human equivalent study material to assess the general image quality, such 
as image noise. Both mentioned phantom studies also did not include pediatric sized 
anthropomorphic thorax phantoms to assess the automatic exposure control systems 
of each CT scanner. 
Indication and applied scan technique
This initiative showed that 44% of the centers acquired chest CT scans only on clinical 
indication, while 56% of centers monitor their CF patients routinely with CT. Acquiring 
chest CT scans only on clinical indication could impose missed or delay in diagnosis 
of structural lung changes in a patient. Structural changes can be detected on chest 
CT scans when infants with CF do not express any clinical symptoms.16 It is important 
to identify early pulmonary changes so treatment can be initiated promptly. Diagnosis 
of structural changes, such as bronchiectasis, was estimated to be delayed by 3 years 
when no routine check was performed.36 
Another finding was that 4 centers acquired non-contiguous chest CT scans. For CF lung 
disease, it has been shown that structural abnormalities will be underestimated with 
non-contiguous acquisition.21 In addition, the use of limited slices will make it difficult 
to evaluate progression of lung disease in longitudinal follow up or to reconstruct the 
image in different planes facilitating recognition of anatomical and abnormal structures 
of the lungs. Some centers aim to forego possible radiation risks and radiation exposure. 
However, with the recent improvements in scanning time and reduction in radiation 
exposure of volumetric CTs, the increased benefits of acquiring continuous CTs routinely 
justifies its use.1 Based on the many advantages for the detection and monitoring of 
the heterogeneous CF lung disease we recommend acquiring volumetric CT scans in 
patients with CF and to forego sequential scanning.37   
Finally, chest CT was acquired during spontaneous breathing in most centers when 
children are non-cooperative and with voluntary breath hold when children are old 
enough to cooperate in most centers.  General anesthesia was only used in 2 centers. 
Since more CT scanners currently have short acquisition times, it is possible to acquire 
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images with sufficiently diagnostic quality in spontaneous breathing children. A 
disadvantage of this approach is that the lung will mostly be scanned at a volume level 
near functional residual capacity. Which has been recognized to reduce the sensitivity 
for the detection of bronchiectasis.19
Radiation dose
Based on the applied dose to the phantoms at various sizes for all centers, 
recommended dose levels were derived. As the phantoms have no shoulders, these are 
not very representative of actual patient anatomy. In patients, tube current modulation 
algorithms might increase the dose in the shoulder region. The recommended dose 
levels below are therefore valid for the thorax region away from the shoulder region 
only.
The median radiation dose of 1 mGy applied to the child phantom in all centers is in 
fairly good agreement with previous levels in the literature,1 and this value was typical 
for an ongoing multi-center trial in Australia. We advised all centers to be aware of their 
applied radiation doses in comparison to the median radiation dose used within the 
SCIFI CF initiative. For the majority of scanners, our recommendation is to consider 
adjustment of the radiation dose for a 5 year old child to the median CTDIvol of 1 mGy. In 
this SCIFI CF initiative, we found 10 out of 16 centers to differ more than 40% from the 
median value of 1 mGy. 
The recommended dose for the newborn child was based on the median dose for a 5 
year old child and on the median ratio between the dose for the newborn child and the 
dose for the 5 year old child. Similarly, the recommended dose for the young adult was 
derived. Only two centers deviate 20% or less from the recommended dose for an adult 
CT scan and only two centers deviate 20% or less from the recommended dose for a 
newborn CT. 
The Image Gently campaign provides dose reduction factors in order to establish 
pediatric patient diagnostic reference levels based on established levels for adult size 
patients.27 The reduction factors are given as a function of patient size. Three series 
of reduction factors are provided that result in a ‘limited’, ‘moderate’ or ‘aggressive’ 
reduction of the pediatric patient dose relative to the dose for an adult patient. 
Based on the ‘aggressive’ reduction factors, the recommended dose in a newborn 
and adult would be 64%, and 190% of the dose in a child, respectively. Thus the 
relative dose recommended by Image Gently for a newborn is in agreement with our 
recommendations based on the median relative dose found in this study. The relative 
dose recommended by Image Gently for an adult patient is approximately 15% lower 
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than our recommendation (190% versus 223%). The reduction factors of the Image 
Gently campaign were designed for a community unaccustomed to adjusting the dose 
for children. The ‘limited’ and ‘moderate’ dose reduction factors changed less with size 
than what we found in clinical practice in this study.  Apparently, the centers involved 
in this study are more accustomed to adjusting the dose for children with CF than 
the centers that the Image Gently campaign had in mind while developing the dose 
reduction factors.
 Doses of expiratory CTs were recommended to be 50% lower than an inspiratory CT. 
A different dose level is recommended for 6 out of 16 scanners, to compensate for 
differences in performance of the scanner. 
In 2 centers dose values were extrapolated from a non-contiguous scan. At these 
centers, the CTDIvol value was adjusted automatically in the scanner’s dose report to 
reflect the dose reduction due to non-contiguous scanning. This adjusted value does 
not, however, reflect the dose used for a single image in case of a volumetric scan. 
Therefore the unadjusted CTDIvol value was used in this study instead. We do feel it 
is reasonable to report the relatively high unadjusted values because this makes the 
comparison between sites easy as if every site uses a volumetric scan protocol and these 
2 extrapolated dose values did not affect the median dose level of all centers. Naturally, 
when we reported the DLP values as well, the sites using a non-contiguous scanning 
protocol would not have had such a high dose level. This report indicates however, that 
these sites should consider lowering the dose per image before switching from non-
contiguous to volumetric scanning. The associated loss of image quality is expected to 
be limited as for the same exposure settings; image noise is different in sequential and 
spiral acquisition even for the same reconstruction kernel.
Some centers also discussed the use of breast shielding with a bismuth shield as a 
method to decrease the radiation exposure of the patient. This is not recommended 
as the use of a bismuth shield counteracts with the automatic exposure control used 
in most modern CT scanners, leading to higher and unpredictable radiation doses.38 
Alternatively, by reducing the tube current, similar reductions in radiation dose can be 
achieved with equivalent image noise levels.
Scanner performance
The SCIFI CF demonstrated large variations in image noise among centers (see Figure 
2a and Figure 3) when CT scanner protocols were not standardized. After compensation 
for differences in spatial resolution, differences in image noise will remain (Figure 2b). 
When standardizing both resolution and radiation dose image quality is expected 
to become equal for the majority of scanners (Figure 2c). Remaining differences can 
be compensated for by doubling the recommended dose for the five centers with a 
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QNOISE,RES,DOSE factor 50% below average. Before doing so, the actual influence of the 
reconstruction kernel should be assessed as the equations used in this manuscript were 
predictions on a theoretical model only. The same holds true when lowering the dose 
for the center with a performance above average. It should be noted that image noise, 
spatial resolution, and dose could not be fully characterized by the variables used in 
the equations. The standard deviation of the image noise reflects the noise magnitude 
only. It ignores the spatial correlations introduced into the noise by the reconstruction 
algorithm.39 To minimize the effect of reconstruction filters on the Q factor, the images 
reconstructed with a typical lung reconstruction filter were used for calculating the Q 
values. 
As no relation was found between scanner performance and applied tube voltage, no 
recommendations on the tube voltage to be applied are given. In practice, a relatively 
low tube voltage may be preferred because the relatively low dose levels technically 
cannot be reached at high voltages.
All the SCIFI CF related results have been discussed so far in this guideline. Following 
is some additional recommendations concerning chest CT in children and adolescents 
based on previous literature.  
Selection of scan protocol for clinical studies including image analysis
The scan protocol to be selected depends on the image analysis method that will be 
used. CF lung disease on chest CT has become important to compare individual patients 
longitudinally and cross-sectionally between patients. Several scoring techniques have 
been developed to assess the extent and severity of CF lung disease.15,19,40–43 It has been 
well recognized that adequate scoring methods require a constant image quality and 
standardization. Scoring techniques like the CF-CT40 and PRAGMA15 currently rely on 
visual assessment by an experienced observer, hence the image quality should be on par 
with clinically accepted diagnostic image quality. For the CF-CT method it is essential for 
CTs to be acquired volumetric in order to detect and score the complete lobes. For the 
SALD41 and PRAGMA scoring methods, a volumetric CT is not required per se, as long as 
there are at least 10 slices between the top and bottom part of the lung. However, being 
able to visualize the entire part above and below the structure needed to be scored, 
improves the accuracy of the different lung structures.  For the airway artery method,19,43 
it is crucial to have thin sliced volumetric CTs with an overlapping increment, to allow 
measuring the airway and artery diameters in reformatted slices perpendicular to the 
airway axis. Fewer slices could be an option when measuring the airway and artery 
dimensions in an axial, coronal, or sagittal view only. Reconstructions with 0.5 to 1 mm 
thickness using a sharp reconstruction filter possibly with enhancement of the edges, 
results in images with the impression of a higher resolution. This is needed to detect and 
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manually delineate the smaller airways. Selection of the scoring technique is dependent 
on the endpoint of the (multi-center) trial. Chest CTs of a multi-center trial should be 
scored centrally instead of each center separately. 
Automated image analysis 
Automatic image analysis methods exist and are in development for quantification 
of lung parenchyma,44,45 air trapping,44 and airway properties.46–49 These methods can 
replace time-consuming manual annotations, and are capable of obtaining a much 
larger number of high precision measurements at any point of the airway structure or 
lung without additional costs. Because of their automatic nature, measurements are 
always performed in the exact same way and will not be influenced by inter- and intra-
observer variability issues.
Automatic methods rely on mathematical models that characterize the CT image 
properties. A high degree of homogeneity between analyzed images is often 
required. Consequently, small variations in acquisition protocols or inspiration level, 
barely perceivable to the human eye, can largely affect the obtained measurements. 
Therefore standardization of inspiration level and image acquisition protocol is very 
important when automated image analysis methods are used, even more so than 
for visual inspection. The requirements to the image acquisition protocol differ for 
different automated analyses. Quantification of trapped air and consolidation based on 
CT intensity values can be performed in thicker slice and soft reconstructions, while 
quantification of the airway walls, identification of the lobes, and characterization of 
parenchymal texture patterns benefit from thin slices and a sharper reconstruction, 
showing more detail. For all automated image analysis purposes, we recommend to 
store thin-slice reconstructions (≤1 mm slice thickness) with overlapping slices with a 
relatively sharp reconstruction kernel. The reconstruction kernel should be as sharp as 
possible, without under- or overshooting (overenhancing). Then, if desired, thick-slice 
resampling or image denoising can be easily performed as image post-processing. 
Because each automatic method relies on different image assumptions, the ideal kernel 
may vary from technique to technique. A safe choice would be a dedicated kernel for 
quantitative image analysis as shown in Figure 4 with the dashed line. All the lung 
kernels we had analysed deviated strongly from this kernel.
To conclude, in order to optimise the image properties for automated image 
analysis, a careful selection of reconstruction kernel and a high level of image quality 
standardization are required to balance between radiation dose and image quality.
For clinical practice there are currently no automated analysis methods available. Using 
a spirometer controlled volumetric scan protocol allows to compare with great precision 
slice per slice to detect changes between the most recent scan and previous scans. It is 
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strongly recommended to use structured reporting to improve consistency between 
and within radiologists. These reports should at least include the components used in 
the scoring systems.50   
Iterative reconstruction techniques
Iterative reconstruction techniques are more and more commonly applied in clinical 
practice. Often a dose reduction is reported when switching to these techniques.51 
Since effect of iterative reconstruction on (automated) image analysis is not yet known, 
it is recommended to store a second reconstruction using filtered back projection aside 
from the iterative reconstruction kernel. Most importantly large dose reductions should 
be avoided when compared to the recommended dose levels in Table 1. 
CONCLUSION
In conclusion, considerable variation was found in radiation dose applied in the 
pediatric CF population among European centers. This difference cannot be explained 
by differences in scanner performance. Specific CT protocols are needed to balance 
between radiation dose and image quality in both clinical practice as for research 
purposes. With increasing demand for more sensitive outcome measures in upcoming 
clinical trials the SCIFI CF project shows that standardization of chest CT is required and 
more importantly feasible in a multi-center cohort. 
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APPENDIX
APPENDIX FIGURE 1. Questionnaire sent to all 30 ECFS-CTN centers for inventory and 
participation with the SCIFI CF initiative. 
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ABSTRACT  
Objectives
To quantify airway and artery (AA)-dimensions in CF and control patients, for objective 
CT diagnosis of bronchiectasis and airway wall thickness (AWT).
Methods
Spirometer guided inspiratory and expiratory CTs of 11 CF and 12 control patients 
were collected retrospectively. Airway pathways were annotated semi-automatically 
to reconstruct 3-Dimensional bronchial trees. All visible AA-pairs were measured 
perpendicular to the airway axis. Inner, outer, and AWT (outer minus inner) diameter 
were divided by the adjacent artery diameter to compute AinA-, AoutA-, and AWTA-ratios. 
AA-ratios were predicted using mixed-effects models including disease status, lung 
volume, gender, height, and age as covariates. 
Results
Demographics did not differ significantly between cohorts. Mean AA-pairs CF: 299 
inspiratory; 82 expiratory. Controls: 131 inspiratory; 58 expiratory. All ratios were 
significantly larger in inspiratory compared to expiratory CTs for both groups (p<0.001). 
AoutA-, and AWTA-ratios were larger in CF than in controls, independent of lung volume 
(p<0.01). Difference of AoutA-, and AWTA-ratios between patients with CF and controls 
increased significantly for every following airway generation (p<0.001).
Conclusion
Diagnosis of bronchiectasis is highly dependent on lung volume and more reliably 
diagnosed using outer airway diameter. Difference in bronchiectasis and AWT severity 
between the two cohorts increased with each airway generation.   
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INTRODUCTION 
In cystic fibrosis (CF), lung disease is characterized by progressive bronchiectasis (BE) 
and airway wall thickening (AWT).1–3 Chest computed tomography (CT) is the most 
sensitive tool to diagnose BE and AWT, which are important outcome measures for both 
clinical and research purposes.1,4 
BE is defined as destructive and irreversible widening of airways with a ratio between 
airway and accompanying artery (AA) above 1 in adults.5,6 Currently, the inner airway 
dimensions are mostly used for comparison with the artery.7–9 However, no clear 
consensus, based on objective quantitative measures, exists on whether inner or 
outer airway diameter should be compared with the artery for the diagnosis of BE.10 
Nonetheless, the approximate ratio of one was based on the outer airway diameter.11 In 
addition, it is not clear whether identical AA-ratios cutoffs can be used to define BE in 
children, where smaller AA-ratio has been suggested.5 Lastly, the AA-ratio is thought to 
increase with age in healthy subjects.12 
AWT like BE is associated to airway inflammation.13,14 AWT is presumed present when 
the airway wall diameter occupies more than 20% of the total outer airway diameter15 
or takes up more than 33% of the adjacent arterial diameter.8 CT assessments of BE and 
AWT are mostly performed in the axial or coronal plane by comparing airway diameter, 
to the accompanying artery diameter. However, to avoid inaccuracy caused by the 
parallax or projection error, the AA dimensions should ideally be evaluated in a view 
perpendicular to the airway centerline.16–18
Airway dimensions are routinely evaluated on inspiratory CT.19 Unfortunately lung 
volume levels during  inspiratory CT acquisition have shown to vary widely between 55 
and 106 % of the measured total lung capacity (TLC) obtained via body plethysmograph.20 
This variability is caused by a lack of breath hold standardization and influences the AA-
ratio and therefore diagnosis of bronchiectasis.7,21,22 Airway dimensions assessed on axial 
view were shown to be highly dependent on the lung volume levels in children below 
the age of 5 years with CF 7, in adults with COPD,23,24 and in healthy controls.22 Hence, 
suboptimal lung volume levels negatively impact objective evaluation of BE and AWT.
The purpose of our study was to develop objective criteria to diagnosis BE and AWT in 
children by comparing AA dimensions between CF patients and control patients with 
spirometer guided CTs. We hypothesized that AA-ratios are increased in pediatric CF 
patients and more prominent on inspiratory CTs. To investigate this, we aimed to assess 
1) AA dimensions in control patients; 2) use of inner or outer airway diameter as a more 
sensitive biomarker to diagnose BE; 3) influence of inspiratory and expiratory CTs on 
AA dimensions. Between CF and control patients we aimed to assess: 4) differences in 
number of visible AA-pairs and AA dimensions; 5) differences by airway location (e.g. 
lobes and airway generations).
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MATERIALS AND METHODS 
This study was approved by institutional review board (MEC-2014-254). Written informed 
consent was waived for all patients because of the retrospective nature of the study.
Study population
Spirometer guided inspiratory and expiratory chest CTs of 11 CF patients and 12 control 
patients without lung abnormalities on CT made between 2007 and 2012 were selected 
retrospectively. All patients were treated at [blinded]. 
CF patients. Inclusion criteria: diagnosis of CF; age between age 6 and 16 years, 
spirometer guided chest CT acquired with SOMATOM® Definition Flash CT scanner 
(Siemens Healthcare, Forchheim, Germany); Slow vital capacity during CT for inspiratory 
CT ≥85% and expiratory CT ≥80% as recommended and described by Salamon et al.25 
Exclusion: poor image quality due to motion artifacts; poor breath hold performance 
as judged by lung function technician. 12 CF patients were randomly selected out of all 
patients that met the selection criteria. 
Control patients. Inclusion criteria: good or excellent spirometer guided chest CT 
acquired with SOMATOM® Definition Flash scanner; clinical reason for CT other than CF; 
report by [blinded] radiologist stating chest CT to be normal; defined normal on second 
reading by an independent radiologist (CY, 20 years of experience in thoracic imaging) 
blinded to patient identifiers and information. Out of 16 control chest CTs that met 
above mentioned criteria, 12 CTs were selected with best matched ages of CF group. 
More detailed control group characteristics are provided in Table 1.
CT scanning
End-inspiratory and end-expiratory volumetric chest CTs were obtained in supine 
position. Details of scan parameters are provided in Table 2.  
Quantitative analysis of airways and arteries
All CTs were scored in random order using the CF-CT scoring system, to quantify 
structural CT abnormalities in CF and controls as described in more detail separately.26 
Dimensions of AA-pairs were measured using Myrian® (v1.16.2, Lung XP module) 
image analysis platform (Intrasense, Montpelier, France) and described previously.26 In 
summary, airway pathways were indicated automatically. Pathways of additional lobar, 
segmental and subsegmental airways not automatically indicated were added manually. 
The bronchial tree was reconstructed in a 3D-view (Appendix video-E1), and cross-
sectional CT reconstructions were generated based on the airway’s centerline (Figure 
1). One measurement per branch was made when both airways and artery were clearly 
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visible. AA-pairs with movement artefacts or too much noise for reliable measurements 
were excluded. In addition, AA-pairs of airways that did not show a visible inner lumen 
(e.g. due to mucous plugging) and airways without a clear identifiable adjacent artery 
(e.g. due to atelectasis or severe cystic bronchiectasis without a traceable artery) were 
excluded.
Inner and outer airway diameters were divided by artery diameter to compute AinA 
and AoutA-ratio, respectively. Wall thickness (difference between outer and inner airway 
diameter) was divided by outer airway diameter to compute AWT-ratio; and divided by 
artery diameter to compute AWTA-ratio.
TABLE 1. Diagnosis of control subjects
Clinical diagnosis Reason for CT Findings No of subjects
Asthma Air trapping, bronchiectasis, 
malacia?
No air trapping, no 
bronchiectasis, no malacia
8
Recurrent respiratory 
infections
Air trapping, bronchiectasis, 
malacia?
No air trapping, no 
bronchiectasis, no malacia
3
Condition after esophageal 
atresia
Tracheomalacie? No tracheomalacie 1
TABLE 2. Scan parameters used to obtain the CTs
CF subjects Control subjects
Scan acquisition Insp Exp Insp Exp
Tube voltage (kV) 80 80 (80-120) (80-120)
Pitch 0.85 0.85 0.85 0.85
Slice thickness (mm), median (range) 1 (0.75-1) 1 (0.75-1) 1 1
Reconstruction increment (mm), 
median (range)
0.6 (0.3-1) 0.6 (0.3-1) 0.8 (0.6-0.8) 0.8 (0.6-0.8)
Reconstruction kernel B70f;B75f B70f;B75f B75f; I70f B75f;I50f
Collimation 128x0.6 128x0.6 128x0.6 128x0.6
Current-time product (mAs), median 
(range)
46 (36-52) 44 (35-53) 28 (11-61) 23 (8-65)
CTDIvol,32 cm (mGy), median (range) 0.74 (0.57-0.83) 0.71 (0.56-0.84) 0.76 (0.32-1.13) 0.56 (0.24-1.05)
DLP(mGy * cm), median (range) 21 (14-28) 17 (11-25) 22.5 (7-38) 14.5 (5-30)
Location of airway artery measures
The lung lobes (right upper (RUL), right middle (RML), right lower (RLL), left upper (LUL), 
left lower lobe (LLL) and lingula (LING)), segmental bronchi (nomenclature as depicted 
by Netter 27), and airway generations were annotated for each AA measurement. Airway 
generation started at the trachea as 0, the main stem bronchi as 1 and continuing after 
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each time the bronchi bifurcates. The upper segmental bronchi begins at generation 
3-4 and lower segmental bronchi begins at generation 4-7. The generation from each 
segmental bronchi as described in Appendix Figure E2a was subtracted from the airway 
generation to compute the segmental generation starting at 1 (see Figure 2). Segmental 
generation ≥ 4 were defined as peripheral airways for the purpose of this paper.
FIGURE 1. The three measurements of the airway and accompanying artery in a perpendicular 
view to the pathway centerline, using an ellipse image analysis tool (Myrian®). The annotated 
surface areas of the inner (#3) and outer (#2) airway and of the artery (#1) were used to estimate 
diameters and to calculate the AA-ratios. The location of all AA-pairs was determined by the use of 
the 3D segmentation (videos of rotating 3D segmentations in color can be found in Appendix E2).
FIGURE 2. The segmental branches are shown in the different colors and the numbering stands 
for each segmental airway generation. The segmental generation ensured all segmental bronchi 
to start at segmental generation 1 avoiding discrepancies in the upper and lower segmental 
airway generations as demonstrated in Appendix Figure E2 (Artist: K. Rubenis).
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Observer reliability
CTs of all patients were anonymized and randomized before scoring. The scorers were 
blinded to all clinical information. All AA measurements were conducted by the first 
observer (WK, 3 years of experience). After 3 months, a total of 386 measurements were 
repeated in one randomly selected segmental branch of every patient to establish intra-
observer variability. A second observer measured a total of 2945 AA dimensions in a 
random subset of 25 CTs (HO, 1 year of experience) in order to determine inter-observer 
variability.
Statistical Analysis
Difference between patients’ characteristics in the two cohorts were assessed with Mann-
Whitney U test. Difference in number of AA-pairs visible was assessed using Wilcoxon 
signed-rank test. Relationship between number of AA-pairs visible with height and age 
was evaluated with linear regression analysis. Mixed-effect models were used to predict 
AA-ratios using disease status and lung volume. Influence of other covariates (i.e. 
gender, age, and height) on AA-ratios was assessed univariately. Univariate covariates 
found to be significant were added with interaction to the main model. Variable 
selection in the main model was performed with a likelihood ratio test. Mixed-effect 
models were used to evaluate differences between CF and controls and volume level 
predicting AA-ratios for each segmental generation and lung lobes. Random-effects of 
lobes and individuals were included in all mixed-effect models to capture heterogeneity. 
For diagnosis of bronchiectasis receiver operating characteristics (ROC) curves with the 
corresponding area under curves (AUCs) and 95% confidence interval (CI) were plotted 
to identify the threshold values for AinA and AoutA-ratios with the highest combined 
sensitivity and specificity. The intraclass correlation coefficient (ICC) was used to measure 
inter- and intra-observer agreement, with the use of mixed-effects models. In these 
mixed-effects models the structure was taken into account specifically the segmental 
branches within generation within patients. ICC values between 0.4 and 0.6, 0.6 and 
0.8 or ≥ 0.8 were considered to indicate moderate, good and very good agreement, 
respectively.28 
Results were expressed as median, interquartile range (IQR). A p-value of 0.05 or less 
was considered significant. All analysis were conducted using R version 3.1.0.29 
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RESULTS
Study population
A detailed description of the group characteristics is shown in Table 3. One subject in the 
CF group was excluded after image analysis since the patient appeared to be mislabeled 
and diagnosed with common variable immunodeficiency. Hence, 11 patients with CF 
(6 males) were included for further analysis with a median age of 11 years. 12 control 
patients with normal CTs (7 males) were included with a median age 13.9 years. All but 
one control patient had spirometry performed on the same day or maximally one month 
apart from the CT scan. One control patient did not have a recent spirometry available, 
so spirometry of 8 months prior to the CT was used. Re-analysis without this subject 
did not influence difference between the groups in demographics or spirometry. No 
significant difference was found in age, gender, height, weight, and PFT’s between the 
two groups. All CF-CT scores were significantly higher in CF compared to the control 
group.
TABLE 3. Demographics of the CF and normal cohort
Patients with CF, 
median (IQR) 
Control patients,  
median (IQR) P –value
Age at CT (years) 11 (9.3-11.1) 13.9 (8.7-15) 0.385
Age at PFT (years) 11 (9.3-13) 13.9 (8.7-15) 0.385
Time between CT and PFT (months) 0.0 (0.0-0.0) 0.5 (0.1-0.7) 0.011*
Gender 6 males; 5 females 7 males; 5 females 0.808
Height (cm) 144.4 (138.2-146.8) 149 (136.6-170.9) 0.296
Weight (kg) 34.5 (30.4-45.3) 40.1 (28.6-65.8) 0.461
BMI 17.5 (15.5-19.4) 18.1 (15.9-20.2) 0.435
CF-CT BE score (%) 5.2 (1.4-12.1) 0.0 (0.0-0.7) <0.001*
CF-CT AWT score (%) 5.6 (0.0-19.3) 0.0 (0.0-0.0) <0.001*
CF-CT MP score (%) 2.8 (0.0-22.9) 0.0 (0.0-0.0) <0.001*
CF-CT AT score (%) 51.2 (25.9-66.7) 3.7 (0.0-8.3) <0.001*
CF-CT total score (%) 7.8 (6.2-18.4) 1.2 (0.4-1.4) <0.001*
FEV1 (z-scores) -1.3 (-2.2-0.1) -1.7 (-2.1- -0.4) 0.668
FVC (z-scores) -0.1 (-1.2-0.8) -0.4 (-2.3-0.8) 0.409
FEV1/FVC 0.82 (0.76-0.83) 0.82 (0.70-0.91) 0.385
FEF25-75 (z-scores) -1.8 (-2.3- -0.6) -1.4 (-2.5- -1) 0.939
Wilcoxon signed rank test to test the difference in demographics between the CF and control group. CF-
CT scores of mucous plugging (MP), air trapping (AT), and the total score were compared as well as CF-CT 
scores of BE and AWT. Spirometry was compared using Z-scores according to Quanjer et al. 41. PFT: pulmonary 
function test, BMI: body mass index, FEV1: forced expiratory flow in 1 s, FVC: forced vital capacity, FEF25-75: 
forced expiratory flow during the 25-75% portion of the FVC
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Quantitative analysis of airways and arteries
A total of 6464 AA-pairs were measured in perpendicular view of the airway axis. In CF 
patients a mean of 299 AA-pairs were measured on end-inspiration and 82 AA-pairs on 
the end-expiration CTs. In control patients a mean of 131-pairs were measured on end-
inspiration and 58 AA-pairs on the end-expiration CTs. Number of visible AA-pairs was 
significantly higher in inspiration compared to expiration CTs in both CF and control 
group (p<0.001). This difference is especially prominent after segmental generation 4 
(Figure 3). CF patients had significantly more visible AA-pairs (p<0.001) than controls in 
inspiratory CTs, but not in expiratory CTs (p=0.54). As seen in Figure 3, patients with CF 
have a large number of visible AA-pairs in higher generations (8 to 12), whereas control 
patients had none. Number of AA-pairs counted was not correlated with age (p=0.72) 
or height (p=0.77).
FIGURE 3. Average number of AA-pairs visible per segmental generation for controls (green) and 
CF patients (red), separated by inspiratory (light colors) and expiratory (dark colors) CT. Note that 
the total number of visible airways on the inspiratory scans in CF is increased relative to controls. 
Airway-artery dimensions
Median (range) of the inner, outer, wall and vessel diameter were 1.65 (0.36-6.58), 3.74 
(1.00-9.84), 2.08 (0.50-6.28), and 3.42 (0.94-11.99) mm respectively (Appendix Figure 
E3).  AinA- and AoutA-ratio was independent of age in both CF and controls (Figure 4). 
Gender, age and height were not significantly related with AinA, AoutA or AWTA-ratio in 
an univariate mixed-effect model. Height, but not gender and age, was found to be 
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significant in the mixed-effect model with AWT-ratio (p=0.001), so height was included in 
the model describing AWT-ratio. 
AinA, AoutA, AWT and AWTA-ratios differed significantly on inspiratory CTs compared to 
expiratory CTs for both CF and control groups (P<0.001). The significant differences in 
AA- and AWT-ratios between CF and control patients are shown in Table 4.
FIGURE 4. The AA-ratio is plotted as a function of age, for AinA (left) and AoutA (right). The CF 
patients are depicted as black X and dashed line and the control patients as gray O and solid lines. 
AinA-ratio remained constant with increasing age in the CF (value=0.010, p=0.28), and control 
group (value=0.006, p=0.22). The AoutA-ratio in the CF group (value=0.026, p=0.10), and control 
group (value=0.002, p=0.52) do not increase significantly either with age. 
TABLE 4. Comparison of airway dimensions between CF patients and controls 
Significant difference between 
disease status (Control/CF) AinA-ratio AoutA-ratio AWTA-ratio AWT-ratio
Inspiration 0.156 <0.001* <0.001* 0.215
Expiration 0.996 0.003* <0.001* 0.036*
P-values of mixed-effect model analysis of differences between airway dimensions between CF and control 
patients. AoutA and AWTA -ratios were higher in CF than controls in both inspiratory and expiratory scans. AinA-
ratios was not significant and the AWT-ratio only in the expiratory subgroup. * indicantes significance
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FIGURE 5. Boxplots of the AA-ratios in the control group (green) and in the cystic fibrosis (CF) group 
(red) for each segmental generation. Inspiratory scans are shown in light colours and expiratory 
scans in dark colours. Each box shows median (horizontal line), interquartile range (solid box), 
1.5*interquartile range (whiskers) and outliers (points). a When focusing on the inspiratory scans, 
an increasing difference can be found in AoutA- ratio between the CF and control group from 
generation 2 to generation 6 (increasing difference of 0.08–0.19, p≤0.02). The difference between 
CF and the control group of the AoutA-ratio in the expiratory scans was found to be significant from 
generation 2 to 5 (difference of 0.13–0.15, p≤0.04). b On the inspiratory scans, a difference can be 
found in AWTA-ratio between the cystic fibrosis (CF) and control groups starting from segmental 
generation 1 to 6 (difference of 0.05–0.12, p≤0.04). The difference in AWTA-ratio between CFand 
the control group in the expiratory scans was found to be significant from generation 1 to 5 
(difference of 0.08–0.13, p≤0.003). c There was no difference in AinA-ratio between the cystic 
fibrosis (CF) and control groups on inspiratory CTs (p≥0.08), neither was there for the expiratory 
scans (p≥0.28). A difference in AinA-ratio was observed between inspiration and expiration CTs of 
both the CF (difference of 0.12–0.20, p≤0.04) and control group (difference of 0.13–0.14, p≤0.001). 
d There was no difference in AWT-ratio between the cystic fibrosis (CF) and control groups in all 
segmental generations on the inspiratory CTs. On expiratory CTs only a difference was found in 
segmental generation 1 (difference of 0.05, p=0.021). An apparent difference was found between 
inspiratory and expiratory scans in AWT-ratio for the CF group (0.08–0.11, p≤0.001), as well for the 
control group (0.09– 0.15, p≤0.001) in all segmental generations (all absolute values can be found 
in Appendix Table E1a–d).
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Comparison CF vs control group
The optimal threshold to define BE was reached at a value of 0.5 for AinA-ratio and 1.11 
for AoutA-ratio. AUC (95% CI) for AinA was 0.6 (0.59-0.61) and 0.72 (0.71-0.74) for AoutA-ratio 
(Appendix Figure E4). The optimal threshold for BE of peripheral airways (segmental 
generation≥4) was 0.56 for AinA-ratio (AUC=0.63, 95% CI=0.61-0.65) and 1.17 for AoutA-
ratio (AUC= 0.75, 95% CI=0.73-0.77).
Location of airway and artery measures
Figure 5A and B show AoutA and AWTA-ratio by segmental generation. The difference in 
AoutA and AWTA-ratio between inspiratory CF and controls was significant for segmental 
generation 2 to 6 (p≤0.02). Difference of AoutA between patients with CF and control 
patients became larger with each following segmental generation. AinA and AWT-ratio did 
not differentiate significantly between CF and control group on inspiratory CT in each 
segmental generation (Figure 5C, D). More detail on the differences and significance 
values by each segmental generation can be found in Appendix Table E1a-d.
Quantitatively, bronchiectasis has an upper lobe predominance. Appendix Table E2a-d 
shows the detailed results of the mixed-effect model regarding the different lung lobes. 
In both CF and control patients, AoutA-, AWTA-, and AWT-ratio was significantly higher in 
RUL compared to all other lobes (p<0.001). In CF patients, AoutA- and AWTA-ratio was 
significantly higher in LUL compared to right middle lobe (RML), right lower lobe (RLL) 
and left lower lobe (LLL) (p<0.001). LLL was significant lower than all other lobes for 
AoutA-, AWTA-, and AWT-ratio in CF patients (p≤0.004).
Reproducibility of airway measurements
For the inter-observer variability, ICC for AA dimensions were as follows: Inner airway 
(0.69), outer airway (0.72), wall (0.66) and vessel diameter (0.69). For the intra-observer 
variability, ICC for the different dimensions were as follows: Inner airway (0.70), outer 
airway (0.74), wall (0.71) and vessel diameter (0.79).
DISCUSSIONS 
To our knowledge, this is the first study measuring all visible AA-pairs perpendicular to 
airway centerlines in maximal inspiration and expiration CTs of CF patients and control 
patients. Major differences were observed in number of visible AA-pairs and in AA-ratios 
between inspiratory and expiratory CTs and between CF patients and control patients.
Our study showed that end-inspiratory CTs were most sensitive to detect structural 
airway disease. Overall 2 to 3 times more AA-pairs were detected on end-inspiratory 
CTs of a patient with CF than on CTs of controls. Difference in number of visible AA-pairs 
became more striking with each generation. Beyond the 7th segmental generation, AA-
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pairs were still visible in CF but not in control patients. Our study confirms that number 
visible of AA-pairs could be used as a surrogate outcome for bronchiectasis.26,30–32 
Nevertheless, it is important to keep in mind that the number of visible airways can 
be affected by patient size as well as inspiration level and scan protocol. In this study, 
patient size did not influence the number of AA-pairs counted and scan protocol did not 
play a role as inspiratory CTs of both CF and control patients were scanned using the 
same scanner and protocols.
AoutA and AWTA-ratios on inspiratory CTs progressively increased with segmental 
generation in CF subjects, while they remained relatively constant over generations in 
control subjects. Increased AA-ratios and higher number of visible peripheral airways 
suggests more structural abnormalities due to CF lung disease in the more peripheral 
airways compared to central airways. These are findings that to our knowledge have 
not been established by quantitative assessment previously and strongly support the 
importance of peripheral airways in CF lung disease.32–35 An increase in visible AA-pairs 
or in AA-ratios might, however, easily be missed on visual routine CT. 
AA-ratio based on outer airway diameter was more sensitive to detect BE compared to 
inner diameter as demonstrated by the higher AUC in the ROC curve. Furthermore, the 
AoutA-ratio was less influenced by the inspiration level compared the AinA-ratio. Lastly, AinA-
ratio could not differentiate between CF and controls within all segmental generations. 
This can be explained by simultaneous airway wall thickening due to inflammation and 
mucus impaction, leading to decreased AinA-ratio. This finding supports previous
11 and 
recently published guidelines12,26 that rely on outer airway diameter for diagnosis of 
bronchiectasis on CT. A lower AA-ratio was reported in children by Kapur et al,5 but this 
was based on inner luminal diameter instead of the outer diameter. In our dataset, an 
AA-ratio based on outer diameter of 1.1 was optimal to differentiate between normal 
and abnormal. However AoutA-ratios above 1.1 were found in the control group as well. 
Number of AA-pairs visible and AA-ratios between the groups were only significantly 
different in end-inspiration and not in end-expiration CT. Additionally AWT values were 
higher in end-expiratory CTs, possibly due to folding of the airways in expiration.33 Thus, 
in case an ‘inspiratory’ CT is performed below TLC, number of bronchiectatic airways will 
be underestimated. On the other hand AWT increased and became more apparent in 
end-expiratory. Hence, when lung volume is below TLC during CT acquisition, AWT could 
be overestimated. These findings strongly support the need for volume control during 
acquisition to allow consistent, sensitive, and objective detection of BE and AWT.7,25 
In control patients the AA-ratio did not change significantly with age as also reported 
in previous studies.5,21 In CF a trend was observed of an increasing AoutA-ratio  with age, 
which can be due to disease progression. Nevertheless, we dealt with a small sample 
size, thus, a larger study population is needed to investigate changes of the AA-ratios 
by age. 
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Higher AoutA-ratios were observed in the upper lobes, especially the RUL. This observation 
is in concordance with previous publications observing more severe abnormalities and 
inflammation in the RUL of CF patients.13,36,37 Hence, bronchiectasis detection most likely 
has to take lobes into account. Intra-subject differences in airway dimensions between 
lung lobes have previously been reported in COPD patients,23,24,38 and control subjects.22 
Our study has several limitations. First, the control patients were not healthy as they 
were referred for chest CT through the pediatric respiratory department. Even though 
all CTs were reported to be normal by two independent radiologists, we cannot exclude 
that subtle changes in AA dimensions could have influenced our comparisons. Secondly, 
scan and reconstruction parameters were not identical in all CTs of this retrospective 
study. In theory this could have caused a small bias, but we believe this the bias to be 
small at most since there was no automated post-processing involved in detecting the 
airway and artery dimensions, but instead they were measured manually with an ellipse 
tool. However, it is unlikely that these limitations can explain the large differences found 
between CF and control patients. Importantly, a constant AA-ratio was observed for each 
airway generation in control patients while this ratio steadily increased in CF. Moreover, 
the CF-CT scored almost no abnormalities in control subjects, except for some trapped 
air which can be physiologic in healthy patients.39 A second limitation is that we only 
studied a relatively small population. This was due to the time needed to manually score 
all 48 inspiratory and expiratory CTs (average of 15 hours per scan). However, a large 
number of AA-pairs could be measured to test our research questions. Thirdly, radiation 
dose for expiratory CTs was lowered after 2012, in 5 out of 12 control patients. This 
reduced the sensitivity of measurements and could have reduced the number of visible 
AA-pairs, leading to overestimation of the effect of inspiration level in control patients. 
Finally, reproducibility of single AA measurements was hard to assess as repeated 
manual measurements were unlikely to be measured at identical anatomical locations, 
causing variability. However ICC’s showed good inter- and intra-observer agreements.  
In conclusion, the results of this study showed greater structural lung changes with each 
airway generation on chest CTs of children with CF. In children with CF, more airways 
were visible on CT due to the increase of AA-ratios in the peripheral part of the lungs. 
For diagnosis and quantification of BE outer airway diameter should be used, as this is a 
better differentiator between CF and control patients. Our findings strongly support the 
need for volume standardization in chest CTs of children 6 years and above, for objective 
and sensitive evaluation of airway dimensions.7 To generate reference values for airway 
dimensions in children, a larger study population of normal chest CTs acquired at TLC is 
needed. Automatic methods to quantify bronchiectasis are in development to support 
clinicians’ diagnosis and reduce the time of annotations.40
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APPENDIX
MATERIAL AND METHODS
Appendix E1
CF subjects: Patients with CF were monitored routinely with a biennial chest CT. 
Since 2007, a protocol for spirometer guided inspiratory and expiratory chest CT was 
introduced for all chest CTs to optimize and standardize lung volume and reduce 
movement artefacts. Consequently all CTs of CF patients were spirometer guided 1. 
Disease control subjects: Indication for CTs in this control group can be found in Table 1. 
Pulmonary function test
Routine pulmonary function tests (PFT) were performed in all CF patients and controls. 
For both groups PFT closest to, or on the same day, of CT acquisition was used for 
analysis. The following parameters were included and expressed as Z-scores: FEV1, FVC, 
forced expiratory flows between 25 and 75% of expiratory VC (FEF25-75) 
2. Age at the day 
of the CT was used to define patient characteristics.  For height and weight we used 
values as recorded at the time of PFT.  
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APPENDIX VIDEO E1. Screen-shot of the video with rotating 3D segmentations. The full video 
can be found with the published article online: https://link.springer.com/article/10.1007%2
Fs00330-017-4819-7 
APPENDIX FIGURE E2. Anatomy of the airways. The segmental branches are shown in the 
different colors and the numbering stands for the airway generation. Each segmental branch 
starts with a different generation, eg generation 3-4 in the upper segmental branches whereas it 
starts at generation 4-7 in the lower segmental branches (Artist: K. Rubenis).
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Appendix Figure E4. ROC curves to distinguish between patients with CF and control subjects 
show that AoutA-ratio (right) had better detection capability than AinA-ratio (left). The gray stars 
indicate the AA-ratio with optimal sensitivity + specificity.
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ABSTRACT 
Objective
To evaluate lung disease progression using airway and artery (AA) dimensions on chest 
CT over 2-year interval in young CF patients longitudinally and compare to disease 
controls cross-sectionally.
 
Methods
Retrospective analysis of pressure controlled end-inspiratory CTs: 12 routine baseline 
(CT1) and follow up (CT2) from AREST CF cohort; 12 disease controls with normal CT. All 
visible AA-pairs were measured perpendicular to the airway axis. Inner and outer airway 
diameters and wall (outer - -inner radius) thickness were divided by adjacent arteries to 
compute AinA-, AoutA-, and AWTA-ratios, respectively. Differences between CF and control 
data were assessed using mixed effects models predicting AA-ratios per segmental 
generation (SG). Power calculations were performed with 80% power and α=0.05.
 
Results
CF: median age CT1 2 years; CT2 3.9 years, 5 males. Controls: median age 2.9 years, 
10 males. Total of 4798 AA-pairs measured. Cross-sectionally: AinA-ratio showed no 
difference between controls and CF CT1 or CT2. AoutA-ratio was significantly higher in 
CF CT1 (SG 2-4) and CT2 (SG 2-5) compared to controls. AWTA-ratio was increased for CF 
CT1 (SG 1-5) and CT2 (SG 2-6) compared to controls. CF longitudinally: AinA-ratio was 
significantly higher at CT2 compared to CT1. Increase in AoutA-ratio at CT2 compared to 
CT1 was visible in SG≥4. Sample sizes of 21 and 58 would be necessary for 50 and 30% 
AoutA-ratio reductions, respectively, between CF CT2 and controls. 
 
Conclusion
AA-ratio differences were present in young CF patients relative to disease controls. 
AoutA-ratio as an objective parameter for bronchiectasis could reduce sample sizes for 
clinical trials.
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INTRODUCTION 
Most patients with cystic fibrosis (CF), develop progressive structural lung disease (SLD) 
early in life.1 SLD on chest computed tomography (CT) has been observed as early as 
3 months of age, and in young asymptomatic patients with CF.2,3  Early detection of 
SLD is considered important for clinical studies and for treatment guidance to prevent 
irreversible SLD or progression.4–6 Therefore, sensitive outcome measures are needed to 
monitor lung disease in young and non-cooperative patients with CF.7 
Chest CT is currently the most sensitive imaging modality to assess SLD. The most 
important structural change related to CF is bronchiectasis, usually defined as an 
airway artery (AA)-ratio greater than one. Another important change is airway wall 
thickening.8–10 Both components have been objectively quantified on chest CT by 
measuring airway and adjacent artery dimensions perpendicular to the airway axis11 
and showed good correlations with CF-CT and PRAGMA-CF scoring systems.12 Using 
this AA-method in children with CF aged 6 years and older, major differences in AA-
ratio and airway wall thickness were observed in our previous study,11 particularly in 
the small airways. In addition, to diagnose bronchiectasis the outer airway diameter 
was more reliable than the inner airway diameter11 and the sensitivity of inspiratory 
scans to diagnose bronchiectasis was better compared to expiratory CTs.11 Airway 
wall thickness, however, could be detected on both inspiratory and expiratory CTs. 
Lastly, the number of AA-pairs was shown to be more than doubled in patients with 
CF relative to controls.11 Hence, the AA-method seems to be a promising, sensitive 
quantitative method to detect structural airways changes that could be used as an 
outcome measure in clinical intervention trials. A sensitive method to detect changes is 
required in particular, for children below 6 years old in whom CT changes can be subtle 
and for whom interventions to prevent development and/or progression of disease 
are highly desirable. To gain further insight regarding this approach, AA-ratios on CTs 
were measured in a small group of pre-school children with CF and control subjects 
showing promising results.3,13 Limitations of previous studies were that measurements 
were executed on limited number of axial slices introducing a projection error, and only 
a small number of detectable AA-pairs was analyzed. 
The aims of this study were to objectively assess early airway changes on chest CTs 
of young CF patients using the same AA-method as used for children above 6 years 
old,11,12 and to estimate the sensitivity of the AA-method which could be used as a 
sensitive outcome measure to detect structural airway changes in CF, relative to disease 
controls. We hypothesized that the AA-method is sensitive to detect changes in airway 
dimensions of small airways and that the AA-ratio is greater in young children with CF 
compared to disease controls. 
100 | CHAPTER 5
METHODS 
Study population
Chest CTs of 12 randomly selected patients with CF from the Australian Respiratory 
Early Surveillance Team for Cystic Fibrosis (AREST CF) cohort with two CTs 2 years apart 
were analyzed retrospectively. Additionally chest CTs of 12 disease control patients 
were included for cross-sectional comparisons to CF. All patients were treated at the 
Princess Margaret Hospital, Perth, Australia. 
CF subjects: Patients with CF diagnosed through newborn screening were monitored 
routinely with annual chest CT according to AREST CF protocol.14 Inclusion criteria 
were: diagnosis of CF; availability of two longitudinal pressure controlled inspiratory 
chest CTs; ages between 0 and 6 years old; absence of exacerbation requiring a course 
of intravenous antibiotics, meaning that all children were free of acute symptoms at 
the time of the CT scan and in the  month prior to scanning. A course or maintenance 
with oral antibiotics for milder pulmonary symptoms were not considered an exclusion 
criteria for executing routine chest CT scans. In this cohort, children less than 2 years old 
were routinely prescribed prophylactic oral antibiotics. . 
Disease control subjects: Control CTs were selected when meeting the following criteria; 
pressure controlled inspiratory chest CT scan; age between 0 and 6 years old; clinical 
indication for chest CT other than CF; CT acquired for a variety of clinical indications 
(Table 1) but assessed as normal with no lung abnormalities by experienced pediatric 
radiologist (CM, 15 years of experience). Single scans from the cross-sectional control 
population matched the paired CF scans with regard to average age during acquisition.
TABLE 1. clinical diagnosis and indications for chest CT of the disease control group.  
Controls
Clinical diagnosis
Reason for CT No of subjects
Recurrent respiratory infections/  
chronic cough/ persistent tachypnoea
Bronchiectasis?  
Tracheobronchomalacie?
10
Developmental delay Aspiration? 2
CT scanning
All CTs of CF and disease control subjects were made supine, with pressure control 
under general anesthesia. To reduce atelectasis, alveolar recruitment maneuvers were 
performed consisting of 10 consecutive slow breath with inspirations pressure of 40 cm 
H2O followed by a breath hold with end-inspiration pressure of 25 cm H2O. Volumetric 
end-inspiratory acquisitions were obtained using a Philips Brilliance 64 scanner prior 
to 2012 and Siemens Definition Flash scanner from 2012 (for additional scanner 
information see Appendix Table E1).
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Quantitative analysis of airways and arteries 
AA dimensions were measured with image analysis platform Myrian®, v1.18.1 (Lung 
XP module, Intrasense, Montpelier, France) as described previously.11 In short, the 
bronchial tree was segmented automatically in 3D and remaining visible airways were 
added manually. Next, AA dimensions of all AA-pairs were measured perpendicular to 
the airway centerline. Measurements were made using an ellipse tool surrounding the 
inner and outer airway and adjacent artery boundaries in a window width of 1500 HU 
and window level of -200 HU (see Appendix Figure E1). Short and long axis diameters 
of the inner-, outer airway and adjacent artery were measured preferably in the middle 
of each reconstructed airway branch. The mean of short and long axis of the airway 
and artery was used to compute airway and artery diameters, respectively. Inner and 
outer airway diameters were divided by artery diameter to compute AinA-, AoutA -ratio 
respectively. Wall thickness (= [outer airway - inner airway diameter] / 2) was divided by 
artery diameter to compute AWTA-ratio.
Airway generation and segmental bronchi were registered for every AA-pair. Segmental 
bronchi were numbered according to Netter nomenclature.15 As previously described,11 
segmental generation (SG) was computed to allow all segmental bronchi to start at 
SG 1, correcting for generation discrepancy in each segmental bronchi (see Appendix 
Figure E2). 
Observer reliability
All AA measurements were conducted by one observer (TS, medical student after 
one month training) blinded to disease status and time of scans. Three months after 
completion, 10 measurements were repeated in randomly selected segmental branch 
in each of the 36 CTs to establish intra-observer variability. In case less than 10 AA-
pairs were visible and measured in the original random selected segmental branch, the 
following segmental branch was executed until 10 AA-pairs were measured per CT.
Statistical Analysis
Patients’ characteristics were summarized using median (range). Difference in number 
of AA-pairs was assessed using Wilcoxon signed-rank test and relationship between 
age and number of AA-pairs using linear regression. Differences in AA-ratios per SG for 
cross-sectional data (CF CT1 and CT2 versus disease controls) and longitudinal data (CF 
CT1 vs CT2) were examined with mixed effects models , accounting for correlation within 
patients and lobes by including random effects. Influence of gender and age on AA-
ratios was assessed by including them as potential confounding variables in the original 
models. Bonferroni correction was applied per outcome for 16 mixed effects models to 
predict AA-ratios per SG, with p≤0.003 considered to be significant.
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Receiver operating characteristics (ROC) curves with corresponding area under curves 
(AUCs) were plotted to find AA-ratios with highest combined sensitivity and specificity 
differentiating between CF and disease controls. 
Power calculations were performed assuming clustering of AA-pairs within individual 
patients and presented for AA-ratios based on a range of effect sizes, estimated as 
relative difference between CF and disease control group with 80% power and α=0.05.16 
Intraclass correlation coefficient (ICC) using a mixed effects model was calculated to 
determine intra-observer agreement with structure taken into account. The structure 
specifically included segmental branches within generation within patients. All analysis 
were conducted using R v3.1.0.17 
IRB approved prospective collection of CTs according to AREST CF study and written 
informed consent was obtained for each procedure.
RESULTS 
Study population
Description of group characteristics is shown in Table 2. 
TABLE 2. Demographics of the CF and control cohort
Patients with CF
Disease 
controls
CT1 CT2 CT1+CT2
N 12 12
Gender (% male) 42% (5) 83% (10)
Age (in years) 2 (0.6-3.2) 3.9 (2.6-5.2) 2.9 (0.6-5.2) 2.9 (1-5.2)
Homozygote delta F508 50% (6)
Heterozygote delta F508 50% (6)
Pancreatic sufficiency 25% (3)
Pseudomonas aeruginosa infection (%) 0% (0) 8% (1)
Pseudomonas aeruginosa infection ever (%) 25% (3)
Inner airway diameter (in mm) 1.46 ± 0.49 1.59 ± 0.55 1.63 ± 0.53
Outer airway diameter (in mm) 2.77 ± 0.70 2.91 ± 0.76 2.78 ± 0.80
Vessel diameter (in mm) 2.58 ± 0.72 2.67 ± 0.81 2.82 ± 0.85
AinA-ratio 0.57 ± 0.10 0.60 ± 0.13 0.58 ± 0.09
AoutA-ratio 1.09 ± 0.14 1.12 ± 0.18 1.00 ± 0.14
AWTA-ratio 0.52 ± 0.11 0.52 ± 0.13 0.42 ± 0.10
Data is represented as mean ± standard deviation or percentage (absolute numbers) as appropriate, with the 
exception of age which is described as median (range).   
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Quantitative analysis of airways and arteries
A total of 4798 AA-pairs were identified in perpendicular view of the 3D airway 
segmentations. 37 Outliers by manual errors and 14 AA-pairs before beginning of the 
segmental branch were omitted (for more detail see Appendix), leaving 4747 AA-pairs 
for analysis. In the CF group, a mean (range) of 127 (91-185) AA-pairs were measured at 
CT1 and 148 (115-277) AA-pairs at CT2. In controls a mean (range) of 121 (47-198) AA-
pairs were measured. There were no significant differences cross-sectionally in number 
of AA-pairs between controls and CF at CT1 (p=0.83) or CT2 (p=0.31) and longitudinally 
between CF CT1 and CF CT2 (p=0.09). Figure 1 shows the number of AA-pairs by SG. 
As demonstrated in Figure 2 the number of AA-pairs is correlated with age (adjusted 
r2=0.28, p<0.001) for CF and  control patients combined.
Overall mean (range) of the inner, outer, vessel diameter and wall thickness in all 
measurements in the CF and control group were 1.6 (0.3-4.4), 2.8 (1.3-6.6), 2.7 (1.1-
6.8) and 0.3 (0.1-0.7) mm respectively. AinA-, AoutA-, and AWTA-ratio did not increase 
significantly with age in the CF or control group (Appendix Figure E3). Gender and age 
were found not to be significant in a mixed effects model with AinA-, AoutA-, or AWTA-ratio. 
In the cross-sectional analyses, AinA-ratio did not show significant differences between 
control and CF CT1 or CT2 in any SG (Figure 3, Table 3). Difference in AoutA-ratio between 
CF and control (Figure 4, Table 3) was significant from SG 2-4 for CT1 (p≤0.002) and SG 
2-5 for CT2 (p≤0.001). Difference in AWTA-ratio between CF and control (Figure 5, Table 3) 
was significant from SG 1-5 for CT1 (p<0.001) and SG 2-6 in CT2 (p<0.001). Difference in 
AoutA-, and AWTA-ratio between patients with CF CT2 and disease controls became larger 
with each next segmental generation. 
In the CF longitudinal analyses, AinA-ratio showed small but significant differences 
between CT1 and CT2 along most SG (Figure 3, Table 3). AoutA-ratio showed an increasing 
difference between CT1 and CT2 as a function of SG, only significant in SG 6 (p<0.001) 
(Figure 4, Table 3). A significant difference in AWTA-ratio was observed between CF CT1 
and CT2 in SG 1 and SG 3 respectively (Figure 5, Table 3). 
The optimal threshold for AinA-ratio was 0.7 (AUC= 0.49; sensitivity=0.14; specificity=0.91) 
and for AoutA-ratio was determined to be 1.06 (AUC=0.69; sensitivity= 0.58; specificity= 
0.69). The optimal threshold for AWTA-ratio was 0.44 (AUC= 0.75; sensitivity=0.75; 
specificity=0.64). ROC curves based on AoutA- and AWTA-ratio between the CF and control 
group are shown in Appendix Figure E4.
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FIGURE 1. Average amount of AA-pairs visible per generation per control (light gray) and CF 
patients, for CT1 (gray) and after a two-year interval for CT2 (black). 
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FIGURE 2. Amount of AA-pairs visible per generation per control (open circles, gray line) and CF 
patients, divided at CT1 (filled circles, dotted gray line) and CT2 (filled diamonds, black striped line). 
The number of AA-pairs increases significantly with age (p<0.001). Note that for CF we have a CT1 
and CT2 while for controls we have only a CT at one time point
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FIGURE 3. Boxplots of the AinA-ratio in the control group (light gray) and in the CF group at CT1 
(gray) and CT2 (black). Each box shows median (horizontal line), interquartile range (solid box), 
1.5*interquartile range (whiskers) and outliers (points). Table 2 describes the mean differences 
and p-values for each generation as plotted in the AinA-ratio graph. 
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FIGURE 4. Boxplots of the AoutA-ratio in the control group (light gray) and in the CF group at CT1 
(gray) and CT2 (black). Each box shows median (horizontal line), interquartile range (solid box), 
1.5*interquartile range (whiskers) and outliers (points). Table 2 describes the mean differences 
and p-values for each generation as plotted in the AoutA-ratio graph. Note that the AoutA-ratio 
increases in the CF CT2 group by segmental generation compared to controls. Secondly note 
that the number of AA-pairs observed decreases in the higher segmental generation for all three 
groups as shown in Figure 1 and Table 2.
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FIGURE 5. Boxplots of the AWTA-ratio in the control group (light gray) and in the CF group at CT1 
(gray) and CT2 (black). Each box shows median (horizontal line), interquartile range (solid box), 
1.5*interquartile range (whiskers) and outliers (points). Table 2 describes the mean difference and 
p-value for each generation as plotted in the AWTA-ratio graph. Note that the AWTA-ratio is higher in 
the CF groups at CT1 and CT2 compared to controls. The number of AA-pairs observed decreases in 
the higher segmental generation for all 3 groups as shown in Figure 1 and Table 2.
Reproducibility of airway measurements
388 AA-pairs were re-measured in total. ICC and 95% confidence interval for intra-
observer variability was 0.62 (0.60-0.64) for inner airway diameter; 0.63 (0.63-0.65) for 
outer airway diameter; 0.55 (0.53-0.56) for artery diameter.    
Sample size estimates 
Mean (SD) AoutA-ratio for SG 3, 4 and 5 combined was 1.12 (0.18) in CF at CT2 and 1.00 
(0.14) in controls. Sample sizes of 21, 33, 58 and 131 per treatment arm were calculated 
based on 50, 40, 30 and 20% reduction in AoutA-ratio respectively in difference between 
CF CT2 and controls. Mean (SD) AWTA-ratio for SG 3, 4 and 5 combined was 0.47 (0.08) in 
CF at CT2 and 0.42 (0.07) in controls. Sample sizes of 53, 83, 148 and 331 per treatment 
arm were calculated based on 50, 40, 30 and 20% reduction in AWTA-ratio respectively in 
difference between CF CT2 and controls. Mean number of AA-pairs with AoutA-ratio>1.1 
for SG 3, 4 and 5 combined was 0.51 in CF at CT2 and 0.22 in controls. Sample sizes of 
30, 46, 82 and 184 per treatment arm were calculated based on 50, 40, 30 and 20% 
reduction in number of AA-pairs with AoutA-ratio>1.1 respectively in difference between 
CF CT2 and controls.
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DISCUSSION
This study presents an unique dataset with all visible AA-pairs detected in 3D bronchial 
trees reconstructed from CT scans of young patients with CF. We compared AA-ratios 
between CF patients and disease controls and assessed progressive changes with time 
in children with CF.
This study confirms our previous study in older CF patients that the outer airway 
diameter should be used for comparison with the adjacent artery rather than the 
inner airway diameter in order to separate diseased CF airways from non-diseased CF 
airway.11 AinA-ratio did not show a significant difference between the disease control 
and CF group at CT1 or CT2. Relative to disease controls the AoutA-ratio in CF patients was 
significantly higher in segmental generation two to four at CT1 and higher in segmental 
generation two to five for CT2. AoutA-ratio > 1.06 was the best threshold to detect 
bronchiectasis in young children when using outer airway diameter for comparison to 
the artery diameter. This is in contrast to previous studies that have suggested a smaller 
AA-ratio to define bronchiectasis.3,18 This difference could be explained as these studies 
used the inner airway diameter to determine the AA-ratio. An additional finding of this 
study is that wall thickening was detected in our young CF population compared to 
disease controls. AWTA-ratio was significantly higher in CF at segmental generation one 
to five for CT1, and in segmental generation two to six for CT2. Similar but more apparent 
changes have been demonstrated in the AoutA,- and AWTA-ratios of older children with 
CF compared to controls.11 Furthermore, AA-, and AWTA-ratios of disease controls in this 
study were independent of age and gender, which is in concordance to previous control 
studies.11,18,19
Another important finding of this study is that in the longitudinal analysis of children 
with CF, a progressive increase in AoutA-ratio on CT2 relative to CT1 was seen in the 
peripheral airways after a two-year interval (segmental generation ≥ 4), with a significant 
increase in segmental generation six. For the AinA-ratio, small but significant changes 
over the two-year interval were detected for segmental generation one to four and six. 
This could be interpreted as the outer diameter reflecting irreversible airway dilation 
i.e., bronchiectasis and this diameter is, in contrast to the inner diameter, less influenced 
by lung volume and/or mucus impaction.20 The systematic increase in AoutA-ratio by 
segmental generation after an interval of two years suggests that there is progressive 
bronchiectasis in the peripheral airways of young children with CF, although not 
statistically significant due to the small number of patients observed in this study. 
Based on our observations, larger studies that separately compare outer wall and inner 
wall to artery ratios could help to determine whether mucous impaction precedes the 
development of irreversible bronchial dilatation. For these studies automated analyses 
would be particularly useful.21 Structural lung changes has been reported in young 
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children with CF previously,1,22–25 and this study supports previous observations that the 
small airways play an important role in early CF lung disease.11,26,27 In the longitudinal 
analysis of AWTA-ratio, no changes in airway wall thickness were detected after two years, 
except for a very small but significant reduction observed in segmental generation 
three. Similarly, airway wall thickness did not increase significantly over a two years 
interval in older CF patient using visual CF-CT scoring.22 These observations differ to 
those by de Jong et al.13 who demonstrated progression of airway wall thickening over 
two years in older children and adolescents with CF using quantitative measures. This 
discrepancy between our study and that of de Jong et al. is likely to be explained by 
differences in the study populations. The study by de Jong et al. investigated a cohort 
of patients between 4 and 18 years of age. Disease progression at that time was likely 
to be more severe relative to our patient population diagnosed through newborn 
screening and evaluated between 0 and 6 years old. Furthermore, AWTA-ratio in early CF 
lung disease is relatively stable and progression too small to be detected in the small 
group of patients in our study, even with very sensitive quantitative assessment in a 
large number of airways. 
Previous studies suggested that the number of visible AA-pairs could be used as a novel 
CT outcome measure to establish CF lung disease severity.11,12,28,29 In our cross-sectional 
analysis we did not observe a significant difference in number of AA-pairs between CF 
and disease controls, nor did the longitudinal analysis between the two time points in CF 
patients demonstrate significant differences in number of AA-pairs. Age was found to be 
positively correlated to the number of AA-pairs in these young CF and disease controls. 
Number of airways that can be detected is highly dependent on lung volume during 
CT acquisition and on image resolution of the CT.30,31 All CF and control patients in this 
study had identical volume control protocol during CT acquisition. Hence, this did not 
likely influence our results. It was possible that due to the resolution limitations of even 
modern CT scanners we were not able to pick up sufficient number of high generation 
small airways in these young patients, as airways with a diameter less than 1 mm were 
mostly not measureable on CT. Hence, based on our findings we do not recommend 
to use number of visible airways as an outcome measure in patients below the age of 
6. Number of airways as outcome measure in studies of these young children could be 
confounded by age and resolution of chest CT.32 Nonetheless, in a cross-sectional study 
in children 6 years and older a sufficient amount of (small) airways can be sampled in CF 
and a control population to detect significant differences between those two groups.11 
We believe that in older children the size of airways, and therefore the detection of 
number of AA-pairs is to a lesser extent confounded by age or CT resolution.  
Lastly, this study suggests that with objectively quantified AA-ratios, small sample sizes 
are needed to test effects of interventions or disease progression. A sample size of 21 
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per treatment arm was estimated based on 50% reduction in AoutA-ratio at age 6. In 
comparison, the semi-quantitative scoring technique PRAGMA-CF estimated a sample 
size of 100 per treatment arm based on 50% reduction in total airway disease at age 
3.25 However, it must be noted that the smaller sample size required with objective AA-
ratios could have been caused by the older age of the patients studied. Additionally, 
the sample size estimation is likely an underestimation of the true sample size needed 
due to the comparison between CF and non-CF airways as baseline. Nonetheless, the 
AA-method appears to be sensitive for detecting abnormal airway dimensions on chest 
CT compared to controls, supporting the potential for AA-ratio determination as an 
outcome measure in clinical trials in young patients. 
We acknowledge a number of limitations with the study. First, we have only studied a 
relative small population, due to the time consuming task to quantify AA dimensions 
manually. However, with 3,297 AA-pairs in CF and 1,450 in controls we had sufficient 
power to demonstrate differences in AA-dimensions between CF and disease controls. 
For the longitudinal analysis a larger number of patients are needed to determine 
whether progressive increase in AA-ratios and in the number of AA-pairs can be 
detected. Second, our control group cannot be considered healthy, as they were patients 
referred by the pediatric pulmonologist for respiratory complaints. However, their chest 
CTs were considered to be normal as evaluated by an experienced pediatric radiologist. 
The constant AA-ratios in disease controls over successive generations observed in this 
study and in relation to age, is consistent with reported measures in controls.3,11,13 In 
addition, it is likely that the use of disease controls underestimates differences between 
CF and controls. Unfortunately, despite the low radiation dose of modern scanners there 
are still ethical barriers for studying healthy children with chest CT, due to the potential 
risks from ionizing radiation. For this reason we were only able to collect single control 
CTs over the same age range covering the age range of CF patients with each two CTs.
Third, the measurements made in the smaller airways are near the resolution limits of 
the CT scanner. However, with edge-enhancing reconstruction kernel and high image 
contrast between airway wall tissue and surrounding air or soft tissue, measurements of 
sub-millimeter structures were feasible. In addition, the accuracy of the measurements 
were improved by fixing the window width and level settings.  
Finally, the intra-observer analysis was difficult to standardize as the manual 
measurements at mid-airway positions could have been made at different anatomic 
locations leading to the ICC of 0.62.  However, this is being compensated by the large 
number of airway-artery pairs that could be sampled per patient (on average 132 pairs) 
resulting in small confidence intervals. The variability between the airway measurements 
can be improved when using automated analysis. Algorithms to do so are feasible and 
currently under development.21 
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Summary
Our study demonstrates that young children with early CF lung disease have more 
dilated airways and thicker walls than disease controls. In CF, progression in outer 
diameter AA-ratio was detected after two years, especially in the peripheral airways. 
Results of this study are in concordance with previous literature reporting structural 
airway changes early in life of patients with CF on chest CT.2,3 AA-ratios are an objective 
tool for measuring CF related airway disease severity in early life, and a sensitive outcome 
measure for use in clinical trials aiming to prevent early SLD. A larger study population 
of CF patients is needed to accurately define the progression of SLD on chest CT in 
young children, which will be the next step using automatic analysis techniques.21 
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APPENDIX
Results
Excluded outliers
36 outliers due to typos in the manual annotations were excluded. This was determined 
as follows: outer airway diameter < inner airway diameter; generation > 40; AoutA-ratio 
>8; AinA-ratio> 2; difference surface area as annotated and surface area calculated with 
the short and long diameter > 3.
14 measurements before the segmental branches were excluded in the analysis as well. 
APPENDIX TABLE E1. CT settings
CT setting Prior to 2012 From 2012
CT Scanner Philips Brilliance 64 Siemens Definition Flash
Scan type Inspiratory Inspiratory
Acquisition Volumetric Volumetric
Rotation time (ms) 400 280
Pitch 0.61 3
Slice thickness (mm) 0.9 1.0
Increment (mm) 0.45 0.7
Collimation (mm) 0.63 0.63
Tube voltage (kVp) 120 100
Current-time product (mAs) 25 10
CTDIvol (mGy) 1.51 (0.06) 0.46 (0.00)
Dose-Length Product (mGy cm) 34.75 (4.01) 12.33 (0.58)
CTDIvol and Dose-Length Product were based on a 32-cm phantom and reported as mean (standard deviation).
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APPENDIX FIGURE E1. Example of a CF airway and artery pair (top row) measured with the 
ellipse tool (bottom row) in Myrian®. The airway and artery measurement are made during 
baseline (left) and follow up (right). 
 
APPENDIX FIGURE E2. Anatomy of the airways. A) The segmental branches are shown in the 
different colors and the numbering stands for the airway generation. As shown in figure 1A each 
segmental branch starts with a different generation, eg generation 3-4 in the upper segmental 
branches whereas it starts at generation 5-7 in the lower segmental branches. B). To correct for 
this discrepancy we computed the segmental generation which ensured all segmental bronchi to 
start at segmental generation 1 (Artist: K. Rubenis).
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APPENDIX FIGURE E3. The airway artery ratio is plotted as a function of age, for AinA-,(top 
left) and AoutA-ratio (top right) with the regression line based on the mixed model. Age was not 
significant in the mixed-effect model for AinA-ratio for the CF CT1 (p=0.78), CF CT2 (p=0.22) or 
control group (p=0.15). The AoutA-ratio in the CF CT1 (p=0.78), CF CT2 (p=0.23), and control group 
(p=0.22) do not increase significantly either with age. The airway wall ratio is plotted as a function 
of age, for AWTA-, (bottom left). Age was not significant in the mixed-effect model for AWTA ratio in 
the CF CT1 (p=0.41), CF CT2 (p=0.80), and control group (p=0.97). 
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APPENDIX FIGURE E4. Receiver-operating characteristic (ROC) curves to distinguish the most 
optimal AoutA- (left) and AWTA-ratio (right) between patients with CF and the control patients. The 
gray stars indicate the AA ratio with the optimal sensitivity + specificity.
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ABSTRACT 
Background
CF-CT and PRAGMA-CF are commonly used scoring methods to quantify the severity 
of bronchiectasis (BE) and airway wall thickening (AWT) on chest CTs of children with 
cystic fibrosis (CF). We aimed to validate CF-CT and PRAGMA-CF sub-scores for BE and 
AWT against quantitative airway-artery (AA) dimensions.
Methods
This is a retrospective study with 23 spirometer guided inspiratory chest CTs (11 CF, 
12 controls; age range 6 to 16 years old) included. AA-, and AWTA-ratios of all visible AA 
pairs were computed by dividing diameters of the outer airway and wall (outer-inner 
airway) by the accompanying artery diameter, respectively. BE, AWT and total airway 
disease (TAD) were scored using CF-CT (% max score) and PRAGMA-CF (% extent). 
Correlations were computed using Spearman rank. Akaike information criterion (AIC) 
from the mixed-effects models were used to investigate whether CF-CT or PRAGMA-CF 
was a better predictor for AA-, and AWTA-ratios (lower AIC equals a better fitted model).
Results
4,861 AA pairs were measured in total. Correlations between CF-CT and PRAGMA-CF: BE 
(r=0.93, P<0.001); AWT (r=0.62, P<0.001); TAD (r=0.88, P<0.001). PRAGMA-CF TAD sub-
score had lowest AIC in the mixed-model predicting AA-ratio. CF-CT AWT and PRAGMA-
CF TAD sub-score had equal low AIC in the mixed-model predicting AWTA-ratio. 
Conclusion
PRAGMA-CF TAD sub-score was more precise predicting BE. CF-CT AWT and PRAGMA-CF 
TAD sub-scores predicted AWT equally well. CF-CT and PRAGMA-CF were both sensitive 
methods to score BE and AWT in children with CF lung disease, with PRAGMA-CT TAD 
sub-score being most accurate predicting AA dimensions. 
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INTRODUCTION 
Lung disease is the leading cause of morbidity and mortality in cystic fibrosis (CF) 
patients.1 Bronchiectasis (BE) and airway wall thickening (AWT) are two important 
components of CF lung disease.2 Currently chest CT is the gold standard and most 
sensitive imaging tool to assess these structural lung changes.3,4 To quantify disease 
severity, different CT scoring systems have been developed to score CF related 
components such as BE, AWT, mucous plugging (MP) and trapped air.5–7 The CF-CT is a 
well standardized scoring system with extensive instruction module and standardized 
training sets.3,5,8,9 A disadvantage of this system is that it is not sensitive to quantify early 
CF lung disease as the extent of disease is scored as absent; less than 33%, between 33 
and 67%, or more than 67%. Hence, lung disease in young children will mostly be scored 
as either absent or less than 33%. More recently PRAGMA-CF was developed as a more 
sensitive alternative to quantify structural lung abnormalities in early CF lung disease.6 
However, this scoring method requires validation and independent verification. 
A downside of CF-CT and PRAGMA-CF scoring methods is that they are subjective 
and have not been properly validated against an objective system measuring airway 
dimensions.10
For objective measurements of BE and airway dimensions several systems have been 
used to measure airway and artery (AA) dimensions of AA pairs on axial slices of CT 
scans.11–13 A disadvantage of this approach is that it can cause inaccuracy due to a 
projection or parallax error,14 which is an error that causes the AA dimensions to be 
perceived larger or smaller depending on the plane it is visualized in. More recently an 
improved method was developed to manually measure AA dimensions perpendicular 
to the airway centerline.15 This AA-method is currently the most objective quantitative 
method to measure AA dimensions. Therefore, we used the AA-method as reference 
standard and compared it with BE, AWT, and total airway disease (TAD) scored with CF-
CT and PRAGMA-CF. 
This study compares quantitative AA dimensions with semi-quantitative CF-CT and 
PRAGMA-CF scores for BE, AWT and TAD in children and adolescents with CF and 
controls. We hypothesized that PRAGMA-CF is a better predictor of the quantitative AA- 
and AWTA-ratios, hence a better suited tool for disease quantification in children with CF 
than the CF-CT scoring system.
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METHODS
Study population
The dataset for this study was initially used for the development of the AA-method and 
was reported separately.15 In summary, CF patients were between 6 and 16 years of 
age and were treated at the Erasmus MC-Sophia Children’s Hospital between 2007 and 
2012. Chest CTs of 12 CF patients with a routine spirometer guided inspiratory chest 
CT were randomly selected and analyzed. However, one subject in the CF group was 
excluded since the patient appeared to be mislabeled and diagnosed with common 
variable immunodeficiency. 
The control group consisted of patients referred by the pediatric pulmonology 
department, Erasmus MC-Sophia Children’s Hospital, for a spirometer guided chest CT. 
Patients were included if they had no visible lung abnormalities on chest CT according 
to two independent radiologists. Out of 16 normal chest CTs available, 12 CTs of the 
subjects with best matching ages to CF patients were selected.
CT scanning and scoring 
End-inspiratory spirometer guided volumetric CT of all patients with CF and the control 
subjects were obtained in supine position with a SOMATOM® Definition Flash CT scanner 
(Siemens  Healthcare, Forchheim, Germany). Detailed scan parameters were reported 
separately15 and described in the Appendix Table E1.  All CTs were anonymized and 
analyzed using the AA-method in random order by observer (WK) and a random subset 
by a second observer (HO).15 CF-CT and PRAGMA-CF scoring was performed by a single 
scorer (HO) with 1-year experience in scoring. Table 1 summarizes CT components (BE, 
AWT and TAD) scored with the three different methods. 
TABLE 1. Scoring algorithms
AA-method CF-CT PRAGMA-CF
Bronchiectasis AA-ratio =
outer airway diameter
artery diameter
% of max BE sub-score 
including severity and extent 
of BE
% of BE extent
Airway wall thickening AWTA-ratio = 
outer–inner airway diameter
artery diameter
% of max AWT sub-score 
including severity and extent 
of AWT
% of AWT extent
Total airway disease % of max BE, AWT and MP sub-
score including severity and 
extent of BE, AWT and MP
% of BE, MP, 
AWT extent
Scoring components of bronchiectasis (BE), airway wall thickening (AWT) and total airways disease (TAD) 
using the AA-method, CF-CT and PRAGMA-CF scoring technique.
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Quantitative analysis of airways and arteries 
Dimensions of all visible AA pairs were measured with image analysis platform Myrian®, 
version 1.16.2 (Intrasense, Montpelier, France). The bronchial trees were interactively 
reconstructed in 3D for each CT. Next, AA dimensions of all visible AA pairs were 
measured in the middle of each branch perpendicular to the longitudinal airway axis. 
All measurements were made with an ellipse tool which was adjusted manually to the 
edges of the AA dimensions, in a window width of 1500 HU centered at -200 HU. Of 
each visible airway branch, areas of the inner-, outer airway and adjacent artery were 
measured.
Average diameters (d) were computed from annotated surface areas (a) using the 
following formula: d = 2 × aπ  . Outer airway diameters were divided by the artery 
diameters to compute AA-ratio. Wall thickness (difference between outer and inner 
airway diameter) was divided by the artery diameter to compute AWTA-ratio. Number of 
AA pairs was defined as the number of AA observations visible per CT scan. 
CF-CT scoring
CF-CT scoring system evaluates the five lung lobes and lingula for severity and extent 
of central and peripheral CT components. The following sub-scores were assessed: BE; 
AWT; MP; opacities (atelectasis, consolidation, ground glass pattern) 5. More detail on 
scoring algorithm for BE, AWT and MP are provided in Appendix Table E2. TAD sub-
score was computed as the sum of BE, AWT and MP. BE, AWT and TAD sub-scores are 
expressed as percentage of maximum score (0-100%). 
PRAGMA-CF scoring
PRAGMA-CF computes the volume fraction of CT components using a grid overlaying 
10 equally spaced axial slices between lung apex and base.6 Each grid cell that contains 
at least 50% coverage of the lung is scored. Any sign of the disease component in the 
grid cell will be scored with the following hierarchical system (highest to lowest priority): 
1. BE, 2. MP, 3. AWT, 4. atelectasis or 5. normal lung. Atelectasis was subtracted from the 
total lung volume.6 TAD was computed as the sum of BE, MP and AWT. We used volume 
fraction of the lung with BE, AWT and TAD sub-scores. 
Statistical Analysis
Descriptive statistics of the patient’s key characteristics are displayed as median (range). 
Receiver operating characteristic (ROC) curves with corresponding area under curves 
(AUC) were plotted to identify the AA- and AWTA-ratio thresholds with the highest 
combined sensitivity and specificity to differentiate CF from controls. 
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Spearman rank correlation was used to describe the relationship between CF-CT and 
PRAGMA-CF scoring methods. To compare CF-CT and PRAGMA-CF with AA related 
components graphically, we standardized BE, AWT and TAD sub-scores by converting 
them into a Z-score using the following formula: (  ). Univariable 
linear regression analysis was used to evaluate relation between BE, AWT and TAD sub-
scores for each scoring module with AA parameters: the number of AA pairs; and the 
percentage AA pairs above ROC cut-off value for AA and AWTA-ratio. Adjusted R
2 was 
used to compare the models, with higher adjusted R2 equaling better fit.
Effects of the BE, AWT and TAD sub-scores derived from CF-CT and PRAGMA-CF, on AA- 
and AWTA-ratios were investigated using mixed-effect models. The mixed-effects models 
took correlation between multiple AA ratios obtained from the same patients into 
account. Akaike information criterion (AIC) was used to compare models fit using the 
two scoring methods, where a lower AIC equals a better prediction model. An AIC with 
5 points difference or more was regarded as a significant difference.16,17 To account for 
multiple repeated testing for 14 linear regressions and 8 mixed-effect models, a p-value 
≤ 0.002 was considered significant using the Bonferroni correction.
Intra-observer agreement of CF-CT and PRAGMA-CF sub-scores were calculated using 
intraclass correlation coefficients (ICCs). All analyses were conducted using R version 
3.1.0,18 except for the ICC analysis which was performed using SPSS version 21 for 
windows.
This retrospective study was approved by the institutional review board (MEC-2014-
255). Written informed consent was waived for all patients because of the retrospective 
nature of the study.
RESULTS
Study population
11 patients with CF (6 males) were included aged 11 (7-16) years and 12 control subjects 
(7 males) aged 13.9 (6-16) years. There was no significant demographic difference 
between the CF and control group in age, gender height and weight  (Appendix Table E3). 
CT scoring
Characteristics of CF-CT and PRAGMA-CF sub-scores are shown in Table 2. Intra-observer 
reliability with CF-CT was 0.95 for BE; 0.9 for AWT; 0.94 for MP; 0.95 for TAD. Intra-observer 
reliability with PRAGMA-CF was 0.87 for BE; 0.5 for AWT; 0.98 for MP; 0.94 for TAD.
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TABLE 2. Summarized characteristics of the scoring parameters
CF-CT % of max score PRAGMA-CF % extent Number  
of AA  
pairs
AA pairs 
with AA 
ratio  
> 1.11 (%)
AA pairs 
with AWTA 
ratio > 
0.58 (%)BE AWT TAD BE AWT TAD
CF 
n=11
5.2  
(0-68.1)
5.5  
(0-26.4)
4.8  
(0-44.6)
1.3  
(0-13.2)
1.2  
(0.2-4.6)
4.9  
(0.6-16.7)
283  
(149-503)
0.52  
(0.15-0.82)
0.51  
(0.34-0.79)
Control
n=12
0  
(0-4.2)
0  
(0-0)
0  
(0-1.8)
0  
(0-0.3)
0  
(0-1.3)
0.1  
(0-1.4)
130  
(42-183)
0.22  
(0.08-0.39)
0.26  
(0.06-0.69)
Bronchiectasis (BE), airway wall thickening (AWT) and total airway disease (TAD) as scored with CF-CT and 
PRAGMA-CF. All results shown are median (range).   
FIGURE 1. Scatterplots of CF-CT (left columns) and PRAGMA-CF (right columns) BE sub-scores 
(normalized into Z-scores), in relation to the number of AA pairs (top row) and the percentage 
of AA ratios above 1.11 (bottom row). CF patients are shown in black open circles and the 
control subjects in filled gray circles. All control subjects have a number of AA pair below 183 
and percentage AA ratios > 1.11 of 0.4 or lower. The linear regressions were better fitted with 
PRAGMA-CF than with CF-CT in the CF and control subjects (Table 3).   
128 | CHAPTER 6
AA parameters
A total of 4861 AA pairs were annotated perpendicular to the airway axis, 3293 in CF and 
1568 in controls (see Table 2). AA-ratio with the most optimal threshold differentiating 
CF from control patients was determined to be 1.11 (AUC=0.72; sensitivity = 0.56; 
specificity=0.77). The optimal threshold for AWTA-ratio was 0.58 (AUC = 0.7; sensitivity = 
0.56; specificity = 0.75). 
FIGURE 2. Scatterplots of CF-CT (left columns) and PRAGMA-CF (right columns) AWT sub-scores 
(normalized into Z-scores), to the number of AA pairs (top row) and the percentage of AA ratios 
above 1.11 (bottom row). CF patients are shown in black open circles and the control subjects in 
filled gray circles. The linear regressions were better fitted with CF-CT than PRAGMA-CF in the CF 
and control subjects (Table 3).    
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Bronchiectasis
CF-CT and PRAGMA-CF BE sub-scores were strongly correlated (r = 0.93, p < 0.001) 
(Appendix Figure E1a). Summary of all linear regressions is shown in Table 3. CF-CT 
(Figure 1a) and PRAGMA-CF BE sub-score (Figure 1b) were associated with the number 
of AA pairs (R2 = 0.53, p < 0.001; R2 = 0.67, p < 0.001, respectively). CF-CT (Figure 1c) and 
PRAGMA-CF BE sub-scores (Figure 1d) were associated with the percentage of AA pairs 
with AA-ratios > 1.11 (R2 = 0.41, p < 0.001; R2 = 0.53, p < 0.001, respectively). 
Mixed-effect model with AA-ratios as outcome showed an AIC of -1034 with CF-CT BE, 
-1042 with PRAGMA-CF BE, -1048 with CF-CT TAD and -1055 with PRAGMA-CF TAD sub-
score. PRAGMA-CF TAD sub-score was highest predicting AA-ratios.
Airway wall thickening
CF-CT AWT was correlated with PRAGMA-CF AWT sub-scores (r = 0.64, p < 0.001) 
(Appendix Figure E1b). CF-CT AWT sub-score (Figure 2a) was associated with the 
number of AA pairs (R2 = 0.65, p < 0.001). PRAGMA-CF AWT sub-score (Figure 2b) was 
not significantly associated with the number of AA pairs (R2 = 0.27, p = 0.006). CF-CT 
(Figure 2c) and the PRAGMA-CF AWT sub-score (Figure 2d) were associated with the 
percentage of AA pairs with an AWTA-ratio > 0.58 (R
2 = 0.55, p < 0.001; R2 = 0.43, p < 0.001, 
respectively). 
Mixed-effect model with AWTA-ratio as outcome showed an AIC of -4919 with CF-CT AWT 
sub-score, -4908 with PRAGMA-CF AWT sub-score, -4908 with CF-CT TAD and -4919 with 
PRAGMA-CF TAD. CF-CT AWT and PRAGMA-CF TAD performed equally well predicting 
AWTA-ratio.
Total airway disease
CF-CT TAD was correlated with PRAGMA-CF TAD sub-score (r = 0.88, p < 0.001) 
(Appendix Figure E1c). CF-CT (Figure 3a) and PRAGMA-CF TAD sub-score (Figure 
3b) were associated with the number of AA pairs (R2 = 0.62, p < 0.001; R2 = 0.71, p < 
0.001, respectively). CF-CT (Figure 3c) and PRAGMA-CF TAD sub-score (Figure 3d) were 
associated with the percentage of AA pairs with AA-ratios > 1.11 (R2 = 0.60, p < 0.001; R2 
= 0.72, p < 0.001, respectively). CF-CT (Figure 3e) and PRAGMA-CF TAD sub-score (Figure 
3f ) were associated with the percentage of AA pairs with AWTA-ratios > 0.58 (R
2 = 0.42, p 
< 0.001; R2 = 0.57, p < 0.001, respectively). 
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FIGURE 3. Scatterplots of CF-CT (left columns) and PRAGMA-CF (right columns) total airway disease 
(TAD) sub-score (normalized into Z-scores), to the number of AA pairs (top row), AA-ratio above 
1.11 in percentage (middle row) and AWTA-ratio>0.58 in percentage (bottom row). CF patients are 
shown in black open circles and the control subjects in filled gray circles. The linear regressions 
were better fitted with PRAGMA-CF than with CF-CT in the CF and control subjects (Table 3).
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DISCUSSION
CF-CT is a frequently used CT scoring technique to quantify structural lung disease in 
children with CF.3,8,19,20 PRAGMA-CF has been developed specifically for young children 
to quantify structural changes better in children with early CF lung disease,6 but this 
has not been validated against other scoring methods previously. This study compares 
semi quantitative CF-CT and PRAGMA-CF sub-scores with quantitative AA dimensions 
in children with CF and a control group. 
Our study showed that BE in children and adolescents can be scored reliably with 
both CF-CT and PRAGMA-CF scoring systems. CF-CT and PRAGMA-CF BE sub-scores 
correlated well with the number of AA pairs and with AA-ratios. Previous study by de 
Jong et al. also showed a correlation between AA-ratio and the Brody score (on which 
CF-CT scoring system was based) even when only limited AA pairs were assessed.21 For 
quantification of BE in children with CF, our study showed that performance of PRAGMA-
CF was better than the CF-CT scoring system. 
Another important finding is that AWT can be scored using CF-CT and PRAGMA-CF AWT 
sub-scores as they correlated with objectively quantified AWTA-ratios. Quantitatively 
assessed AWT was more accurately predicted with the CF-CT scoring system compared 
to PRAGMA-CF. This is probably due to the hierarchical system used in PRAGMA-CF.6 
Extent of airways disease is determined by grid cells overlaying axial CT images. For 
each grid cell only one disease component is scored using a hierarchical order. When 
both BE and AWT are present in the grid cell, only bronchiectasis will be scored even 
though bronchiectatic airways are often accompanied by AWT. This is demonstrated in 
our results showing that PRAGMA-CF TAD correlated better than CF-CT TAD sub-score 
with the number of AA pairs, AA- and AWTA-ratios. PRAGMA-CF is a more quantitative 
method to determine structural lung disease in children compared to CF-CT.  
Visual scoring of AWT is known to be difficult as illustrated by low intra- and inter-
observer reproducibility of AWT sub-scores using various scoring systems,7,22–24 and 
as shown with the PRAGMA-CF scoring of this study. This is likely a consequence of 
the airway wall being a thin structure making it more difficult to visually compare it 
to the adjacent artery. Manual AA-method is currently used for the development of 
an automated AA-system.25 Clearly, it will be beneficial to have sensitive objective 
automated AA system to assess AWT in children with CF. 
Next, our study confirms previous observations that the number of AA pairs visible on 
chest CT could be a marker for severity in CF lung disease. In a number of studies a higher 
number of AA pairs was observed in CF patients with more severe lung disease,15,26 
confirming the importance of small airways in CF lung disease.27–29 Our dataset showed 
299 AA pairs on average in patients with CF relative to 131 AA pairs in control subjects.15 
Elevated numbers of AA pairs in CF can easily be missed in routine clinical care, as 
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numbers of AA pairs are not counted and no reference values are available. Both CF-CT 
and PRAGMA-CF correlated significantly with the number of AA pairs, but do not take 
this component into account in their scorings algorithm. An important issue to address 
with using the number of AA pairs as a disease marker is that the number of airway 
branches is determined by the CT resolution. Variations in CT scanning protocol, lung 
volume during acquisition, patient size and growth can all affect the number of visible 
airways.11,30 With standardized CT protocols and lung volume, number of AA pairs could 
be a sensitive marker for CF lung disease in older children without detectable airway 
growth on CT.26,29 
Another unique feature of our study is that CF-CT and PRAGMA-CF scores were 
compared in control patients with normal chest CTs for the first time.10 For CF-CT and 
PRAGMA-CF sub-scores there was a slight overlap in CF and control patients (Table 2). 
Similarly, AA-ratios showed overlap between CF and control patients. To some extent 
this overlap might be related to the fact that control patients were not healthy, as they 
were referred for chest CT through the pediatric respiratory department. Unfortunately, 
it is not feasible to study healthy children using chest CT due to ionizing radiation 
exposure.31 Importantly, CTs of control and CF patients were collected from the same 
center using the same CT scanner. In addition, control CTs were reported as normal 
by two independent chest radiologists. Hence, we think that some overlap in AA-ratios 
between normal and abnormal subjects exists, similarly to most biomarkers.32 
A limitation of this study was that we only studied a relatively small population. This 
was related to the time consuming task to quantify AA dimensions. However, due to the 
large numbers of AA pairs we had enough power to compare the AA-method with CF-
CT and PRAGMA-CF scoring techniques. 
In conclusion, both CF-CT and PRAGMA-CF were valid scoring techniques to evaluate 
airway disease in children aged 6 years and older with CF lung disease. Once the AA-
method is automated, it can replace manual AA measurements, BE and AWT scoring for 
spirometer controlled inspiratory chest CTs.
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ABSTRACT
Purpose
To establish reference values for airway tapering and to assess the usability of tapering 
as a bronchiectasis biomarker in paediatric populations.
Methods
Reference airway tapering values were obtained from 156 computed tomography 
(CT) scans of an international multicentre cohort. Airway tapering as a bronchiectasis 
biomarker was assessed on spirometer-guided inspiratory CTs from 12 patients with 
bronchiectasis (11 cystic fibrosis, 1 common variable immunodeficiency) and 12 age- 
and gender-matched controls.
Automatic image analysis software was used to quantify intra-branch tapering 
(reduction in airway diameter along the branch), inter-branch tapering (reduction 
in airway diameter before and after bifurcation), and airway-artery ratios on chest 
CTs. Visual bronchiectasis sub-scores were collected for the 12 patients and matched 
controls.
Results
Bronchiectatic subjects showed significantly reduced inter-branch and intra-branch 
tapering as well as increased airway-artery ratios compared to controls. When airways 
were stratified by size only tapering measurements were significantly different between 
diseased and controls across all airway size groups. Bronchiectasis visual scores 
correlated better with tapering measurements than with airway-artery ratios.
Conclusion
Airway tapering is a promising biomarker for bronchiectasis, as subjects with 
bronchiectasis show a significant reduction in airway tapering across all airway sizes 
and it does not require comparison with pulmonary arteries.
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INTRODUCTION
Bronchiectasis is an important characteristic of diseases such as cystic fibrosis (CF) 
lung disease,1,2 chronic obstructive pulmonary disease (COPD),1 common variable 
immunodeficiency (CVID),3 tuberculosis,4 and human immunodeficiency virus (HIV).4 
Chest computed tomography (CT) is currently the most sensitive imaging tool to detect 
bronchiectasis5,6 and is a sensitive outcome measure in CF for both clinical and research 
purposes.7-9
In healthy subjects the diameter of an airway branch is similar to that of the accompanying 
artery10 and there is subtle but progressive diameter reduction along the branch named 
intra-branch tapering.4 In addition, diameter of the airway branch is reduced compared 
to the airway branch before bifurcation11 and this is named inter-branch tapering.
Bronchiectasis is defined as an irreversible dilation of the bronchial lumen accompanied 
with lack of tapering.4 Bronchiectasis is commonly quantified by comparing the airway 
diameter to the diameter of the accompanying artery and computing the Airway-Artery 
Ratio (AA-Ratio).12-16 Lack of tapering, defined as an unchanged airway diameter for two 
cm after branching,4 is also a recognized criterion for diagnosing bronchiectasis, in 
particular for the identification of cylindric bronchiectasis.17 In accordance, tapering has 
been included in various semi-quantitative visual scoring systems for bronchiectasis.14 
Nevertheless, quantification of airway tapering has received very limited attention.
Bronchiectasis is associated with an enlargement of peripheral airways but not of the 
trachea or central airways18. We hypothesize that an abnormally dilated peripheral 
airway might coincide with reduced tapering further up in the bronchial tree, as shown 
in Figure 1. Thus, reduction in airway tapering should be observable in larger, more 
central airways than changes in AA-Ratio.
In this study we used newly developed state-of-the-art automated image analysis 
software to 1) obtain reference values for intra-branch and inter-branch tapering in 
patients with a normal chest CT; and to 2) assess differences in airway tapering between 
control patients and bronchiectatic patients, comparing the diagnostic value of airway 
tapering and AA-Ratios.
MATERIALS AND METHODS
This study was approved by institutional review board (MEC-2014-254 and MEC-2011-
494). Written informed consent was waived for all patients because of the retrospective 
nature of the study.
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FIGURE 1. A: Bronchial tree with tapering similar to its accompanying artery, showing 
approximately constant airway-artery ratio. B: Same bronchial tree with reduced airway tapering 
uniformly distributed across the entire bronchial tree, showing an increased airway-artery ratio 
more pronounced in the more peripheral airways.
Study population
A total of 180 CT scans from three datasets were used.
Airway tapering reference values were obtained in the NormalCT dataset. This dataset 
consisted of 156 CTs acquired during free breathing or after a voluntary breath-hold 
of paediatric subjects (0 to 18 years old) found to be normal by the centre radiologist 
and a second radiologist (Dr. Chen Yong, 20 years experience). 42 of these 156 subjects 
were scanned with contrast. This NormalCT dataset is a subset from three centres 
participating in the international multicentre Normal Chest CT Study.
To assess differences between bronchiectatic patients and controls, the Matched-
Bronchiectasis and Matched-Controls datasets were collected retrospectively. The 
Matched-Bronchiectasis consisted of spirometer-guided inspiratory chest CTs of 12 
patients between 8 and 16 years old (11 CF and 1 non-CF bronchiectatic patient with 
CVID; 7 females) with visible signs of bronchiectasis. The Matched-Controls consisted of 
12 spirometer-guided inspiratory scans of age- and gender-matched control patients 
referred for several clinical indications but found to be normal on chest CT by the 
Erasmus MC radiologists and a second radiologist (CY). Both groups were treated at the 
Erasmus MC-Sophia Children’s Hospital; See Appendix for scanning and patient details. 
The Matched-Bronchiectasis and Matched-Controls datasets have been previously used 
to study changes in AA-Ratios,10,19,20 but airway tapering has not been investigated.
Visual scores were obtained for all CTs from both Matched datasets using the CF-CT 
scoring module,10,14 as detailed in the Appendix.
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Automatic quantification of airways and arteries
In-house developed software (written in C++ and MATLAB) was used to measure 
AA-Ratio and airway tapering. The method, which has previously been validated,20 
automatically extracts the arteries and the bronchial tree using a classifier approach,21 
obtains diameter measurements every 0.5 mm via a graph-based method,22 and pairs 
airway and artery branches according to their proximity and similarity in size and 
orientation. Because of the large variations in inspiration level and scanning protocols 
in the NormalCT dataset, the automatic extraction of initial airway centrelines was 
replaced by manually drawn airway centrelines, as detailed in the Appendix. For each 
airway-artery pair, the following measurements were obtained for the inner and outer 
airway diameter measurements separately:
Airway-artery ratio (AA-Ratio)
Ratio between airway diameter and the diameter of its accompanying artery, measured 
at the point where outer airway and artery were most similar in terms of size, orientation, 
and position.
Intra-branch tapering (intraBT)
A line (y = mx + n, where m is the slope of the line and n the y-intercept) was fitted to the 
diameters measured along the airway branch, using the bi-square weights method (see 
Figure 2). Intra-branch tapering was obtained as intraBT =  100 * (-m / n), demonstrating 
the percentage reduction in airway diameter per mm along the centreline. For example, 
a value of 2 means that the airway diameter is reduced 2% each mm. 
Inter-branch tapering (interBT)
interBT = 100 * (1 - (d / d_p)), where d is the average diameter of the analysed airway 
branch and d_p is the average diameter of the parent airway (the airway branch one 
generation previously). A value of 20% would indicate that the airway branch is 20% 
smaller than before bifurcation.
Tapering was measured for all airways, but for ease of comparison with AA-Ratio, only 
measurements of airways paired with an artery are reported, unless otherwise stated.
Reference values
The median was used to summarize all airway-artery measurements per subject. For each 
population, the median and inter-quartile ranges were then reported as reference values.
Image biomarkers for bronchiectasis quantification
Per-subject median AA-Ratio, interBT and intraBT of inner and outer airway were 
compared between Matched-Bronchiectasis and Matched-Control populations to 
assess their value as biomarkers for bronchiectasis.
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To assess changes in biomarkers for varying airway sizes, all airways from the Matched-
Controls dataset were divided in three equally sized groups according to the diameter 
of their accompanying artery. Airways with an accompanying artery smaller than 3.08 
mm, between 3.08 mm and 4.23 mm, and greater than 4.23 mm were considered 
small, medium, and large airways respectively. These thresholds were also applied to 
the Matched-Bronchiectasis and NormalCT datasets. Per subject median values of each 
airway size group were compared between datasets.
FIGURE 2. Diameter measurements along an airway branch in a control subject showing 
progressive reduction of diameter due to intra-branch tapering. Left (0) corresponds to the point 
after bifurcation (closest to the trachea), and right (19) to the point before the next bifurcation.
Stability of biomarkers under varying scanning conditions
In order to assess the stability of the extracted biomarkers to variations in scanning 
conditions, biomarkers extracted from the single-centre spirometry-controlled 
inspiration CTs from the Matched-Bronchiectasis dataset were compared to the 
biomarkers obtained in the CTs from the multicentre NormalCT group that included 
large variation in inspiration level and scanning protocols.
Statistical analysis
Differences between patient groups were assessed with Mann-Whitney U test. 
Spearman correlation coefficient (SCC) was used to assess correlations. P-values < 0.05 
were considered significant.
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RESULTS
Table 1 describes the demographics of all subjects in this study. A total of 22,275 airway 
branches and 153,238 artery branches were automatically extracted in the 180 CT scans 
analysed. Of these, 13,987 airway-artery pairs were detected and their AA-Ratio and 
tapering measurements were automatically measured.
TABLE 1. Demographics and visual scores
Matched-
Bronchiectasis
Matched- 
Controls NormalCT
Age at CT (years) 10.58 [9.74, 11.73] 13.85 [8.72, 15.02] 10.66 [5.52, 14.99]
Gender 7 males; 5 females 7 males; 5 females 101 males; 54 females
Height (cm) 143.7 [137.4, 146.2] 149 [136.6, 170.9] Not Available
Weight (kg) 34.25 [29.52, 40.75] 40.1 [28.58, 65.78] Not Available
BMI 17.22 [15.64, 18.47] 18.05 [15.89, 20.19] Not Available
CFCT BE (%) † 7.5 [1.4, 13.3] 0.0 [0.0, 0.7] * Not Available
CFCT AWT (%) † 5.1 [0.0, 16.3] 0.0 [0.0, 0.0] * Not Available
CFCT MP (%) † 1.4 [0.0, 18.8] 0.0 [0.0, 0.0] * Not Available
CFCT AT (%) † 46.3 [22.2, 66.7] 3.7 [0.0, 8.3] * Not Available
CFCT Total (%) † 8.4 [7, 17.8] 1.2 [0.4, 1.4] * Not Available
All values are expressed as median [lower quantile, upper quartile]. 
* Statistically significant differences with Matched-Bronchiectasis (p-value < 0.05)
† CFCT categories are as follows BE: Bronchiectasis; AWT: Airway wall thickening; MP: Mucus plugging, AT: Air 
trapping.
Reference values
In the NormalCT dataset, median inner intraBT and outer intraBT were 1.16% and 
0.94% respectively, expressed as a percentage reduction in diameter each mm. Median 
inner interBT and outer interBT were 38.54% and 23.75% respectively, expressed as the 
percentage diameter reduction for each airway branching.
Stratified by size, inner intraBT was 1.33%, 1.33%, 0.95%; outer intraBT was 0.94%, 
1.00%, 0.93%; inner interBT was 42.02%, 39.35%, 34.20%; and outer interBT was 25.39%, 
25.08%, 22.08% for small, medium and large airways respectively. See Appendix Tables 
E3,E4 and E5 for details.
Image biomarkers for bronchiectasis quantification
Bronchiectatic patients from the Matched-Bronchiectasis group did not show a 
significant difference (p<0.470) in inner AA-Ratio compared to the Matched-Controls 
population. Outer AA-Ratio was significantly increased (p<0.022) in Matched-
Bronchiectasis compared to Matched-Controls.
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All inter-branch and intra-branch tapering measurements were significantly lower 
(p<0.003) in bronchiectatic subjects, compared to the matched controls.
Figure 3 shows the distribution of each image biomarker, with the descriptive statistics 
detailed in Table 2.
Since tapering measurements do not require a paired artery, tapering measurements 
for all 22,275 airways (13,987 AA-pairs and 8,288 airways without a matching artery) are 
also reported in Appendix Table E2. No significant differences in tapering were observed 
between measurements obtained from all airways and measurements obtained using 
only airways for which a matching artery was found.
Image biomarkers for bronchiectasis quantification, stratified by airway size
Inner and outer AA-Ratio were not significantly different between Matched-
Bronchiectasis and Matched-Controls for any airway size group. In contrast, inner intraBT, 
inner interBT, and outer interBT were significantly lower in Matched-Bronchiectasis than 
in Matched-Controls for all airway size group. Outer intraBT trended to be lower (p<0.08) 
in Matched-Bronchiectasis than in Matched-Controls for all airway size groups.
Figure 4 shows the image biomarkers distribution in the three datasets divided in small, 
medium, and large airways. See Appendix Tables E3 to E5 for detailed values. 
Stability of biomarkers under varying scanning conditions
When all airways were analysed together, inner AA-Ratio and inner intraBT were 
significantly different between control groups. See Figure 3 and Table 2.
When airways were stratified by size, all inner AA-Ratios and intraBT for small airways 
were significantly different between the spirometry-controlled subjects of the Matched-
Controls and the free-breathing subjects of the NormalCT dataset. See Appendix Figure 
E4, and Tables E3-E5.
Correlations with visual scoring
Per-subject median values correlated well with CF-CT bronchiectasis sub-score for all 
biomarkers (Table 3). Only inner interBT and intraBT showed a strong and significant 
correlation with CF-CT bronchiectasis across all airway size groups.
DISCUSSION
Reduced airway tapering has long been known to be an important criterion to define 
bronchiectasis in clinical practice.24 However, to our knowledge, this is the first study 
to obtain reference values for intra- and inter-branch airway tapering and to quantify 
tapering differences between patients with bronchiectasis and control patients.
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An important finding of this study was that a significant reduction in intra-branch 
and inter-branch tapering was observed in bronchiectatic patients in comparison to a 
matched control group, for both inner and outer airway diameter. This is in concordance 
to the lack of tapering described visually in bronchiectatic airways in previous 
studies.4,14,17
More importantly, tapering measurements were significantly reduced in bronchiectatic 
subjects across all airway size groups (Figure 4) and correlated well with visual scores 
(Table 3). This is a clinically important finding because it suggests that lack of tapering 
of the larger airways (with an accompanying artery diameter larger than 4.23 mm) 
is associated with lack of tapering in the smaller airways reflecting a diffuse process 
throughout the bronchial tree. This is in contrast with AA-Ratio, which in this study was 
significantly increased in patients with bronchiectasis only in small airways. Previous 
studies also observed a more pronounced changes in AA-Ratio in the small airways of 
patients with bronchiectasis than in larger airways.10,18 Hence, an increase in AA-Ratio of 
the small airways parallels reduced airway tapering across the bronchial tree and both 
can be used as independent biomarkers reflecting airway disease.
Tapering measurements offer two important advantages over AA-Ratios. First, tapering 
measurements do not require extraction and quantification of arteries, pairing airways 
with arteries, or airway generation labelling. These steps are all likely to introduce 
errors in an automated system. Second, and more importantly, AA-Ratio measurements 
assume that artery size is not affected by disease. This assumption might not hold for 
example in patients with pulmonary hypertension, which is commonly associated with 
COPD,25 or for smokers, where increase in AA-Ratios has been shown to be driven by a 
reduction in vessel diameter.26
Another interesting finding was that significant differences in inner AA-Ratio and inner 
intraBT were observed between the spirometry-controlled inspiration scans of the 
Matched-Controls and the CTs acquired without lung volume control of the NormalCT 
dataset, while none of the outer airway measurements differed significantly between 
control groups. This is in line with previous studies10 that reported that biomarkers 
derived from the outer diameter are more robust to variations in lung volume and 
scanning protocol.
While no reported values exist for inner and outer intra-branch tapering or outer inter-
branch tapering, inner inter-branch tapering (also known as homothety ratio) has been 
previously reported in adult healthy subjects measured in bronchial casts11 and CT 
scans27,28 ranging between 21% and 29%. These values are lower than the median inner 
inter-branch tapering of 38.5% reported as reference value in this study. A possible 
explanation for this difference is that the automatic diameter measurements are 
consistently lower than measured by human observers.20 The same absolute reduction 
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in diameter will then lead to higher values expressed as a percentage. Additionally, these 
studies analysed healthy adults while the present study analysed paediatric diseased-
controls. Two previous studies have measured airway tapering in bronchiectatic 
subjects, focusing solely on inner inter-branch tapering computed over multiple airway 
branches and correlatingchanges in airway tapering with changes in visual scores. In 
line with the results of this study, both studies found a significant correlation between 
taper indices and visual scores: Odry et al.29 found a correlation between inner airway 
tapering and visual inspection of bronchiectasis in one healthy and 8 diseased subjects. 
Weinheimer et al.30 found a correlation between lobar inner airway taper indices and 
visual scores in 144 CTs of paediatric CF patients. Finally, Venkatraman et al.31 detailed a 
method to quantify airway tapering but no measurements were reported.
This study has several limitations. A first limitation is the small number of subjects with 
bronchiectasis analysed. However the high number of airways analysed per CT  meant 
that 2,398 airways were analysed on the 12 Matched-Bronchiectasis CTs. A second 
limitation is that the control groups might be affected by other diseases. All control 
subjects were checked by two independent radiologists who discarded any subject 
with signs of lung abnormalities or bronchiectasis on the CT scan, but we cannot 
exclude that subtle signs of lung abnormality may have been missed which could have 
reduced the differences between bronchiectatic and control groups. A third limitation 
is that median values were analysed, and therefore pathological changes that affect 
only a minority of airways in each subject or each airway size group within a subject 
might have been missed. A fourth and final limitation is that a previous study that used 
the same dataset10 found significant differences in outer AA-Ratio between healthy and 
bronchiectatic subjects when airways were stratified by generation. This differs from the 
current study, where no significant differences in outer AA-Ratio were found between 
diseased and controls when airways where stratified by size. This discrepancy might 
be explained because in this study the median outer AA-Ratio of each airway group 
and subject was used to assess differences between diseased and controls in order 
top cope with spurious measurements, while the previous study included all AA-Ratio 
measurements in a mixed model analysis, leading to higher statistical power.
In conclusion, we demonstrated that with the use of automated medical image analysis 
techniques it is possible to quantify airway tapering in chest CTs of paediatric patients 
with and without bronchiectasis. We reported tapering reference values, showed that 
tapering changes associated with CF bronchiectasis occur nearly uniformly across all 
airway sizes, and that airway tapering changes can be readily observed in larger airways 
than changes in AA-Ratios.
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APPENDIX 
MATERIALS AND METHODS
Detailed description of datasets used
Matched-Bronchiectasis: Spirometer-guided inspiratory chest computed tomography 
(CTs) of 12 patients with bronchiectasis (11 cystic fibrosis and 1 common variable 
immunodeficiency) on CT were selected retrospectively between 2007 and 2012. All 
patients were treated at Erasmus MC-Sophia Children’s Hospital. Inclusion criteria were: 
age between 6 and 17 years old, spirometer guided chest CT acquired with SOMATOM® 
Definition Flash CT scanner (Siemens Healthcare, Forchheim, Germany). Exclusion: bad 
image quality due to motion artefacts; negative remark on breath hold performance 
by lung function technician. The dataset initially consisted of 12 randomly selected CF 
patients that meet the selection criteria of which the subject with common variable 
immunodeficiency was mislabelled.
Matched-Controls: Spirometer guided inspiratory chest CTs of 12 subjects without 
lung abnormalities on CT acquired with SOMATOM® Definition Flash scanner. Subjects 
were referred to Erasmus MC-Sophia Children’s Hospital due clinical reasons for CT 
other than CF with the Erasmus MC radiology report stating chest CT to be normal, and 
confirmed as normal by a second independent radiologist (Dr. Chen Yong, 20 years of 
experience in thoracic imaging) who was blinded to patient identifiers and information. 
Out of 16 chest CTs that met the above mentioned criteria, we selected the 12 CTs with 
best matched ages to the Matched-Bronchiectasis group.
NormalCT: The Children Chest CT Study Group is a group of 10 multinational centres 
who retrospectively collected chest CTs of children aged 0-19 years old. Inspiration 
and expiration Chest CTs were made for various diagnostic indications but reported as 
normal by the centre’s radiologist. All patient data was anonymized, with the exception 
of gender and age at the time of exam. Scans were sent to Erasmus MC where a 
second radiologist (CY, 20 years experience in thoracic imaging) discarded any scans 
not assessed as normal. A subset of 156 CTs from 3 different centres were ready to be 
analysed at the time of this study: Barcelona (Spain), Boston (United States), and Utrecht 
(the Netherlands). 42 scans (27.10%) were obtained with contrast. 82 scans (52.90%) 
were not spirometry-controlled or pressure-controlled and no information was available 
for the rest.
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CT scanning parameters
End-inspiratory volumetric acquisitions from the Matched cohorts were obtained with a 
SOMATOM® Definition Flash scanner (Siemens Healthcare, Forchheim, Germany) under 
spirometry-guided conditions. Subjects from the NormalCT cohort were scanned in 6 
different scanners mainly without lung volume control. Details of the scan parameters 
are provided in e-Table 1 of this Appendix.
CF-CT visual scores 
All de-identified CTs from the Matched datasets (both diseased and controls) were 
scored (Hadiye Ozturk, 1 year experience) in random order for structural changes using 
the CF-CT scoring module.1,2 The CF-CT scoring system evaluates the five lung lobes 
and lingula for severity and extent of bronchiectasis, airway wall thickening, mucous 
plugging, and opacities on inspiratory CT.  Only the CF-CT score component regarding 
bronchiectasis is reported in this study.
Automatic quantification of airways and arteries
Initial coarse segmentations of airway lumen for both Matched datasets, and for arteries 
in all scans, were obtained automatically using a voxel classifier approach.3
For the Normal CT dataset, where large variability exists between CTs in terms of scanning 
protocols and levels of inspiration, we opted for a semi-automated approach to obtain 
the initial coarse segmentation of airway lumen. First an automatic segmentation was 
obtained  using the region growing algorithm tool of Myrian® (v1.16.2, Lung XP module) 
image analysis platform (Intrasense, Montpellier, France) and then the segmentation 
was refined manually using the same platform to include all airway branches and 
remove false positives. A full CT was annotated in around 1 hour.
All initial segmentations were automatically refined using a graph-cut method to detect 
the inner and outer surfaces of the airways and the artery surfaces.4 Next, artery and 
inner and outer airway diameter measurements were extracted every 0.5 mm along the 
centrelines. Diameter measurements of airway and artery branches shorter than 5 mm 
were not considered reliable and were discarded. Airway and artery branches located in 
close proximity and with similar orientation and size were automatically paired together 
as airway-artery pairs, using the formulation described in Perez-Rovira et al.5
To adjust for variations in lung size due to differences in subject size, gender, and 
inspiration level, all centrelines and associated diameter measurements were isotropically 
rescaled using the cubic root of the lung volume measured in CT to correspond to a 
lung of 4 litres in volume, which is close to the mean measured lung volume of all scans.
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RESULTS
Image biomarkers for bronchiectasis quantification, stratified by airway 
size
Appendix Tables E3 to E5 detail the descriptive statistics of the Figure 4 shown in the 
main document. In these the median and distribution of each image biomarker are 
shown for each datasets divided in small, medium, and large airways.
APPENDIX TABLE E1. Scan parameters used to obtain the CTs. 
Matched-
Bronciectasis
Matched-Controls NormalCT
Scanner model SOMATOM Definition 
Flash
SOMATOM Definition 
Flash
Brilliance 16P (x18), 
Brilliance 64 (x90), 
Mx8000 IDT 16 (x1), 
SOMATOM Definition 
AS+ (x12), Sensation 16 
(x2), Sensation 64 (x19)
Slice thickness (mm) 1.00 (0.75, 1.00) 1.00 (1.00, 1. 00) 1.50 (0.75, 2.00)
Reconstruction increment 
(mm)
0.60 (0.30, 1.00) 0.80 (0.60, 0.80) 1.00 (0.40, 1.50)
Reconstruction kernel B70f (x5), B75f (x7) B75f (x5), 
I70f\3 (x7)
B (x5), B20f (x5), B30f 
(x1), B50f (x4), B60f (x7), 
B70f (x16), C (x20), D 
(x1), L (x14), YA (x81), 
YB (x2)
Tube voltage (kV) 80 (80 - 80) 100 (80, 120) 120 (80, 120)
CTDI 0.74 (0.57, 0.83) 0.76 (0.32, 1.13) 1.90 (0.40, 17.60) *
Values expressed as: median (min, max).
* 21 scans did not include CTDI data
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ABSTRACT 
Objective
To provide normative data of central airway dimensions on chest CT in the pediatric 
population. 
 
Methods
Chest CTs reported as normal by a radiologist were collected retrospectively in ten 
international centers. An experienced and independent thoracic radiologist reevaluated 
all CTs for image quality and for normality. Semi-automated image analysis (Myrian®, 
Intrasense, Montpelier, France) was performed to measure dimensions of trachea, right 
(RMB) and left main bronchus (LMB) at inspiration. Intrathoracic tracheal length was 
measured from carina to thorax inlet. Cross sectional area, short and long axes were 
measured perpendicular to the longitudinal airway axis starting from carina every cm 
upwards for the trachea and every 0.5 cm downwards for the main bronchi. The effect of 
age, gender, intrathoracic tracheal length and distance from carina on airway diameters 
was investigated using mixed-effect models analysis.
  
Results
Out of 1160 CTs collected, 390 (33.6%) were evaluated normal by the independent 
radiologist with sufficient image quality and adequate inspiratory volume level. Central 
airways were successfully semi-automatically analyzed in 294 (75.4%) out of 390 CTs. 
Age, gender, intrathoracic tracheal length and distance from carina were all significant 
predictors in the models for tracheal, RMB and LMB diameters (p<0.001). The central 
airway dimensions increased with age up to 20 years and dimensions were larger in 
adolescent males compared to females.
 
Conclusion
Normative data were determined for the central airways of children and adolescents. 
Central airway dimensions were dependent on distance from the carina and on the 
patient’s intrathoracic tracheal length. 
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INTRODUCTION 
Currently, central airway dimensions can be accurately assessed with chest computed 
tomography (CT). Unlike bronchoscopy, chest CT is a non-invasive method and can 
allow objective measurements of the central airway dimensions.1 Configuration and 
dimensions of the central airways have shown to be dependent on age in children.2–4 
The integrity of the central airways is an important determinant for lung health. Several 
congenital and acquired abnormalities of the intrathoracic airways cause reduction 
in the dimensions of the trachea or mainstem bronchi, which can lead to mortality 
and morbidity such as severe and chronic respiratory symptoms.5 For the objective 
assessment of central airway dimensions, comparison to a reference population is 
needed.6 Normative data can be used to assess and diagnose various central airway 
structural abnormalities such as trachea-broncho-megaly,7 tracheobronchomalacia,8 
congenital or acquired stenosis9,10 or extrinsic compression by surrounding mediastinal 
masses or vascular anomalies.11,12 Reference values can especially be valuable for 
radiologists, anesthesiologists, pediatricians, otolaryngologists and thoracic surgeons.
 Normative dimensions of the trachea are currently based on studies with small sample 
sizes,13 studies in adults14 or on studies more than 30 years old using older generation CT 
scanners.4,15 To the best of our knowledge, mainstem bronchus dimensions have never 
been assessed on CT of pediatric patients. In addition, the dimensions of the trachea 
have only been assessed at few tracheal points and not over its entire intrathoracic 
length from the carina to the thoracic inlet. Finally, in the previous studies, central 
airway dimensions were obtained with manual measurements, and not with semi-
automatic segmentation software, which reduces operator dependency and lead to 
more objective measurements.16 
Prospective and systematic assessment of central airways in healthy growing children 
using chest CT would involve exposure to ionizing radiation and may therefore be 
considered unethical.17 In order to overcome these limitations while obtaining pediatric 
CT reference values, the Children Chest CT study group was founded to collect chest CTs, 
obtained for various clinical indications, and eventually considered to be normal by 
the reporting radiologist. This study aimed to provide normative data of central airway 
dimensions on chest CT in the pediatric population. 
METHODS 
This study was approved by institutional review board (IRB) at the Erasmus Medical 
Center (MEC-2011-494), followed by approval by the local IRB from each participating 
institution. Written informed consent was waived for all subjects because of the 
retrospective study design.
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Study population 
Chest CTs of children and adolescents were collected retrospectively by the international 
multicenter Children Chest CT study group. Details on participated centers are included 
in the Appendix. CT data were collected between December 2011 and March, 2013 and 
CT scans were made from 2003 to 2013 for various diagnostic indications. Inclusion 
criteria were: all chest CT protocols, age at the time of CT between 0 and 20 years old; 
normal trachea, lung and heart according to the radiologist’s report. 
CT scanning and scoring
All CTs were anonymized for patient specific and clinical information by the participating 
centers and sent to the Erasmus MC LungAnalysis core laboratory for further analysis. 
An independent radiologist (CY, 20 years of experience in pediatric thoracic imaging) 
reevaluated all CTs made in supine position for image quality and abnormalities. CTs 
were included for this study if they fulfilled the following requirements: no pulmonary, 
thoracic cavity or cardiac abnormalities; contiguous helical CT acquisition overlap in the 
images defined as slice thickness > reconstruction increment; sufficient inspiratory lung 
volume as defined by a round shape of the trachea and presence of lung parenchyma 
between the heart and sternum; no visible endotracheal tube; no artifacts or mild 
artifacts with minimal effect on the visualization of the central airways. More detailed 
information on the scan parameters is provided in Appendix Table E1.
The measurements of the central airways were conducted by two trained observers (A.H. 
and N.E., both medical students with two months training in thoracic CT image analysis). 
The CTs were divided in 2 equal batches which were scored by the two observers 
supervised by a PhD-student (W.K.) with 4 years’ experience in thoracic imaging 
research. Detection of the central airways was done automatically using Myrian® v1.19.1 
(XP Lung module, Intrasense, Montpelier, France) designed to segment the bronchial 
tree on CT with a soft kernel reconstruction filter which suppresses image noise at the 
cost of image resolution (See Appendix Table E1 for all the specific kernels used). The 
algorithm worked in three phases: 1. Detection of seed points belonging to the trachea. 
2. Launch of a region growing based algorithm from previously adapted seed points. 
3. Computation of a centerline for all branches of the segmented region of interest. 
An example of the inner airway segmentation and the measurements of the central 
airways is shown in Appendix Figure E1. The CTs that failed automatic detection of the 
entire central airways including the trachea, RMB and LMB by Myrian were excluded. 
A three-dimensional (3D) volume rendering reconstruction of the trachea and main 
bronchi pathway was generated. The length of the segmented central airway could not 
be measured automatically therefore the . intrathoracic tracheal length was measured 
manually with a digital ruler from the thorax inlet, defined as the first image slice where 
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both lung apices became visible, to the carina. Cross-sectional area (CSA), longest and 
shortest diameters were automatically measured perpendicular to the centerline of 
the airway lumen. A digital ruler was positioned manually on the 3D segmentation to 
annotate the dimensions for the trachea at every cm starting from the thoracic inlet 
to the carina. Similarly, dimensions were annotated for the right (RMB) and left (LMB) 
main bronchi every 0.5 cm (since these structures are shorter than the trachea) from 
the carina to the origin of the upper lobe bronchus, which was considered the end of 
each mainstem bronchus. Since the software could not measure the anterior-posterior 
and lateral diameter, the diameter of the trachea, RMB and LMB at each location were 
computed using the mean of the longest and shortest diameter,. 
The intrathoracic trachea, RMB and LMB were divided in several sections as demonstrated 
in Figure 1. For each patient, the length of the intrathoracic trachea was divided in three 
equal sections; i.e. proximal, middle and distal. Length of the relatively shorter RMB was 
divided in two equal sections (proximal and distal) and the relatively longer LMB was 
divided in three equal sections (proximal, middle and distal).
In addition, ratios between the median LMB and tracheal diameter and between median 
RMB and tracheal diameter were calculated for each subject.  
FIGURE 1. This figure shows the trachea, right (RMB) and left main bronchus (LMB) with the 
sections it was divided in. The intrathoracic trachea starts when both apical lungs are visible and 
was divided in 3 equal sections; i.e. proximal, middle and distal section (from dark to light grey, 
respectively). The relatively shorter RMB was divided in 2 equal sections to define the proximal 
(dark grey) and distal (light grey) section of the main bronchi. The relatively longer LMB was 
divided in 3 equal sections to define the proximal, middle and distal section (from dark to light 
grey, respectively) of the main bronchi (Artist: K. Rubenis). 
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Intra-, and inter-observer reliability
To assess intra-observer variability of the central airway measurements both observers 
repeated measurements on 25 randomly selected CTs after one month of completion. 
To assess the inter-observer variability, the measurements of 25 randomly selected CTs 
from observer 1 were repeated by observer 2.  
Statistical Analysis
Patients were divided into ten age groups by 2 year intervals to express the central 
airway dimensions as median and interquartile range (IQR). Boxplots were made with 
1.5 times IQR whiskers to demonstrate the range of the reference values without the 
outliers. 
Mixed-effect models were performed to model the diameters of the central airways 
(trachea, RMB and LMB) accounting for age, gender, intrathoracic tracheal length and 
distance from carina. A multivariable linear regression model was used assuming one 
measurement per patient to assess the relationship between the ratios of LMB to trachea 
and RMB to trachea with age and gender. A p value < 0.05 was considered significant 
and correction for multiple testing was not performed.  
Intraclass correlation coefficient (ICC) was calculated to measure inter-, and intra-
observer agreement using mixed-effects models. In these models the structure of the 
data was taken into account, specifically the repeated location measurements and 
repeated patient measurements. Generally, ICC values between 0.4 and 0.6, 0.6 and 
0.8, and ≥ 0.8 are considered to represent moderate, good and very good agreement, 
respectively.18
RESULTS 
Study population
In total, 1160 CTs were collected by the Children Chest CT study group of which 258 were 
excluded by the independent thoracic radiologist (CY) since they were defined abnormal 
for reasons such as regions of low attenuations suggestive for pulmonary trapped 
air, pleural thickening and consolidations. 286 CTs were excluded due to insufficient 
overlap of the images (slice thickness > reconstruction increment). Of the remaining 
616 CTs, 388 met the criteria for a good inspiratory lung volume level without artifacts 
impairing the visualization of the central airways. These 388 CTs were analyzed using 
semi-automatic detection of the central airways of which 94 failed related to variations 
in image acquisition settings and reconstruction kernel used (see Appendix Table E1). 
Finally, 294 CTs were included in the analysis (see Appendix Figure E2 for flow chart).
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Demographics of the subjects and median diameters of the trachea and main bronchi 
are presented according to age group and gender in Table 1. The 95% confidence 
intervals are shown for the intrathoracic tracheal length (Figure 2A) and the diameter 
of the trachea (Figure 2B), RMB (Figure 2C) and LMB (Figure 2D) for each age group and 
gender. Older age, male gender, longer intrathoracic tracheal length and closer distance 
from the carina were all significant predictors for larger tracheal, LMB and RMB diameters 
in the mixed-effect model (p<0.001). Moreover, the effect of age on the tracheal, LMB 
and RMB diameters is found to be different for males and females since the interaction 
between gender and age was found to be significant (p<0.001). As shown in Fig 2B, C 
and D, the diameters of the trachea and main bronchi were all increasing equally in 
male and female subjects until the age of 14. After that diameters were greater for male 
compared to female. 
TABLE 1. Dimensions of the central airways by age and gender
Age, 
range  
(in years)
Gender N patients 
Age 
median, 
IQR  
(in years)
Tracheal 
length, 
median, 
Q1-Q3  
(in mm)
Tracheal 
diameter, 
median,  
Q1-Q3   
(in mm)
LMB 
diameter, 
median, 
Q1-Q3  
(in mm)
RMB 
diameter,  
median, 
Q1-Q3  
(in mm)
≥0 and <2 Male 5 1.3, 0.6 32.7, 32.3-35.4 6.8, 6.2-7.5 4.2, 4.1-4.5 5.2,4. 7-5.5
Female 0
≥2 and <4 Male 7 3.6, 0.5 45.5, 37.0-45.9 7.8, 7.3-8.1 5.1, 4.5-5.7 6.7,6.4-7.0
Female 1 3.4, 0.0 30.9, 30.9-30.9 6.7, 6.7-6.7 4.0, 4.0-4.0 5.6,5.6-5.6
≥4 and <6 Male 5 5.2, 0.7 45.6, 43.5-46.5 7.9, 7.6-9.2 5.0, 4.7-5.8 7.0,5.9-7.2
Female 1 5.5, 0.0 45.9, 45.9-45.9 8.3, 8.3-8.3 5.4, 5.4-5.4 7.1,7.1-7.1
≥6 and <8 Male 7 6.8, 0.7 52.2,47.2-56.6 9.0, 8.6-9.2 6.3, 5.9-6.7 8.1,8.0-8.3
Female 9 7.3, 1.1 52.7, 50.5-57.4 9.9, 8.9-11.2 6.4, 6.2-6.8 8.2,7.3-9.5
≥8 and <10 Male 9 9.4, 0.6 60.1, 56.8-62.3 10.5, 10.4-10.9 6.7, 6.2-7.3 8.7,8.1-8.9
Female 6 9.3, 0.9 49.5, 47.8-52.9 10.3, 9.6-10.8 7.1, 6.4-7.3 9.3,8.4-9.7
≥10 and <12 Male 22 11.3, 1.1 63.8, 58.6-71.0 10.6, 10.2-11.3 7.0, 6.6-7.2 8.9,8.6-9.4
Female 13 11.1, 0.8 56.1, 54.4-60.4 11.2, 10.6-11.5 6.7, 6.3-7.4 8.9,8.3-10.2
≥12 and <14 Male 35 13.3, 0.8 71.0, 65.5-77.4 12.7, 11.6-13.5 8.5, 7.7-9.2 10.8,9.7-11.4
Female 14 13.2, 1.1 68.2, 63.0-72.7 12.2, 11.8-13.2 8.4, 7.3-9.0 10.9,10.2-11.1
≥14 and <16 Male 29 14.9, 0.6 77.9, 72.2-83.4 14.8, 13.2-15.8 9.7, 8.6-10.6 12.1,10.9-13.6
Female 28 15.3, 0.8 68.1, 66.6-73.0 11.8, 11.5-13.4 8.0, 7.4-8.8 10.6,9.8-11.7
≥16 and <18 Male 36 17.1, 0.9 76.0, 69.2-84.8 14.9, 14.3-16.4 10.1, 9.1-10.7 12.3,11.8-14.0
Female 13 17.2, 1.0 73.9, 65.5-82.1 12.7, 12.5-13.7 8.4, 7.9-8.8 11.3,10.6-11.9
≥18 and <20 Male 28 18.8, 1.1 81.8, 69.2-87.3 15.8, 15.3-16.9 10.4, 9.4-11.6 13.1,12.7-14.4
Female 26 18.7, 0.8 71.2, 65.2-78.9 13.6, 12.5-14.3 9.0, 7.9-9.5 11.5,10.8-12.5
All Male 183 14.2, 5.7 70.6, 59.8-80.4 13.2, 10.7-15.4 8.7, 7.0-10.2 11.2,8.9-12.8
Female 111 15.2, 5.9 66.9, 58.6-72.9 12.0, 11.1-13.4 7.8, 6.9-8.9 10.6,9.6-11.7
Dimensions of the trachea, left (LMB) and right main bronchus (RMB) separated by age groups and by gender. 
Age is described as median and the 25th to 75th percentile (Q1-Q3). Tracheal length from carina to the thorax 
inlet is described as the median, first and third quartile. The tracheal, LMB and RMB dimensions are described 
as median, first and third quartile of the diameter of the shortest and longest diameter. 
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FIGURE 2. The mean and 95% confidence interval for each age group in males (black) and females 
(gray) subjects are demonstrated for the tracheal length (A), tracheal diameter (B), diameter of the 
right main bronchus (C) and diameter of the left main bronchus (D). An apparent difference in the 
diameter of the trachea, right main bronchus and left main bronchus is visible between male and 
female subjects after the age group of 12-14 year olds.
The diameter of the central airways are depicted for each section in table 2 and cross 
sectional areas of the central airways according to the age group and gender are 
depicted for every distance from the carina in Appendix Table E2. Diameters of the 
trachea (Figure 3), RMB (Figure 4) and LMB (Figure 5) are plotted in boxplots for male 
and female subjects for each section in ten age groups. The mixed-effect model showed 
that the distal section was significantly larger than the middle and proximal section of 
the trachea (p<0.001). Mixed-effect model predicting RMB dimensions showed that the 
proximal section was also significantly larger than the distal section (p<0.001). Lastly, 
the mixed-effect model prediction for LMB dimensions showed that the proximal part 
was significantly larger than the middle and distal sections (p<0.001). In addition, the 
distal section of LMB was larger than the middle section (p=0.002). Diameters of the 
trachea (Appendix Figure E3), RMB (Appendix Figure E4) and LMB (Appendix Figure E5) 
are demonstrated as a function of the distance from the carina for both the male and 
female subjects in the ten age groups.
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FIGURE 3. Boxplots are shown of the mean tracheal diameter for each age group in male (top) and 
female (bottom) subjects in each section of the trachea. The green color scheme demonstrated 
from dark to light represent the proximal, middle and distal section of the trachea. Each box 
shows median (horizontal line), interquartile range (solid box), 1.5*interquartile range (whiskers) 
and outliers (points).
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FIGURE 4. Boxplots are shown of the mean right main bronchi diameter for each age group in 
male (top) and female (bottom) subjects in section of the main bronchi. Dark and light green 
represents the proximal and distal section of the right main bronchi, respectively. Each box shows 
median (horizontal line), interquartile range (solid box), 1.5*interquartile range (whiskers) and 
outliers (points).
Ratios between median RMB and tracheal diameter and between the median LMB and 
tracheal diameter were calculated for each subject. The mean ± standard deviation was 
0.85 ± 0.06 for RMB to trachea ratio and was 0.66 ± 0.06 for LMB to trachea ratio. The 
multivariable linear regression model showed that age, gender and the interaction 
between age and gender were not significant determinants of the RMB to trachea ratio 
(p>0.30) and were not significant determinants for the LMB to trachea ratio (p>0.20). 
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FIGURE 5. Boxplots are shown of the mean left main bronchi diameter for each age group in male 
(top) and female (bottom) subjects in each section of the main bronchi. The green color scheme 
demonstrated from dark to light represent the distal, middle and proximal section of the main 
bronchi. Each box shows median (horizontal line), interquartile range (solid box), 1.5*interquartile 
range (whiskers) and outliers (points).
Reproducibility of measurements
ICCs intra-observer 1: Tracheal CSA = 0.81; diameter = 0.92.  RMB CSA = 0.77; diameter = 
0.79. LMB CSA = 0.81; diameter = 0.83. Intrathoracic tracheal length = 0.99
ICCs intra-observer 2: Tracheal CSA = 0.99; diameter = 0.98.  RMB CSA = 1; diameter = 
0.99. LMB CSA = 1; diameter = 0.99. Intrathoracic tracheal length = 0.99
ICCs inter-observer: Tracheal CSA = 0.79; diameter = 0.88.  RMB CSA = 0.91; diameter = 
0.94. LMB CSA = 0.98; diameter = 0.97. Intrathoracic tracheal length = 0.98. 
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TABLE 2. Tracheal diameter by age and gender for each location
Age range  
(in years) Gender n
Tracheal diameter (in mm) for each section.  
Measurements are in median; IQR
distal middle proximal
≥0 and <2 Male 5 7.1; 0.8 6.9; 1.3 6.3; 1.2
Female 0 NA NA NA
≥2 and <4 Male 7 8.1; 1.3 7.7; 0.8 7. 3; 1. 3
Female 1 8.6; 0.0 6.9; 0.2 6. 5; 0.4
≥4 and <6 Male 5 8.9; 1.0 8.0; 1.2 7.9; 1.8
Female 1 8.4; 0.2 8.3; 0.2 8.2; 0.1
≥6 and <8 Male 7 9.9; 1.5 9.0; 0.6 8.6; 1.3
Female 9 10.6; 2.6 9.5; 2.3 9.9; 2.7
≥8 and <10 Male 9 11.0; 1.0 10.4; 0.9 10.5; 1.3
Female 6 10.9; 2.1 10.2; 1.0 10.0; 1.5
≥10 and <12 Male 22 11.0; 1.3 10.6; 1.0 10.5; 1. 9
Female 13 11.3; 1.9 10.9; 1.2 11.2; 1.3
≥12 and <14 Male 35 13.0; 2.6 12.6; 2.1 12.5; 2.0
Female 14 13.3; 2.2 12.5; 1.8 12.3; 1.7
≥14 and <16 Male 29 15.1; 3.1 14.5; 2.4 14.9; 2.5
Female 28 12.9; 2.4 12.4; 2.3 11.7; 1.9
≥16 and <18 Male 36 15.5; 2.5 14.6; 2.2 15.1; 2.6
Female 13 14.3; 2.5 13.2; 1.4 12.4; 1.8
≥18 and <20 Male 28 16.1; 2.2 15.9; 1. 9 15.9; 2.6
Female 26 14.5; 2.4 13.5; 2.0 13.3; 2.0
All Male 183 14.2; 4.3 13.4; 4.4 13.6; 4.6
Female 111 13.0; 2.9 12.4; 2.4 11.9; 2.2
Diameter of the trachea separated by age groups and by gender for each location of the measurement. 
Results are expressed in median; interquartile range (IQR).  
DISCUSSION 
Normative data for central airway dimensions are provided as a function of age and 
gender, in a large cohort of normal pediatric chest CTs. 
This is the first study to show tracheal and main stem bronchial dimensions to be largest 
near the bifurcations: central airway dimensions are larger near the carina and the 
mainstem bronchi bifurcations. The dimensional increase near a bifurcation is presumed 
to be due to the division into the following two airway branches. 
Secondly, our study in children up to 20 years old shows that central airway dimensions 
increase gradually with age. In particular, male and female subjects have similar 
dimensions of the airways from birth until approximately age 14. After this age, there 
is an apparent difference between genders in terms of the tracheal, LMB and RMB 
dimensions, with significantly larger dimensions found in boys compared to girls. This 
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difference is likely a resultant size differences between boys and girls after puberty,19 
where the growth of the central airways in boys continues and start to declines in 
females. Changes in the tracheal dimensions with age and gender in this study are in 
agreement with a previous smaller study by Griscom et al.4, except gender differences 
were observed only after age 15. Similar cross-sectional dimensions of the trachea were 
shown previously in 38 infants below the age of 2.5 years by Rao at al. 20 however, the 
CSA of the RMB were slightly smaller and the reference values on the LMB were not 
presented20. The entire mainstem bronchi dimensions have not been assessed on CT 
and published in children previously. 
Lastly, this study also confirms that the LMB to trachea ratio is not dependent on age and 
gender in children. Brodsky et al.21 showed that the LMB to trachea ratio was constant 
for 30 adults. A slightly smaller mean ratio of 0.66 was found in children and adolescents 
in this study compared to a 0.75-0.77 ratio found previously in adults.21 This relatively 
small difference could be secondary to slightly different ratios existing in adults relative 
to children, or better CT image quality. The main bronchi to trachea ratio is relevant 
for anesthesiologists for the selection of the appropriate double-lumen endobronchial 
tube for selective intubation of the LMB or RMB.22,23 RMB to trachea ratio is provided in 
the present paper for children and adolescents and demonstrated to be constant as 
well. 
This study, however, comes with several limitations. First, CTs were made for clinical 
reasons and despite our strict selection criteria, we may not be able to completely exclude 
some degree of underlying potential pathology involving central airways. Second, the 
CTs were not acquired using a standardized CT scanning protocol or standardized lung 
volume during CT acquisition, as the dataset was collected retrospectively. This resulted 
in different image qualities which could have impact the reference values presented in 
this study. However, an advantage of this approach was  a larger study population. In 
addition, the heterogeneity of several CT scanners is related with a superior translation 
in the clinical practice where CT scanners and image quality of CTs are also diverse, 
and therefore and improved external validity. Regarding the lung volume during CT 
acquisition, the majority of CT studies were obtained at end-inspiratory which is current 
standard. Shape and dimensions of the central airways are known to be influenced by 
lung volume level during CT acquisition.24,25 In this dataset there was however variance 
in lung volume protocols including scans acquired from free breathing to inspiratory 
and expiratory breath holds in cooperative children or with pressure control in younger 
children. In order to overcome this limitation in this retrospective study, we only 
included CTs with features of an appropriate inspiratory volume level. As more centers 
are nowadays implementing spirometer guided chest CTs in children,26 it should be 
noted that observed dimensions are likely to be somewhat larger on spirometer guided 
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CTs, with lung volume near the total lung capacity, compared to our findings. Third, 
this diverse dataset did not collect information about patient’s height, weight, BMI, 
size of the chest or ethnicity. These factors could be confounders of central airways 
dimensions. However, we believe that our patient’s population who includes patients 
with various height, weight, BMI and ethnicity may be beneficial, because the results of 
study can be more easily generalized to other pediatric populations. Fourth, we were 
not able to measure the entire trachea starting from the vocal cords as this region was 
frequently outside the   CT scan range. Therefore, we decided to use the intrathoracic 
length of the trachea. It should be noted that with older age a larger part of the entire 
trachea is measured. Fifth, the results of this study only included CT data retrieved 
automatically using Myrian®, which was 76% of the available data. Lower image quality 
due to lower radiation exposure might be the reason of the failed automated analysis.27 
In fact, radiation exposure in the scans that failed automated analysis was significantly 
lower. However we believe the exclusion of CT scans did not lead to substantial bias in 
the results as age and gender did not differ significantly between the failed scans and 
the scans included in this study. Lastly, the final sample sizes were smaller in females 
compared to males and smaller in the younger age group. This might have led to a 
somewhat unbalanced comparison between genders and  young children. Additionally, 
there was insufficient data to make smaller interval groups in the first two years of life 
when there is the greatest period of lung growth. Therefore, there is still a need for 
additional normative values in the younger age groups. 
In the future, normative values for central airway dimensions could be ideally collected 
prospectively in healthy children using MRI which is a radiation free alternative for chest 
CT. However, it is currently still challenging to acquire high resolution chest MRI under 
sufficiently standardized conditions from infancy into adolescence. Acquisition of chest 
MRI in young children is challenging and will likely require ethical approval similar 
to chest CT in case sedation is needed.28 In addition, current MRI spatial resolution is 
between 1-2 mm in breath-hold condition and below in 1 mm using the newest free 
breathing ultra-short echo time scans.29,30 Unfortunately, free breathing scans are 
acquired around functional residual capacity; therefore, underestimating the maximal 
dimensions of airway’s lumen.
CONCLUSIONS
In our study, CT normative data were determined for the central airways in a large group 
of children and adolescents. Central airway dimensions were dependent on the location 
of the measurement relative to the location of the carina. The dimensions of the central 
airways increase with age and intrathoracic tracheal length and were larger in males 
compared to females after approximately 13 – 14 years old.
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APPENDIX 
Methods
The following centers contributed to the Children Chest CT study group dataset (ordered 
according the number of CT scan provided, from highest to lowest): University Medical 
Center Utrecht, Utrecht, the Netherlands; Hospital Universitari Vall d’Hebron, Barcelona, 
Spain; Erasmus Medical Center- Sophia Children’s Hospital, Rotterdam, the Netherlands; 
University of Rome Sapienza, Rome, Italy; Cincinnati Children’s Hospital Medical Center, 
Cincinnati, Ohio, USA; Boston Children’s Hospital and Harvard Medical School, Boston, 
MA, USA; Queen Silvia Children’s Hospital, University of Gothenburg, Gothenburg, 
Sweden; University of Leuven, Leuven, Belgium; General Hospital,  Ospedale Ca’Foncello, 
Treviso, Italy; Princess Margaret Hospital for Children and Telethon Kids Institute, Perth, 
WA, Australia 
APPENDIX TABLE E1. Scan parameters of included and excluded CTs.
Included scans Excluded scans P-value
n 294 94
Age 11.79 (7.16-25.96) 13.95 (9.84- 16.76) 0.10
Gender 108 males, 186 females 52  males, 42 females 0.24
CT scanners 14x GE; 109x Philips; 152x 
Siemens; 19x Toshiba 
7x GE; 42x Philips; 39x 
Siemens; 6x Toshiba 
-
Tube voltage (kV) 120 (100-120) 120 (100-120) 0.09
Pitch 1 (1-1) * 5 (5-6) # 0.45
Slice thickness (mm) 1 (1-2.5) 1.5 (1-1.5) 0.51
Reconstruction increment 
(mm)
0.8 (0.7-1.2) 1 (0.7-1.24) 0.13
Reconstruction kernel GE: 9x LUNG; 2x SOFT; 3x 
STANDARD
Philips: 17x B; 40x C; 2x D; 28x 
L; 18x YA; 3x YB; 1x YD
Siemens: 6x B20; 2x B26; 14x 
B30; 21x B31; 1x B46; 2x B50; 
29x B60; 54x B70; 13x B75; 4x 
B80; 6x I30
Toshiba: 1x FC05; 1x FC10; 
10x FC12; 7x FC18
GE: 5x LUNG; 1x SOFT; 1x 
DETAIL
Philips: 2x B; 13x C; 1x L; 25x 
YA; 1x YC
Siemens: 2x B31; 7x B60; 8x 
B70; 6x B75; 6x I70
Toshiba: 1x FC05; 4x FC12; 
1x FC18
-
Current-time product (mAs) 56.36 (36.48-101.2) * 44.55 (23.56-97.36) # 0.03
CTDI (mGy) 3.53 (1.7-5.4) * 2.16 (0.96-4.95) # 0.45
Summary of the scan parameters of the CTs included in this study (middle column) and the scan parameters 
of the excluded CT scans with failed automatic reconstruction (right column). The parameters are shown with 
median, interquantile range. * 238 scans did not include pitch; 4 scans did not include current-time product; 
127 scans did not include CTDI. # 70 scans did not include pitch; 1 scan did not include current-time product; 
30 scans did not include CTDI. The Wilcoxon rank sum test was performed to test difference between the scans 
included and excluded.
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APPENDIX FIGURE E1. Example of the segmentation of the central segmentation (right figure in 
blue) with the yellow airway centerline and red dot indicating the position of the cross sectional 
area measurement in the left bottom figure. A manual digital ruler was used to indicate each 1 cm 
position of the trachea and each 0.5 cm in the main bronchi (blue diamonds).    
APPENDIX FIGURE E2. Flowchart of the scans excluded in this study. 
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APPENDIX FIGURE E3. Boxplots show the diameter of the trachea relative to the distance from 
the carina for male (top graph) and female (bottom graph) subjects. Each box shows median 
(horizontal line), interquartile range (solid box), 1.5*interquartile range (whiskers) and outliers 
(points) for every age group (lighter to darker colors represent younger to older age groups). Note 
that the diameter of the trachea is larger when closer to the carina. 
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APPENDIX FIGURE E4. Boxplots show the diameter of the right main bronchi relative to the 
distance from the carina for male (top graph) and female (bottom graph) subjects. Each box 
shows median (horizontal line), interquartile range (solid box), 1.5*interquartile range (whiskers) 
and outliers (points) for every age group (lighter to darker colors represent younger to older age 
groups). 
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APPENDIX FIGURE E5. Boxplots show the diameter of the left main bronchi relative to the 
distance from the carina for male (top graph) and female (bottom graph) subjects. Each box 
shows median (horizontal line), interquartile range (solid box), 1.5*interquartile range (whiskers) 
and outliers (points) for every age group (lighter to darker colors represent younger to older age 
groups). Note that the diameter of the left main bronchi is larger when closer to the carina and 
when closer to the bifurcation into the upper lobes.
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ABSTRACT
Rationale
To provide normative values of airway dimensions measured on chest CT in children 
and adolescents.
 
Methods
Chest CTs evaluated as normal were collected retrospectively in ten international 
centers. The airway tree was interactively extracted and airway dimensions were 
automatically quantified using image analysis software. Airway to artery (AA)-ratios, 
intra-branch tapering (reduction in airway diameter along the branch) and inter-branch 
tapering (reduction in airway diameter before and after bifurcation) were determined. 
Four airway groups were established based on lumen diameter: the largest 18 (central), 
the second largest 18 (segmental), the following 36 (subsegmental) and the remaining 
airways (peripheral). Effect of age, gender and airway group on the AA-ratios and 
tapering values were investigated using mixed-effect models.
Results
516 (80%) out of 645 CTs were successfully analyzed automatically. Mean of 0.5 for 
inner and 1.2 for outer AA-ratio; 1% for inner and outer intra-branch tapering; 36% for 
inner and 23% for outer inter-branch tapering was found. Age and gender were not 
significant predictors of the AA-ratios (p>0.36), intra-branch tapering (p > 0.68) or inter-
branch tapering (p > 0.59). Airway group was a significant predictor for inner AA-ratio 
(value = -0.09, p < 0.0001), inner intra-branch tapering (value = 0.29, p = 0.0005), inner 
inter-branch (value = 6.43, p < 0.0001) and outer intra-branch tapering (value = 2.78, p 
< 0.0001). 
 
Conclusion
AA-ratio and tapering measures for children and adolescents were not dependent on 
age or gender. Inner AA-ratio decreased from central to peripheral airways, while inner 
intra-branch and both inner and outer inter-branch tapering increased from central to 
peripheral airways. 
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INTRODUCTION 
Various imaging modalities can be used to assess airway and artery dimensions in the 
lungs, with the most sensitive being chest computed tomography (CT).1 Airways and 
accompanying arteries are routinely imaged on chest CT in children to assess structural 
changes such as bronchiectasis and airway wall thickening. An airway to artery ratio 
larger than one is considered a sign of bronchiectasis.2,3 Another important sign for 
bronchiectasis is lack of tapering with only a few studies defining objective criteria.4–6 
Wall thickening is defined by an enlarged airway wall to artery ratio,7 or as an enlarged 
airway wall to the overall airway area.8 Even though semi quantitative criteria are being 
used in day to day radiological reports reference values in the pediatric population 
is lacking. Ideally, to generate such reference values a large number of CT scans from 
healthy children from infancy into the adolescent age is needed. However, due to the 
radiation exposure related to CT scanning is only performed in children with known 
or suspicion of thoracic diseases. Performing CT scans in healthy children to generate 
normative values is not justified. As a consequence, only a few studies have reported 
normative airway and artery dimensions and only in small study populations.7–9 Previous 
study showed that hundreds of airway artery pairs could reliable be measured on each 
chest CT and that major differences could be detected between patients with CF and 
a control group.7 To generate reliable reference data of airway and artery dimension 
in children from infancy into adolescence the Children Chest CT Study Group was 
established aiming to collect a sufficiently large number of control CTs, assessed to be 
free of any disease signs. Manual quantification of hundreds of airway-artery pairs per 
CT in such a large dataset would be unfeasible due to the laborious and time consuming 
nature of the task, and (semi-) automated image analysis tools need to be used instead.
To our knowledge the cross-sectional airway and artery dimensions of the entire 
pulmonary airway tree visible on CT have never been studied in a large pediatric 
control population before. The aim of this study is to derive normative values for airway 
and artery dimensions, inter-, and intra-branch tapering and airway to artery ratios in 
children and adolescents. 
METHODS 
This study was approved by institutional review board (MEC-2011-494). Written informed 
consent was waived for all patients because of the retrospective nature of the study.
Study population 
Chest CTs of children aged 0 to 19 were collected retrospectively in an international 
multicenter study group, the Children Chest CT Study Group. The CTs were acquired 
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between 2003 and 2013 for various diagnostic indications but were reported as normal 
by the radiologist. All CTs were anonymized for patient specific and clinical information 
and send to LungAnalysis (Erasmus MC, Rotterdam) for further analysis. A second 
independent thoracic radiologist (CY, 20 years of experience in thoracic imaging) 
checked all the CTs for pulmonary and cardiac abnormalities.   
CT acquisition parameters
All CTs that were defined as normal by the second radiologist were further selected 
for our current study when they met the following: volumetric CT; slice thickness ≥ 
increment; field of view (FOV) encapturing the entire lungs. More detailed information 
on the scan parameters is provided in Appendix Table E1. 
Quantitative analysis of airways and arteries
In-house developed software was used to segment airway branches and their 
accompanying artery, and to quantify their diameters, the airway tapering and the 
airway-artery ratio in a fully 3D manner. The method has been previously described 
and validated with the use of 8,000 manual annotations 6,10 and can be summarized 
as follows: Firstly, airways were automatically segmented in all CTs. Pathways of 
additional visible airways not automatically segmented were added manually using 
Myrian® (v1.16.2, Lung XP module) image analysis platform (Intrasense, Montpelier, 
France) 7. Secondly, the lung fields were extracted automatically using thresholding and 
morphological smoothing.11 A multi-scale Hessian Eigen analysis approach was used 
to extract an initial segmentation of the lung vasculature, as implemented in Lo et al.11 
Then, accurate surface of the initial airway and vessel segmentations were automatically 
corrected using a graph-cut method.12 Centerlines of the segmented airway and vessel 
trees were extracted using a front-propagation method [LO12]. Centerline branching 
points were then located and used to split the whole segmentation into individual 
branches. Inner, outer airway and vessel diameters were then extracted every 0.5 mm 
along their centerlines with subvoxel accuracy. With trachea considered generation 0, 
airway generation was increased at each branching. Airway and artery branches shorter 
than 5 mm, and airways from generation 15 onwards were considered not reliable and 
discarded. Airway and artery branches located in close proximity, with similar orientation 
and size were automatically paired together as an airway-artery pair. Of each airway and 
artery branch the average diameter for the full branch was determined to compute the 
normative airway and artery dimensions. Normative tapering biomarkers were obtained 
for all airway branches (including those without artery pair). Intra-branch tapering 
(intraBT) is defined as the percentage reduction in airway diameter per mm along the 
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centerline. For example, a value of 2 means that the airway diameter is reduced 2% 
each mm. Inter-branch tapering (interBT) is defined as the percentage that the average 
diameter of the analyzed airway is reduced compared to the average diameter of the 
airway branch before bifurcation. For example, a value of 20% would indicate that the 
child branch is 20% smaller than the parent branch. Finally, for each airway-artery pair 
the following biomarkers were obtained at the point where airway and artery were 
most similar in terms of size, orientation and position: AinA-, AoutA- and AWTA-ratios as 
computed by dividing the inner, outer, and airway wall diameter (difference between 
outer and inner) by the adjacent artery diameter, respectively. Wall area percentage 
(WAP), is the percentage of airway wall in the total area. 
Statistical Analysis
Patients were grouped by age, with 1 year intervals. Airways of each subject were 
grouped in four categories depending on lumen diameter: the largest 18 (central), the 
second largest 18 (segmental), the following 36 (subsegmental) and the remaining 
airways (peripheral).
All projections of the CT segmentations were visually inspected and excluded if they 
were considered a failed segmentation (more than 50% erroneous airways). In addition, 
any airway measurement with AA-ratios or tapering values above and below 1.5 times 
the inter-quartile range (IQR) was considered an extreme outlier likely due to errors in 
the automated analysis and was excluded from the main analysis. Mixed-effect models 
under heavy-tailed distributions were used to predict AA dimensions, AA ratios and 
tapering measures using age, gender and the airway group as covariates. A p-value of 
<0.05 was considered significant. 
RESULTS
Study population
In total, 1160 CTs were collected by the Children Chest CT study group of which 258 were 
considered abnormal by the independent thoracic radiologist (CY) and were excluded. 
An additional 257 CTs were excluded due to slice gap (slice thickness ≥ reconstruction 
increment). 
Manual segmentation was performed on the remaining 645 CTs prior to the automatic 
analysis. All 645 CTs were automatically analyzed of which 516 CTs (80%) returned with 
a visual projection of the inner and outer airway. The visual inspection of all 516 CT 
projections resulted into 29 CT scans to be excluded. 39 branches were omitted due 
an airway generation >15. After outlier omission, 487 subjects with a total of 46,306 
airway measures and 24,618 AA pairs were included in this study. Details on the extreme 
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outliers of the AA-ratio and tapering values that were omitted are described in the 
Appendix. The mean (range) age was 11.85 (0.45-19.9) with 272 males (56%). Detailed 
demographics of the airway dimensions are shown in table 1 and the AA ratios and 
tapering values in table 2.
TABLE 2. Characteristics of AA-ratio and tapering by airway size
Airway size 
AA-ratio Intra-branch tapering Inter-branch tapering
n Inner Outer n Inner Outer n Inner Outer 
Central 3562 0.7±0.2 1.2±0.2 8759 0.8±1.8 1.0±1.4 5953 25.6±13.1 17.6±10.0
Segmental 5817 0.5±0.2 1.2±0.3 8653 0.7±1.9 1.1±1.4 5697 31.9±13.9 22.0±10.5
Sub-segmental 11879 0.5±0.1 1.2±0.3 15495 1.2±2.0 1.0±1.4 11696 37.6±14.4 24.4±11.5
Peripheral 11523 0.4±0.1 1.2±0.3 15330 1.5±1.9 0.9±1.5 12333 42.6±13.2 25.0±11.3
All airways 32781 0.5±0.2 1.2±0.3 48237 1.1±1.9 1.0±1.4 35679 36.4±14.9 23.1±11.3
This table shows the mean ± standard deviation for the AA-ratio and tapering for each airway size. 
Airway and artery dimensions 
The mean number of visible airways and visible AA pairs are shown by age in Figure 1. 
The number of airways increased with age (estimate = 4.3, p < 0.0001) and was higher in 
males (estimate = -7.7, p = 0.005) in the linear model. The number of AA pairs increased 
with age (estimate = 4.6, p < 0.0001) and was higher in males (estimate = -7.1, p = 0.01) 
in the linear model. 
FIGURE 1. The 95% confidence interval for number of airway branches (left) and number of AA 
pairs (right) for each age group for male subjects (black) and female subjects (gray). 
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FIGURE 2. Boxplots of the a. inner intra-branch and b. outer intra-branch tapering is shown by age 
for the central (white), segmental (light grey), subsegmental (grey) and peripheral airways (dark 
grey). Each box shows median (horizontal line), interquartile range (solid box), 1.5*interquartile 
range (whiskers) and outliers (points). Note that the inner intra-branch tapering is uniformly 
decreased from the central airways to the peripheral airways across all ages. The outer intra-
branch tapering is more consistent among the airway groups across most ages.
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FIGURE 3. Boxplots of the a. inner inter-branch and b. outer inter-branch tapering is shown by age 
for the central (white), segmental (light grey), subsegmental (grey) and peripheral airways (dark 
grey). Each box shows median (horizontal line), interquartile range (solid box), 1.5*interquartile 
range (whiskers) and outliers (points). Note that the inner inter-branch and the outer inter-branch 
tapering is uniformly decreased from the central airways to the peripheral airways across all ages. 
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Airway intra-branch tapering
The inner and outer intra-branch tapering values are demonstrated for each age group 
and airway group in Figures 2a and 2b, respectively. Age and gender were not significant 
predictors of the inner and outer intra-branch tapering (p > 0.68). The airway group was 
a significant predictor for the inner intra-branch tapering (value = 0.29, p = 0.0005), with 
increasing intra-branch tapering from central to peripheral airways. The airway group 
was not a significant predictor for the outer intra-branch tapering (p=0.78).
The airway generation was not a significant predictor in the mixed-effect model for the 
inner intra-branch tapering (p = 0.72) nor the outer intra-branch tapering (p = 0.14).
Airway inter-branch tapering
After outlier exclusion, 34,187 inter-branch tapering measurements were analyzed. The 
inner and outer inter-branch tapering values are demonstrated for each age group and 
airway group in Figures 3a and 3b, respectively. Age and gender were not significant 
predictors of the inner and outer inter-branch tapering (p > 0.59). The airway group 
was a significant predictor for both the inner inter-branch (value = 6.43, p < 0.0001) and 
outer intra-branch tapering (value = 2.78, p < 0.0001), with an increasing inter-branch 
tapering from central to peripheral airways.
The airway generation was a significant predictor in the mixed-effect model for the inner 
inter-branch tapering (value = 0.85, p = 0.007), with increasing inter-branch tapering by 
generation. The airway generation was not a significant predictor in the mixed-effect 
model for the outer inter-branch tapering (p = 0.93).
Airway to artery ratio
The inner and outer AA-ratios, AWTA-ratio and WAP are demonstrated for each age 
group and airway group in Fig 4a-d respectively. Age and gender were not significant 
predictors of the inner and outer AA-ratio or the AWTA-ratio (p>0.36). Age was a predictor 
of WAP (value -0.005, p = 0.02). In the mixed-effect model the airway group was a 
significant predictor for: inner AA-ratio (value = -0.09, p < 0.0001), with decreasing AA-
ratios from central to peripheral airways; AWTA-ratio (value 0.09, p < 0.0001) and WAP 
(0.07 p < 0.0001), with increasing AWTA-ratio and WAP from central to peripheral airways. 
The airway group was not a significant predictor for the outer AA-ratio (p=0.45). 
The airway generation was a significant predictor in the mixed-effect model for: inner 
AA-ratio (value = -0.03, p<0.0001) and outer AA-ratio (value = -0.02, p=0.012), with 
decreasing AA-ratios by generation; WAP (value = 1.4, p<0.0001), with increasing WAP 
by generation. The airway generation was not a significant predictor in the mixed effect 
model for AWTA-ratio (p = 0.11). 
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DISCUSSION
This study provides normative data for the airway and artery dimensions and tapering 
measures based on a large dataset with normal pediatric chest CTs. Normative data of 
AA dimensions are provided and the AA-ratios, intra-, and inter-branch tapering values 
have been determined by central, segmental, subsegmental and peripheral airway 
groups in children and adolescents.
The most important finding of this study is that the AA-ratios, intra- and inter-branch 
tapering values are not dependent on age or gender from birth to 20 years old. These 
findings confirm previous studies7,9,13 reporting that AA-ratios in control patients are 
constant regardless of age and gender. A mean inner AA-ratio of 0.5 and an outer 
AA-ratio of 1.2 was found in this study, which is in concordance with previous studies 
assessing the AA-ratios in studies with smaller sample sizes.7,13,14 Both the intra-, and 
inter-branch tapering values are similar to the findings by Perez-Rovira et al. using a 
subset of 168 CTs from the Children Chest CT Study Group dataset.6 A mean inner and 
outer intra-branch tapering of 1% was found, however with large standard deviations, 
indicating a low signal to noise ratio that highlights the difficulty to measure such a small 
change in airway size. The mean inter-branch tapering was 36% for the inner airway and 
23% for the outer airway diameter. The inner inter-branch tapering reference values of 
36% in the Children Chest CT Study Group is higher than previous studies in adults and 
with small sample sizes reporting an inner inter-branch tapering value of around 26%.4,5 
The next important finding of this study is that the airway group influences the AA ratio 
and tapering values. The inner AA-ratio was lower in the subsegmental and peripheral 
airways compared to the central and segmental airways. However, the outer AA-ratio 
remained constant by airway group. Wall thickening defined as AWTA-ratio and WAP 
were found to be higher from peripheral to central airways. The inner intra-branch, 
inner and outer inter-branch tapering were higher in the peripheral airways compared 
to the central airways, but the outer intra-branch tapering remained constant. The outer 
AA-ratio and outer intra-branch tapering were uniform across all airway sizes, which 
make the reference values easy to use in clinical practice.
Lastly, the number of visible airways and AA pairs that could be measured with 
automated analysis algorithms increases with age. The number of visible AA pairs was 
previously suggested to be a potential biomarker for disease severity.7,15 However, as 
shown with this study age should be taken into account as the number of AA pairs 
increase at least till the age of 15 years old for both male and females.
This study has some limitations. First, the control patients could not be considered truly 
healthy as they were referred for chest CT for clinical indications. Even though all CTs 
were reported to be normal by two independent radiologists, we cannot exclude that 
subtle changes in AA dimensions could have been present.
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Secondly, CTs were not acquired using a standardized protocol and were not 
standardized for lung volume during acquisition, as the dataset was collected 
retrospectively. Parameters in the scan protocol such as radiation dose, reconstruction 
kernels and slice thickness influence the image quality and spatial resolution of a CT 
scan.16 With this heterogeneous dataset this may have affected the size measures. 
While the automated algorithm has been previously validated for CTs of diseased and 
controls subjects obtained with different scanning protocols, the method has only been 
validated using CTs form a single clinical center.10 However to decrease the inclusions of 
erroneous values in this study extreme outliers were excluded. Standardization of lung 
volume during CT acquisition has shown to influence the AA ratios7,17 and the inner 
intra-branch tapering.6 AA ratios and intra-branch tapering were significantly higher in 
CT scans with inspiratory volume control.7,10,17 The data presented in this study could be 
an underestimation of the values on volume controlled inspiratory CT scans. Yet, even 
with this variable dataset the AA ratios found in this study are comparable to previous 
studies using spirometer guided inspiratory volume control.7 
Thirdly, as in all CT-based studies of airways, the limited image resolution on CT scans 
means that only airways larger than certain size would be visible. Thus, the peripheral 
airway group, and any of the other airway groups if fewer than 18, 36 or 72 airways 
were found, shows a bias towards larger airways. In addition, we included the analysis 
based on airway generation. However, as described previously,7 a downside of the 
airway generation is that the generations found in the lower lobes are higher than 
generations in the upper lobes. The difference in airway generation of upper and lower 
lobes could not be corrected in the automated extracted data. This could therefore have 
led to different results between analysis with airway groups and generations. Since both 
grouping methods had limitations we included the reference values for both the airway 
group and generation.  
The normative airway dimensions presented in this paper can be used to assess and 
diagnose various structural airway abnormalities such as bronchiectasis and airway wall 
thickening. The identification of bronchiectasis can be performed with the airway to 
artery ratio and the novel tapering values. Normative airway values could be of value for 
radiologists and pediatric pulmonologists, particularly when automated airway analysis 
will be incorporated in clinical practice.  
CONCLUSION
In our study, normative airway and artery dimensions, airway-artery ratios and tapering 
values were quantified on chest CT of a large group of children and adolescents. All 
AA-ratios and tapering values were found to be independent of age and gender. Airway 
group influenced tapering values: the inner intra-branch tapering, inner and outer inter-
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branch tapering were larger in the peripheral airways compared to the central airways. 
The reference values established in this study could be used for thresholds of diseased 
lungs and could be the groundwork for automated airway disease quantification in 
children. 
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APPENDIX
Outliers: 
39 measures deleted with generation ≥15
1.5*IQR AoutA-ratio: lower limit: 0; upper limit: 1639 (3.9%)
1.5*IQR AinA-ratio: lower limit: 0; upper limit: 1909 (4.6%)
1.5*IQR AWTA-ratio: lower limit: 34 (0.1%); upper limit: 1542 (3.7%)
1.5*IQR inner intraBT: lower limit:4289 (6.9%); upper limit: 1558 (2.5%)
1.5*IQR outer intraBT: lower limit: 4238 (6.8%); upper limit: 1201 (1.9%)
1.5*IQR WTR: lower limit: 870 (1.4%); upper limit: 0
1.5*IQR inner interBT: lower limit: 2048 (4.4%); upper limit: 114 (0.2%)
1.5*IQR outer interBT: lower limit: 2374 (5.1%); upper limit: 171 (0.4%)
 intraBT 62,567 -> 48,237
 interBT 46,988-> 35,679
 AA pairs 41,833-> 32,781
Appendix Table E1. Scan parameters.
CT scanners 17x GE; 228x Philips; 251x Siemens; 19x Toshiba
Tube voltage (kV) 110 (90-120)
Pitch* 1 (1-1)
Slice thickness (mm) 1 (1-1.5)
Reconstruction increment (mm) 0.8 (0.7-1)
Reconstruction kernel GE: 15x LUNG; 2x STANDARD
Philips: 18x B; 74x C; 1x D; 44x L; 82x YA; 6x YB; 3x YD
Siemens: 7x B20; 2x B26; 12x B30; 20x B31; 1x B40; 2x B46; 4x B50; 76x 
B60; 78x B70; 35x B75; 1x B80; 1x I30; 12x I70
Toshiba: 16x FC12; 3x FC18
Current-time product (mAs)* 48.17 (25.36-83.38)
CTDI (mGy)* 2.2 (1.1-4.6)
Summary of the scan parameters used. The parameters are shown with median, interquantile range. 
* 414 scans did not include pitch; 1 scan did not include current-time product; 189 scans did not include CTDI
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In patients with CF, progressive structural lung disease starts early in life and leads to 
respiratory symptoms. Eventually CF lung disease leads to a premature death in most 
CF patients. Close monitoring of CF lung disease using various outcome measures is 
essential to guide treatment and for clinical trials. CT is currently the most sensitive 
imaging technique to assess structural lung disease, such as bronchiectasis, airway 
wall thickening and mucous plugging. In children with CF it is important to detect 
structural lung changes at an early stage before irreversible alterations of the lung 
have established. The studies presented in this thesis address the challenges of chest 
CT usage in children with CF and the further validation of objective image analysis 
strategies to assess structural lung disease.  
Image acquisition 
The acquisition of CT images in the pediatric population and in multi-center studies 
comes with two challenges described in the first part of this thesis. The first challenge 
is the associated radiation exposure. Routine chest CT has shown to be beneficial for 
detecting and monitoring structural lung damage in children with CF. Unfortunately, 
chest CT exposes patients to ionizing radiation, which has potential carcinogenic 
risks. In the past decades the radiation dose for a volumetric chest CT has decreased 
substantially for which updated risk estimates were needed to adequately assess the 
risk to benefit ratio in patients with CF. In the review on this issue described in Chapter 
2 we estimated that the additional life time mortality risk for routine biennial chest CT 
scanning from birth till the age of 18 years was 0.2%. This finding was in concordance 
with previous risk estimates by Gonzalez et al.1 Most importantly the estimated risk is 
about 2.5 times lower when taking into account the reduced life expectancy of patients 
with CF. Our review allows the assessment of the risk to benefit ratio of chest CT scans 
acquired in children with chronic diseases such as CF. 
The second challenge with chest CT usage in clinical trials is the large variety of CT 
scanners and CT protocols used in children with CF. Standardization is required to 
compare chest CTs of patients across different centers or even within centers when 
different scanners and/or protocols are being used. Previous standardization studies 
were only performed with adult sized phantoms.2–4 For the study presented in Chapter 
3, custom designed anthropomorphic thorax phantoms composed of human tissue 
equivalent material were developed specifically for pediatric patients. The infant, child 
and adult phantoms were scanned at 16 European CF centers. A large variation in image 
noise and radiation dose was found between centers when scanning protocols were not 
standardized. After correction for differences in spatial resolution, differences in image 
quality remained. We found that standardization can be achieved with equal image 
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quality across centers with proper adjustment of resolution and radiation dose. The 
findings of this study allow for standardization of chest CTs in multi-center clinical studies. 
Image analysis
The second part of this thesis describes the sensitive and objective image analysis 
method to assess airways disease on chest CT scans. The studies described in Chapter 4 
and 5 compare the objective quantification of airway and artery dimensions in children 
and adolescents with CF with control patients. 
The main finding of our studies is that the diagnosis of bronchiectasis based on the 
inner airway diameter should be revisited. We found that diagnosis of bronchiectasis 
by diameter comparison with the adjacent artery was more reliable for the outer 
than for the inner airway diameter. In clinical practice and in recent studies, the inner 
airway diameter is generally compared with the adjacent artery for the diagnosis of 
bronchiectasis.5–7 Our data show that the prevalence of bronchiectasis in children with 
CF is underestimated using the inner airway diameter since it does not show clear 
differences with a control group and is more influenced by lung volume. On the other 
hand, the outer airway diameter does differentiate CF from controls patients significantly 
from birth into adolescence. 
The second finding is that more AA pairs are visible in children with CF compared to 
controls. The increase in AA pairs could be a consequence of airway inflammation with 
more dilated airways and bronchiectasis in patients with CF. Therefore the number of 
visible AA pairs could be a biomarker for disease severity in patients with CF. However, 
aside from disease severity it should be noted that the number of AA pairs is also 
dependent on age and inspiration level. Our studies demonstrate that the number of AA 
pairs is 2 to 3 times higher on spirometer guided inspiratory CT compared to expiratory 
CTs, which could subsequently affect the detection of bronchiectasis in the peripheral 
airways. The difference in number of AA pairs visible and in AA ratios between CF and 
control patients was larger in end-inspiration than in end-expiration CTs. 
Chapter 4 and 5 also quantified the airway wall thickness to artery ratio in patients 
with CF compared to controls. The third finding is that airway wall thickness was better 
visible in end-expiratory compared to end-inspiratory CTs, likely because of a higher 
intensity on CT due to the folding of the airways. Findings related to bronchiectasis and 
airway wall thickness reiterate the need for lung volume standardization for sensitive 
detection and monitoring of structural lung disease in a consistent manner.5 
Furthermore, Chapter 5 shows that differences as determined by the AA method 
between 12 CF and 12 control subjects is initially small in children around 3 years old, 
but increased after a follow up of 2 years. In the longitudinal comparison, the change 
in inner airway to artery ratio was small but significant over two years in these young 
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children with CF. However, the change in outer airway to artery ratio was not significant 
over two years. An explanation for this finding could be that the outer diameter reflects 
irreversible airway dilation accurately, and in contrast to the inner diameter, is less 
influenced by early inflammation.8 However, another explanation for this finding could 
be that the studied population was too small to detect significant differences in the 
outer airway diameter.
Lastly, the AA ratios were more abnormal in peripheral airways than in central airways 
in infants, children, and adolescents with CF compared to normal subjects.  This finding 
confirms previous studies that suggested that the small airways play an important 
role in CF lung disease.9,10 Our findings suggest that the small airways more affected 
by chronic infection compared to the larger airways and we speculate that the small 
airways are affected first in infants with early CF lung disease. This however needs to be 
further investigated in a larger cohort.
 
The sixth important finding of our AA studies, as described in Chapter 6, is that 
established scoring techniques, such as the CF-CT6 and PRAGMA-CF11 can be used 
to assess airways disease in children and adolescents with CF. The CF-CT is a well-
standardized scoring system but it is not sensitive to quantify early CF lung disease as 
the extent of disease is scored as absent, less than 33%, between 33 and 67%, or more 
than 67%. Hence, determinants of lung disease such as bronchiectasis in young children 
will mostly be scored as either absent or less than 33%. For this reason PRAGMA-CF was 
developed especially for scoring young children with early CF lung disease as a more 
sensitive alternative. We investigated the two scoring systems in children aged 6 to 16 
years old and showed that both CF-CT and PRAGMA-CF scores correlated well with the 
number of AA pairs and outer AA-ratios. The outer AA-ratio for bronchiectasis correlated 
better with the bronchiectasis and total airways disease sub-score for PRAGMA-CF 
scoring than with the CF-CT scoring. The AA-ratio for airway wall thickening correlated 
better with the airway wall thickness sub-score of CF-CT scoring than with PRAGMA-
CF. This is most likely due to the hierarchical system using in PRAGMA-CF, where only 
bronchiectasis is scored when both bronchiectasis and airway wall thickening are 
present. This explanation is supported since there is a higher correlation with the total 
airway disease sub-score by PRAGMA-CF than with CF-CT. The results of this study are 
important as they validate the role of scorings system for the assessment of CF lung 
disease in children and adolescents with CF.
The quantification of airway and artery dimensions in Chapter 4, 5 and 6 as discussed 
above, was performed largely manually. Quantifying thousands of airway and artery 
dimensions manually was a very time consuming task. Overall it took 15 hours on 
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average to analyze one CT scan, depending on the quality of the scan and severity of the 
lung disease. Manual assessment of the airway and artery dimensions was an important 
step for the validation of an automated analysis technique12 which was used in Chapter 
7 and 9. Automatic analysis of the airway and artery dimensions is essential to analyze 
larger sample sizes. It limits the timely and costly assessment of semi-automatic analysis 
and eliminates intra-, and interobserver variation. 
The seventh important finding of our AA studies is that we developed an algorithm to 
objectively assess airway tapering as a determinant of airway disease. Lack of tapering 
is considered a determinant of bronchiectasis by radiologists, however objective 
automated methods to assess lack of tapering are lacking to date. In Chapter 7 we 
describe state-of-the-art medical image analysis software for the automated assessment 
of tapering. Unique of the method is that both the inter- and intra-branch tapering were 
assessed automatically. The intra-branch tapering is defined as reduction in diameter 
along an airway branch and inter-branch tapering is defined as reduction in diameter 
between an airway before and after bifurcation. For the validation of this algorithm we 
used spirometer guided inspiratory CTs of bronchiectatic patients and compared them 
with controls. A significant reduction in intra-, and inter-branch tapering was observed 
in the large, medium and small airway branches of bronchiectatic patients compared to 
controls. This result was in contrast with the AA-method which showed the AA-ratios of 
bronchiectatic patients  to be increased compared to controls only in the small airways 
. These findings suggest that the analysis of the more central airways could suffice as a 
determinant of the overall severity of CF lung disease. This is a promising result which 
could mean that the use of tapering could improve sensitivity for the detection of 
airways disease in clinical care and for clinical trials. Additionally this study showed a 
difference in the control patients with and without volume control during acquisition 
with the inner AA-ratio and inner intra-branch tapering. This indicates that the inner 
airway diameter is more affected by the inspiration level than the outer diameter. This 
finding is line with the previous statement for the use of the outer airway diameter in 
Chapter 4. 
Reference values 
Airway dimensions can be assessed accurately and non-invasively using chest CT. In 
order to assess abnormal airway dimensions it is important to know the normal range of 
lung dimensions in children with growing lungs. Pediatric reference values are needed 
when using lung image parameters of patients for clinical management. For this reason, 
1160 CTs have been collected in ten centers worldwide. In the third part of this thesis 
we describe the normative data on the trachea, central airways and airway to artery 
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dimensions. We determined the physiological anatomical growth of the lung structures 
on chest CT of children and adolescents and provided normative dimensions of the 
trachea, main bronchi and the airway tree.  
In Chapter 8, the normative dimensions of the trachea and central airways showed the 
position relative to the carina to be of influence on the size of the trachea, left and right 
mainstem bronchi. The central airway dimensions were larger near the carina and near 
the mainstem bronchi bifurcation. In addition, the central airway dimensions increased 
similarly with age in both male and female subjects until the age of 13-14 years old. After 
this age, central airway dimensions are larger in male subjects than in female subjects. 
This finding could be related to the onset of puberty in males or the end of puberty in 
females.13 Similar findings were observed for the trachea by Griscom et al.14 Normative 
data on the entire main stem bronchi was not available and could not be compared. 
In Chapter 9, the normative airway and artery dimensions were quantified automatically. 
AA-ratios were constant regardless of age and gender from birth to 20 years old, 
confirming previous findings in smaller control groups described in chapter 4 and 5. 
In addition to the AA ratio, intra- and inter-branch tapering values were also found to 
be independent of gender and age. However the inner AA-ratio, inner intra-branch, 
inner and outer inter-branch tapering were found to be dependent on airway size. The 
inner AA-ratio was lower in the peripheral airways compared to the central airways 
and the inner intra-branch, inner and outer inter-branch tapering were higher in the 
peripheral airways compared to the central airways. The outer AA-ratio and outer intra-
branch tapering remained constant by airway group. The uniformity across all airway 
sizes makes these reference values easy to use in clinical practice. This indicates the 
robustness of the AA-ratios and tapering biomarkers and their reference values to 
detect airway abnormality in the pediatric population. 
Future directions
Chest CT has become increasingly important in clinical practice for the diagnosis and 
monitoring of CF lung disease. The studies presented in this thesis have contributed to 
the objective assessment of CF lung disease with validation of fully-automated and semi-
quantitative scoring techniques and improved our understanding of the pathogenesis 
of lung disease. In addition, we have generated normative data for central airways and 
airway to artery dimensions. Physical changes of the airways have been assessed in 
control subjects to improve our understanding of the normal thoracic growth. There are 
however many opportunities to further improve the image analysis of lung disease and 
the use of image analysis outcomes in the clinic and for clinical studies. 
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Minimizing radiation dose
Advances in CT technology and reconstruction techniques will allow further reduction 
of the radiation exposure. With the latest generation CT scanners, an ultra low-dose 
chest CT exposes the patient to a radiation dose which is in the range of a chest X-ray.15 
Hopefully, the radiation dose levels of chest CT can be reduced to the level where it 
becomes ethically possible to acquire chest CTs in the healthy population one day. To 
date, normative data have been generated using control patients who were referred 
for CT but did not show any abnormalities on their CT. Clearly this is not an optimal 
solution as these patients cannot with certainty be considered truly healthy. If radiation 
exposure levels of CT scanners decrease in the future and become irrelevant, the 
assessment of reference values should be repeated on a healthy cohort. On the other 
hand, the quality of radiation free alternatives, such as chest MRI is improving rapidly. 
Recent improvements in MRI pulse sequences allow for better detection and resolution 
of the airways.16 If the resolution and signal to noise ratio of MRI images approach the 
level of the current CTs, normative imaging data of the airways can be generated for MRI 
based on a truly healthy population. Regardless of the resolution, scanning with MRI has 
a long acquisition time which is more challenging in the younger age group. Children 
aged 0 to 6 years old are not cooperative and have higher cardiac and respiratory rates 
resulting in more movement artifacts. Hence, for the next decade it is likely that chest 
CT will continue to be the preferred modality for these younger children.   
CT standardization 
We showed that standardization of CT protocols is feasible across international CF 
centers. For multi-center studies, it is of key importance to standardize CT protocols 
and lung volume during acquisition. Image quality and lung volume levels have 
shown to influence the detection and appearance of structural lung disease severity. In 
multi-center studies investigating the effect of expensive drugs it is important to have 
minimal variance on chest CTs to make an unbiased sensitive comparison between 
patients. In addition, standardization of CT protocols will streamline automated image 
analysis. Furthermore, standardization improves the quality and diagnostic yield of the 
CT scan. Hence, the medical community should embrace and implement lung volume 
standardization for routine chest CTs as standard care. 
Image analysis
More quantitative analysis is needed to understand the pathophysiology of CF lung 
disease on the airways. In particular, image analysis of the longitudinal follow-up of 
young children with CF during end-inspiration and end-expiration is required. It would 
be interesting to determine the effect of inflammation in early CF lung disease in a 
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larger study population to assess the change on the inner and outer airway diameter. 
Furthermore, the small airways of the young children were near the resolution limits 
of a CT scanner. This affects the accuracy of the measurements of the small airways.17 
Accuracy of the measurements can be improved in future studies with better image 
quality of the CT scan and advanced automated measurement techniques that take the 
limited spatial resolution of the CT scanner into account. 
A promising biomarker described in this thesis is the lack of tapering in patients with 
CF. Tapering showed to be more sensitive than the airway to artery ratio and occurs 
uniformly across all airway sizes. An additional advantage of the tapering method over 
the AA-method is that it does not require comparison to the pulmonary artery system. 
Hence, segmentation of the pulmonary artery system is not required which makes 
the automatic measurement of tapering less challenging and perhaps more robust as 
the outcome is not influenced by the artery.  Tapering was assessed in a large control 
cohort but only in 12 patients with bronchiectasis and needs to be assessed in a larger 
CF study population. Lastly, it would be of interest to quantify tapering in adults with 
severe airway disease.  
Reference values 
A limitation of the normative data, in addition to the population not being truly healthy 
and not large enough, is the lack of information on height, weight and ethnicity of the 
patient. It is known that the patients’ size and ethnicity can impact the size of the airways. 
However, it was not possible for us to collect this information retrospectively since the 
data for our study needed to remain anonymous and not retraceable to the patient. 
When prospective studies with a healthy population can be repeated, it is important to 
collect all relevant data including the subjects’ height, weight, and ethnicity.
Automated image analysis for clinical practice
Chest CT is sensitive and provides highly relevant information on the presence of lung 
disease and its progression in children. With standardization of CT protocols and lung 
volume levels among multiple centers we can ensure standardized outcome measures 
on CTs for future studies. Standardization is an important condition to allow routine 
use of image analysis software for clinical care and for the analysis of large numbers 
of chest CTs in registries. It will generate longitudinal data which in turn will improve 
our understanding of the pathophysiology and treatment of CF lung disease. Evidently, 
automated lung imaging biomarkers need to be properly validated by comparing them 
with functional tests and clinical outcome measures, such as exacerbations. Adding 
image analysis information to the expert analysis by the radiologist will enhance the 
diagnostic yield of the chest CT.
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SUMMARY 
Children with cystic fibrosis (CF) routinely receive computed tomography (CT) scans 
in many centers to diagnose and monitor their lung disease. This thesis focuses on 
radiation safety, standardization and image analysis techniques related to chest CT of 
patients with CF. 
Chapter 1 provides a general introduction and background to the hereditary disease 
CF, the safety and standardization of chest CT and monitoring and image analysis of 
CF lung disease using chest CT. Regarding radiation safety we aim to estimate the CT 
related radiation risks and put these risks into perspective. For standardization of chest 
CT we characterized and standardized pediatric chest CTs across multiple CF centers. To 
improve the image analysis we developed an objective airway quantification method 
for infants, children and adolescents with CF and to validate fully-automated and semi-
quantitative scoring techniques. 
Part 1 describes the safety and the standardization of routine chest CT. Chest CT is 
an important and sensitive image modality to assess structural changes related to 
CF lung disease. CT scanning, however, exposes the area of the body scanned with 
ionizing radiation and this could result in cancer later in life. Chapter 2 describes the CT 
radiation dose terminology and complexities of estimating radiation risks for a pediatric 
population and reviews the risk estimates of routine chest CT usage in children. The 
estimated radiation induced risk for cancer mortality in a lifetime increases with younger 
ages at exposure. The estimated lifetime cancer mortality risk for nine routine chest CTs 
from birth till the age of 18 was calculated to be 0.2%. This risk is probably even 2.5 
times lower, i.e. 0.08%, for CF patients since they have a lower life expectancy. To put this 
risk into perspective we compared this estimate to other CT indications, other radiation 
sources, CF-related risks and other “daily” risks. In conclusion, we estimated the risk 
associated with CF lung disease monitoring by CT to be relatively small. Nonetheless, 
the use of CT should always be justified and the radiation dose kept as low as reasonably 
achievable. 
Different CT scanners and scan protocols lead to variations in image quality and radiation 
exposure among centers. To utilize chest CT as an outcome measure it is essential to 
standardize image acquisition. Chapter 3 is about the standardization of chest CT for 
multi-center studies. The Standardized Chest Imaging Framework for Interventions and 
Personalized Medicine in CF (SCIFI CF) was founded to characterize chest CT image 
quality and radiation doses among 16 participating CF centers in 10 different European 
countries. The performance of the scanners in each center was assessed using three size 
specific chest phantoms. Considerable differences in CT protocols, image quality and 
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radiation dose were found among the participating centers. However, when adjusted 
for spatial resolution and radiation dose, the performance of the scanners was found to 
be quite similar. The SCIFI CF showed that standardization of chest CT is feasible in an 
international multicenter cohort. 
The chapters in Part 2 describe objective image analysis techniques to quantify lung 
disease on chest CT of pediatric CF patients. A sensitive and objective method to 
quantify the airway and artery dimensions on chest CTs was developed which is used 
in studies described in Chapter 4, 5 and 6. The objectively acquired dimensions of the 
airway and accompanying artery are used to assess structural airways disease, such as 
bronchiectasis and airway wall thickening. 
In Chapter 4, airway and artery dimensions in patients with CF between 6 and 16 years 
old are compared with age- and gender-matched control patients. More than 6000 
airway and artery pairs were measured in total up to the 15th airway generation in 11 CF 
and 12 control patients. The ratios of the inner airway diameter, outer airway diameter, 
and airway wall thickness to the adjacent artery diameter were all significantly larger 
on inspiratory compared to expiratory CTs in CF and control patients. The ratios of 
the outer airway diameter and airway wall thickness to the adjacent artery diameter 
were significantly larger in patients with CF compared to control patients, and this 
difference was increasingly greater in smaller airways. In conclusion, based on the 
objective quantification of the airways, the diagnosis of bronchiectasis was found to be 
most accurate on inspiratory chest CT. This study reiterates the need for lung volume 
standardization during chest CT acquisition. Secondly, the diagnosis of bronchiectasis 
was more reliable by comparing the outer airway diameter, instead of the inner airway 
diameter, with the adjacent artery. Lastly, the airway to artery ratio showed more 
prominent differences in the smaller airways than central airways of patients with CF.
In Chapter 5, the airway and artery quantification method is performed in young 
children with early CF lung disease below the age of 6 years, both cross-sectionally and 
longitudinally. In the cross-sectional analysis, CF patients were compared with control 
patients. In the longitudinal analysis, CF patients were compared at baseline (CT1) and 
2 years later (CT2). In the cross-sectional analysis, the ratio of the inner airway diameter 
to artery diameter in the CF patients did not demonstrate a significant increase. The 
ratio of the outer airway diameter and airway wall thickness to artery diameter was 
significantly higher in patients with CF compared to controls. As was seen in the older 
children in Chapter 4, the outer airway diameter should be used to separate diseased 
CF airways from non-diseased CF airways in the young children with CF. Similarly to the 
older patients with CF, there are more dilated airways and thicker walls in the young 
children with CF compared to control patients. In the longitudinal analysis, a small but 
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significant progression could be detected in the ratio of the inner airway diameter to 
artery diameter after two years. In the longitudinal analysis over the two-year interval 
of children with CF: a small but significant change in the inner airway diameter to artery 
diameter was detected; a progressive increase was seen in the outer airway diameter 
to artery ratio for the peripheral airways; and no changes in airway wall thickness were 
detected after two years. This could be interpreted as the outer diameter reflecting 
irreversible airway dilation i.e., bronchiectasis and this diameter is, in contrast to the 
inner diameter, less influenced by lung volume and/or mucus impaction. 
Our findings suggest that with the objective airway and artery quantification, smaller 
sample sizes could be required to test reduction by treatment than with semi-
quantitative scoring methods. This supports the potential of objective airway and artery 
ratios as outcome measure in young children. We estimated that in young children with 
CF sample sizes of 21 and 33 per treatment arm would be needed to detect 50 and 40% 
reduction in outer airway to artery ratio between CF CT2 and controls, with 80% power 
and α=0.05. In comparison, using the semi-quantitative scoring technique PRAGMA-CF 
a sample size of 100 per treatment arm would be needed, based on 50% reduction in 
total airway disease at age 3. 
Scoring methods are less time consuming than measuring all airway and artery 
dimension manually but their accuracy has not been assessed in children. In Chapter 6, 
two semi-quantitative CT scoring systems are compared with objective quantification 
of airway and artery dimensions. CF and control patients with spirometer guided 
inspiratory chest CTs were scored with the two scoring methods and compared with the 
airway and artery dimension ratios as described in chapter 4. The CF-CT and PRAGMA-
CF scoring methods both showed to be sensitive methods to score bronchiectasis and 
airway wall thickening in children and adolescents with CF. Bronchiectasis and total 
lung disease scores (defined as the sum of bronchiectasis, airway wall thickening and 
mucous plugging) were shown to be the most accurate predictor of airway and artery 
dimensions using the PRAGMA-CF scorings system. On a separate note, we found that 
the actual number of airway and artery pairs visible on the lung images correlated well 
with the CF-CT and PRAGMA-CF scores. Both airway dilation and wall thickening lead to 
a larger number of visible airway and artery pairs on CT. Thus, the number of airway and 
artery pairs on CT could be another potential marker for lung damage, but it should be 
noted that it is dependent on age and lung volume during CT acquisition.
In Chapter 7, airway tapering is investigated as a biomarker for bronchiectasis with 
the use of automated quantification. Tapering is a reduction in the airway diameters 
along the bronchial tree and it can be divided in two biomarkers: the intra-branch 
tapering defined as the progressive reduction in airway diameter along the branch; 
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and inter-branch tapering defined as the reduction in airway diameter before and after 
bifurcation. It is known by radiologists that there is a lack of tapering in bronchiectatic 
airways. Tapering has however not previously been assessed on chest CT using an 
objective automated method in children and adolescents with bronchiectasis. Tapering 
biomarkers and airway artery ratios were assessed on spirometer guided inspiratory CTs 
of patients with bronchiectasis and control patients. In addition, tapering biomarkers 
and airway to artery ratios were assessed in 156 control patients without volume 
control during CT acquisition. Significantly decreased airway tapering was found for 
both the inner and outer airway diameters of patients with CF compared to controls. 
This difference was found across all airway sizes including the central airways. Detecting 
significant change in the central airways could potentially facilitate the assessment of 
structural airway changes on CTs with low resolution and possibly also on chest MRIs. 
Additional advantages of using tapering to assess airways disease is that the airways 
alone are easier to extract automatically than airway artery pairs, and tapering is not 
influenced by changes in dimensions of the accompanying arteries. In addition, tapering 
was found to be less influenced by changes in lung volume levels than airway artery 
ratios.  Automatic quantification of tapering is therefore a promising image biomarker 
for bronchiectasis. 
 
Dimensions of the airways can accurately and non-invasively be assessed in children with 
chest CT. The shape and size of the central and main airways are important determinants 
for lung health. However, reference values based on large study populations are lacking 
to date. The chapters in Part 3 provide reference values of the central and main airway 
structures on chest CT for children and adolescents. The retrospectively collected chest 
CTs were made for various indications but reported as normal by two radiologists. A 
total of 1160 CTs were collected in 10 international centers. 
In Chapter 8, central airways dimensions are established in 294 children and adolescents. 
Semi-automated image analysis was performed to measure dimensions of trachea, right 
and left main bronchus. The intrathoracic tracheal length was measured manually with 
a ruler from carina bifurcation to the thorax inlet. Cross sectional area and diameters 
were measured perpendicular to the airway lumen starting from carina upwards every 
cm for the trachea and downwards every 0.5 cm for the main bronchi. Dimensions of 
the central airways such as the trachea and main stem bronchi were dependent on 
distance to the carina bifurcation. As can be expected the central airway dimensions 
are larger near the carina bifurcation and near the mainstem bronchi bifurcation of 
segmental bronchi into the upper lobes. The diameter of the trachea, left and right main 
bronchi also increased with intrathoracic length and age. Central airway dimensions 
were similar in males and females till the age of 13-14 years old but became higher in 
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males compared to females after this age. This result could be explained by changes 
between genders in relation to the pubertal growth spurt.  
In Chapter 9, dimensions of the airways, arteries and tapering were determined 
automatically in 487 children and adolescents. The inner and outer AA-ratios, intra- 
and inter-branch tapering values were found not to be dependent on age or gender 
from birth to 20 years old. The airway groups (central, segmental, subsegmental and 
peripheral) influenced the AA ratio and tapering values. A lower inner AA-ratio was 
present in the peripheral airways compared to the central airways and the outer AA-
ratio remained constant by airway group. The inner intra-branch, inner and outer inter-
branch tapering were higher in the peripheral airways compared to the central airways. 
The outer intra-branch tapering remained constant. The reference values established in 
this chapter could be used for the detection of early lung disease and are the groundwork 
for the development of automated chest CT image analysis for the detection of airway 
disease in children.
Finally, Chapter 10 discusses the main findings of the studies included in this thesis, 
their clinical implications, potential challenges and future suggestions for research. 
With respect to the latter: Quantitative image analysis should be performed on larger 
pediatric study populations to understand the pathophysiology of early CF lung 
disease and the treatment effect. Studies investigating the dimensions of the airway 
and arteries should be repeated in children with CF and in healthy children if radiation 
dose is negligible or when improvements in MRI allow better resolution of the airways. 
Automated airway analysis is advancing expeditiously and will provide valuable and 
more detailed information on the severity and progressions of lung disease. 
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SAMENVATTING
Cystische fibrose (CF), ook wel bekend als taaislijmziekte, is een ongeneeslijke erfelijke 
ziekte die veel organen in het lichaam aantast door een defect gen. Dit leidt ertoe dat 
alle klieren in het lichaam afwijkend, taai slijm produceren. De organen die hierdoor het 
meest zijn aangedaan, zijn de longen. Patiënten met CF kunnen door het taaie slijm hun 
longen niet goed schoon houden waardoor de luchtwegen chronisch geïnfecteerd en 
ontstoken zijn. Om deze schade zichtbaar te maken en te monitoren krijgen kinderen 
met CF periodiek een computertomografie (CT) scan. Dit proefschrift beschrijft studies 
naar de stralingsrisico’s, standaardisatie en beeldanalyse van long CT scans bij kinderen 
met CF. 
Hoofdstuk 1 is de introductie van dit proefschrift. Patiënten met CF krijgen in het Erasmus 
MC - Sophia kinderziekenhuis eens in de twee jaar een CT scan van de borstkas. Met de 
beelden van een CT scan kunnen we de inwendige organen, zoals het longweefsel en 
de luchtwegen duidelijk in beeld krijgen. Zo kan er op een long CT scan worden gezien 
wanneer er afwijkingen ontstaan in de longen en of deze af- of toenemen. Daardoor kan 
de long CT scan worden gebruikt om het effect van de behandeling te evalueren. Als de 
afwijkingen in een periode toenemen moet de therapie aangepast of geïntensiveerd 
worden om verdere, soms onomkeerbare, schade aan de longen te voorkomen.
In het eerste gedeelte van dit proefschrift worden de mogelijke onveiligheid en de 
noodzakelijke standaardisatie beschreven bij het gebruik van de CT scanner bij kinderen. 
In hoofdstuk 2 worden de mogelijke stralingsrisico’s van een tweejaarlijkse CT scan 
bij kinderen met CF beschreven. Het gebruik van CT scans brengt mogelijk risico’s met 
zich mee vanwege de bijbehorende straling. Gelukkig is de straling van een long CT 
scan tegenwoordig erg laag, maar bij regelmatig gebruik neemt dit risico naar ratio toe. 
Het risico op sterfte op latere leeftijd door straling bij tweejaarlijks gebruik van long CT 
scans van de geboorte tot 19 jarige leeftijd hebben we geschat op minder dan 0.1%. De 
risico’s van straling zijn verder vergeleken met: de risico’s van andere CT indicaties, de 
risico’s van andere stralingsbronnen en andere “dagelijkse” risico’s. 
Hoofdstuk 3 gaat over de standaardisatie van de uitvoering van een CT onderzoek bij 
kinderen met CF. De naam van de studie is ‘Standardized Chest Imaging Framework 
for Interventions and personalized  medicine in CF’, oftewel SCIFI-CF. Deze studie was 
opgezet om de CT scanners van 16 verschillende CF centra binnen Europa te testen. 
Alle centra werden bezocht om de beeldkwaliteit van de verschillende CT scanners te 
meten met behulp van een drietal long fantomen (plastic longen) van verschillende 
groottes. Hiermee was het mogelijk om de kwaliteit van de beelden vast te leggen en 
kon de kwaliteit tussen de CT scanners worden vergeleken en geoptimaliseerd. Tussen 
Samenvatting | 225
11
de deelnemende centra werden substantiële verschillen gevonden in de uitvoering 
van het CT onderzoek, de beeldkwaliteit en de stralingsdosis. Desalniettemin was de 
kwaliteit van de CT scanners voldoende om gebruikt te worden voor internationale 
studies, mits de CT onderzoeken worden gestandaardiseerd.  
In het tweede gedeelte van dit proefschrift worden nieuwe objectieve beeldanalyse 
methodes beschreven om de longafwijkingen bij kinderen met CF te kwantificeren. 
In de hoofdstukken 4,5 en 6 wordt de AA (airway and artery) methode beschreven 
waarbij de afmetingen van luchtwegen zijn gemeten op long CT scans. De afmetingen 
van de luchtwegen werden vergeleken met de bijbehorende bloedvaten. De afmetingen 
van de luchtwegen in gezonde personen zijn vergelijkbaar met de afmeting van de 
bloedvaten. Echter, in de zieke luchtwegen bij patiënten met CF kan door de ontsteking 
de afmeting van de luchtwegen groter worden dan de bijbehorende bloedvaten. Als de 
luchtwegen onomkeerbaar groter zijn spreken we van een bronchiëctasie.
In Hoofdstuk 4 zijn de luchtweg- en bloedvatafmetingen van 11 kinderen met 
CF op CT vergeleken met 12 kinderen zonder zichtbare luchtwegziekten.  Alle CT 
scans werden gemaakt bij kinderen tussen de 6 en 16 jaar oud met behulp van een 
spirometer om de volledige in- en uitademing te kunnen waarborgen. Op alle scans 
werden de verhoudingen tussen de luchtwegen en bloedvaten van elke aftakking van 
de luchtwegen gemeten. Opvallend was dat de afmeting van de luchtwegdiameter 
substantieel groter was bij patiënten met CF in vergelijking met patiënten zonder 
luchtwegziekten. Daarnaast was het aantal zichtbare luchtwegen bij kinderen met CF 
fors toegenomen ten opzichte van de kinderen zonder luchtwegziekte. Deze studie laat 
verder zien dat het erg belangrijk is om long CT scans te maken met behulp van spirometrie 
om de longvolumes te standaardiseren. Verder laten we zien dat bronchiëctasieën het 
beste gemeten kan worden door de buitenste luchtwegdiameter te vergelijken met het 
bijbehorende bloedvat, in plaats van de binnenste luchtwegdiameter wat in eerdere 
studies werd gebruikt. Tenslotte liet deze studie zien dat de AA methode betrouwbaar 
en een objectieve maat is voor luchtwegziekte bij kinderen met CF.
In Hoofdstuk 5 zijn de luchtweg- en bloedvatafmetingen beoordeeld in kinderen jonger 
dan zes jaar met vroege longziekten door CF. De luchtweg- en bloedvatafmetingen 
werden wederom vergeleken met kinderen zonder zichtbare afwijkingen op CT en 
werden beoordeeld over een tussenperiode van twee jaar. Net zoals bij oudere kinderen 
werden er meer verwijde luchtwegen en verdikte luchtwegwanden gezien bij jonge 
kinderen met CF. Bij patiënten met CF was er over twee jaar een subtiele toename te 
zien in de ratio van de binnenste luchtweg diameter met het bijbehorende bloedvat. 
Ook was er een zichtbare toename in de ratio tussen de buitenste luchtwegdiameter en 
het bijbehorende bloedvatdiameter in de kleinere luchtwegen. Ten slotte suggereren 
de bevindingen in dit hoofdstuk dat door gebruik te maken van de AA methode als 
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uitkomstmaat, er minder patiënten nodig zijn voor klinische studies. Een nadeel van 
deze AA methode is dat deze erg veel tijd kost en daarom geautomatiseerd moet 
worden om bruikbaar te zijn in de praktijk.
Er zijn nu verschillende methodes om afwijkingen van de luchtwegen te kunnen meten 
zoals de CF-CT methode, PRAGMA-CF en de AA methode. De CF-CT-scoringsmethode 
is ontwikkeld voor patiënten met matig tot ernstige longziekten en is daardoor niet 
gevoelig genoeg voor het scoren van milde longafwijkingen bij met name jonge 
kinderen met CF. PRAGMA-CF werd daarom speciaal ontwikkeld om longziekte bij 
jonge kinderen te kunnen beoordelen. PRAGMA-CF scoort de afwijkingen met behulp 
van een raster dat over het longbeeld wordt geprojecteerd. Met deze methode kunnen 
de verschillende longafwijkingen die kenmerkend zijn voor CF als percentage van het 
longvolume worden uitgedrukt. De CF-CT en PRAGMA-CF scoring methodes kosten 
minder tijd dan de AA methode. In Hoofdstuk 6 zijn de CT scans tijdens volledige 
inademing uit hoofdstuk 4 gescoord met CF-CT en PRAGMA-CF en vergeleken met de 
objectieve AA methode. De studie liet zien dat zowel CF-CT als PRAGMA-CF gevoelige 
methoden zijn om longziekten bij kinderen en adolescenten met CF te beoordelen. 
Scores voor bronchiëctasieën en voor alle afwijkingen aan de luchtwegen (som 
van bronchiëctasieën, luchtwegverdikking en slijmophoping) die werden bepaald 
met PRAGMA-CF, waren het meest nauwkeurig. Tevens is er met verwijding van de 
luchtwegen en luchtwegwandverdikking is er een grotere aantal luchtwegen zichtbaar 
op CT. Een hoger aantal zichtbare luchtweg- en bloedvatparen op CT was gecorreleerd 
met een hogere CF-CT en PRAGMA-CF ziektescore. Het aantal luchtwegen zichtbaar op 
CT kan ook een mogelijke marker zijn voor longschade, maar het aantal luchtwegen is 
ook afhankelijk van leeftijd en long volume op het moment van de CT.
In Hoofdstuk 7 wordt luchtweg tapering bestudeerd als biomarker voor 
bronchiëctasieën door middel van een automatische methode. Tapering is de natuurlijke 
afname van luchtwegdiameter bij elke volgende generatie van de bronchiaal boom. 
Intra-branch tapering is de versmalling van een luchtweg tussen twee aftakkingen. 
Inter-branch tapering is de vermindering van luchtwegdiameter voor en na de 
splitsing van een luchtweg. Hoewel een afname van tapering een bekend fenomeen 
is van bronchiëctasieën is dit nooit objectief gemeten op CT scans van kinderen en 
adolescenten met CF. Wij vonden een duidelijke afname van tapering bij kinderen met 
CF in vergelijking met patiënten zonder zichtbare longafwijkingen. Deze afname was 
zichtbaar in alle luchtwegen van grote naar kleine luchtwegen. Een groot voordeel van 
de tapering methode is dat hiervoor alleen de luchtwegen gemeten hoeven te worden. 
De afmetingen van alleen de luchtwegen zijn geautomatiseerd makkelijker te bepalen 
dan de geautomatiseerde afmetingen van de luchtwegen met de bijbehorende 
bloedvaten. Ten slotte lijkt de tapering methode minder gevoelig te zijn voor verschillen 
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in longvolume tijdens de CT dan de AA-methode. De tapering methode lijkt een 
veelbelovende meetmethode te zijn om bronchiëctasieën op te sporen.  
Het derde gedeelte van dit proefschrift gaat over de normale afmetingen van de 
luchtwegen bepaald op long CT van kinderen. Meer dan duizend CT scans werden 
hiervoor verzameld afkomstig uit tien verschillende CF centra over de hele wereld. De 
long CT scans zijn afkomstig van kinderen die voor verschillende indicaties een CT scan 
nodig hadden, maar achteraf als normaal werden beoordeeld door twee onafhankelijke 
radiologen. Deze unieke verzameling CT scans werd gebruikt om referentiewaarden 
te bepalen voor de centrale en algemene luchtwegstructuren. Dit werd gedaan door 
middel van geautomatiseerde technieken.
In Hoofdstuk 8 zijn de centrale luchtwegafmetingen bepaald bij 294 kinderen en 
adolescenten. Geautomatiseerde beeldanalysetechnieken werden gebruikt om de 
afmetingen van de centrale luchtpijp en de aftakking naar rechter- en linkerlong te 
meten. De diameter van de luchtpijp en zijn aftakkingen bleken gerelateerd te zijn aan 
de lengte van de luchtpijp en de leeftijd. De afmetingen van deze centrale luchtwegen 
zijn even groot bij jongens en meisjes tot de leeftijd van 14 jaar. Hierna zijn de centrale 
luchtwegafmetingen bij de jongens groter dan bij de meisjes. Dit kan verklaard worden 
door veranderingen in groei in samenhang met de puberteit en geslacht. 
In Hoofdstuk 9 zijn de afmetingen van de luchtwegen, bloedvaten en tapering 
beschreven die met een automatische methode werden gemeten bij 487 kinderen 
en adolescenten. De luchtweg tot bloedvat ratio en intra- en inter-branch tapering 
waren niet afhankelijk van de leeftijd of geslacht vanaf de geboorte tot het 20ste jaar. 
De tapering waarden bleken lager te zijn in de centrale luchtwegen ten opzichte van de 
perifere luchtwegen. Dankzij dit onderzoek weten we nu wat de normale afmetingen 
zijn van de luchtwegen bij kinderen. Deze referentiewaarden zijn nodig om longziekten 
bij CF patiënten in een vroege fase op te kunnen sporen. 
Hoofdstuk 10 bespreekt de belangrijkste bevindingen, de klinische implicaties, de 
mogelijke uitdagingen en suggesties voor toekomstige studies. Om een beter idee te 
kunnen krijgen van het ontstaan van afwijkingen in de luchtwegen en het effect van 
behandeling is vervolgonderzoek nodig. Studies naar de afmetingen van de luchtwegen 
en bloedvaten in de longen zouden uitgebreid moeten worden in grotere groepen 
gezonde kinderen. Dit kan alleen als de stralingsdosis van CT scans verwaarloosbaar 
is. Als alternatief kan dit onderzoek in de toekomst plaatsvinden met de stralingsvrije 
magneetscan. Verdere ontwikkeling van de beschreven geautomatiseerde luchtweg 
analyse methodes is belangrijk om waardevolle en gedetailleerde informatie over de 
ernst en progressie van longziekten te kunnen krijgen.
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This thesis has many chapters, and the chapters of this book are coming to an end. 
However, it cannot be finished without one of the most important chapters. That would 
be the chapter where I would like to thank all the people who have helped me in so 
many ways. In 2012 I starting my PhD as a youngling and now a few years later I am 
finishing another chapter in my life. I sense a great feeling of gratitude to have gotten 
this opportunity and all the assistance along the way preparing and completing this 
thesis, because let’s be honest, I would not have been able to achieve all this on my 
own. I would like to acknowledge the ones contributing to me standing here today with 
a few sentences of appreciation and heartfelt gratitude in the different languages that 
deemed most fit.  
Mijn eerste dank gaat naar mijn promotor, Prof. Dr. Harm Tiddens. Beste Harm, 5 jaar 
geleden heb je mij de mogelijkheid gegeven om verder te gaan in onderzoek. Ik ben 
je dankbaar voor de kans die ik heb gekregen om een promotietraject te volgen. De 
afgelopen jaren bestonden voor mij uit onbetaalbare ervaringen en ik heb ontzettend 
veel van je mogen leren. Je hebt mij door alle jaren heen gesteund ongeacht met welke 
moeilijkheden ik bij je aanklopte. Zo ook in mijn eerste jaar bij mijn eerste internationale 
congres. Dit vond ik des te spannender omdat de abstract die we hadden ingediend 
was geselecteerd voor een presentatie in een grote zaal. Jij fluisterde nog secondes 
voordat ik het podium op moest welke ademhaling manoeuvres het beste waren om 
de zenuwen te kunnen onderdrukken. Ik kan dit moment nog goed herinneren want 
het ging eigenlijk best redelijk met de zenuwen tot het moment dat mijn promotor 
opstond om vooraan foto’s te kunnen maken. Ik ben in het diepe gegooid maar dankzij 
de veelvoudige buitenlandse werk visites en congressen die daarop volgde gingen de 
presentaties steeds wat makkelijker en kan ik hier bij mijn publieke verdediging met 
zelfvertrouwen staan. Je hebt altijd vertrouwen in mij gehad en ik waardeer de vrijheid 
die je mij hebt gegeven tijdens mijn onderzoeken hier in Nederland maar ook in Amerika. 
Ik kon altijd bij je terecht en het was ook altijd mogelijk even te bellen of skypen. Maar 
een volle droppot in de LungAnalysis kamer was tevens erg nuttig want bij binnenkomst 
voor een dropje was je ook altijd bereid even tussendoor van gedachten te wisselen. 
Bedankt voor jouw onbeperkte dosis aan inspiratie en ongekende enthousiasme voor 
onderzoek.
Mijn co-promotoren, Ass. Prof. Dr. Marleen de Bruijne en Dr. Ir. Marcel van Straten. Beste 
Marleen, ondanks jouw begeleiding in de vele projecten, promovendi en postdocs 
binnen de BIGR groep, had je altijd ook een kritisch oog in het werk wat verricht werd 
in het Sophia. Bij het schrijven van de artikelen had jij altijd de meest kritische vragen 
en ik kon jouw expertise goed waarderen. Als het eens allemaal te veel werk was, 
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was jij degene die het in de meetings aankaartte of we nu niet te veel hooi op onze 
vork  hadden genomen en of het wel haalbaar zou zijn. Daarnaast liepen we vaak uit 
Harms kamer waarna jij zorgzaam naging of het allemaal bij mij wel ging lukken. Ik 
waardeer jouw ongekende ambities en jouw kritische blik vanuit de perspectief van de 
beeldanalyse mogelijkheden, waarvoor mijn oneindige dank. 
Beste Marcel, ooit begonnen als jouw eerste promovenda. Ik kan me nog goed 
herinneren dat we op een van onze eerste meetings samen een checklist doornamen 
voor jouw cursus "supervisie". Ik kan je vertellen dat de promovendi die zullen volgen 
van geluk mogen spreken met een supervisor zoals jij. Als groentje heb ik mijn eerste 
artikelen met je samen mogen schrijven en dit was voor mij een zeer leerzaam proces 
geweest. Daarnaast verliep de submissie van mijn eerste twee artikelen erg soepel en 
heeft het ons twee mooie publicaties opgeleverd. Het was altijd een stukje lopen van 
het Sophia of Westzeedijk naar het Hs-gebouw maar dit was het altijd waard. Je wist 
mij altijd heel goed de complexe en technische onderwerpen in simpele termen of 
tekeningen uit te leggen. Je werkt erg secuur en ondanks mijn ongeduldigheid kon 
ik de precisie altijd zeer waarderen. Als ik weer een site visite had uitgevoerd en de CT 
scanner onder handen had genomen was jij ook altijd bereid om dit even te bepreken 
ook al was dat vaak na kantooruren en had je Florian net op bed gelegd. Daarnaast was 
jouw goed gedoseerde hoeveelheid relativerende humor ook precies genoeg om het 
ijs te breken, bedankt voor alles.
De leden van de promotie commissie, Prof. Dr. M. de Hoog, Prof. Dr. G.G.O. Brusselle, Prof. 
Dr. C. K. van der Ent en Dr. M. M. van der Eerden. Hartelijk bedankt voor het beoordelen 
van mijn proefschrift en uw bereidheid zitting te nemen in de commissie. Prof. Dr. J. 
S. Elborn, thank you for travelling all the way to Rotterdam. It is an honor to have you 
partake in my thesis dissertation as a committee member. 
Prof. Dr. G. J. Redding, dear Greg, you were my first research supervisor and taught 
me the basics in the field of research. I can undoubtingly say that your enthusiasm 
inspired me to consider a future in research and the reason I choose to continue 
with a PhD. Thank you for your guidance and enthusiastic encouragements. 
Prof. Dr. M. Rosenfeld, dear Margaret, you have always been very welcoming whenever 
I visited Seattle and I will always remember the potlucks at your beautiful home. Thank 
you for your useful critiques to improve my studies.
Prof. Dr. A. L. Quittner, dear Alexandra, it was an honor participating in your grant writing 
class. Your course gave me a great advantage and confidence in critical writing, which 
is a quality I will benefit from for the rest of my life. It was always a pleasure seeing 
you again at conferences and thank you for your positive outlook and confidence in my 
research.
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I would like to thank all the co-authors for their collaborations and all the valuable 
feedback. The studies would not have reached their current impact without 
your input. The following individuals I would like to acknowledge by name: 
Dr. A. Perez-Rovira. Dear Adria, working closely with you was a fruitful (or a cookie-full) 
business and has saved me many hours of manual work. I appreciate your creative 
thought processing and all the work you performed in the “magical black box”. Thank 
you for making my endless hours of manual work obsolete and I look forward to the 
days we can start cashing in the dinners we owe each other.
Dr. P. Ciet, dear Pier, thank you for all the radiological teachings and explanations. 
Starting from my first study you always ploughed through the manuscript and gave me 
helpful feedback. It was great having you to discuss the perks of a PhD and I am grateful 
for all your advice. I enjoyed the wonderful Italian and Chinese dinners.
Dr. E.R. Andrinopoulou and Dr. K. Nasserinejad, dear Elrozy and Kazem, thank you for 
your essential statistical assistance and guidance. Learning to deal with R studio and 
understanding the basics of coding without any background in computer programming 
was a hefty challenge. I am therefore the more grateful for your helping hand in making 
graphs and solutions for error messages. 
The SCIFI CF study was in collaboration with 20 centers across Europe and the United 
States of America. I would like to thank each CF center and in particular all the 
individuals who contributed to make the SCIFI CF site visits possible. Your hospitality 
and warm welcome to your CF center is something I will always remember dearly. I am 
aware that there were many people involved with arranging the visits and assisting in 
the scanning procedures so my gratitude goes out to each and every one of you. In 
particular, I would like to express my gratitude to the CF clinical trial network and to 
the following physicians of the participating centers: Laureline Berteloot, Kris de Boeck, 
Cesare Braggion, Torkel B. Brismar, Rosaria Casciaro, Matt Cooper, Desmond Cox, Jane C. 
Davies, Stephanie D. Davis C. Kors van der Ent, Thomas Ferkol, Pilar Garcia-Peña, Silvia 
Gartner, Kath Halliday, David Hansell, Lena Hjelte, Herma C. Holscher, Annmarie Jeanes, 
Pim A. de Jong, Ahmed Kheniche, Timothy Lee, Giorgio Lucigrai, Marco Di Maurizio, 
Anne Mehl, Anne Munck, Marianne Nuijsink, Jacqueline Payen de la Garanderie, David 
Rea, Isabelle Sermet, Veronika Skalicka, Florian Streitparth, Philippe Reix, Marleen Smet, 
Alan Smyth and Hana Vitouskova 
The last part of my thesis consisted of studies part of the Normal Chest CT study group. 
This was a collaboration to collect normal chest CT scans retrospectively in order to 
facilitate reference values. I am thankful for the contribution of ten different centers 
across the world. Without your contribution these studies would not have been possible. 
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Lauren Akesson, Silvia Bertolo, Alan S. Brody, Kris de Boeck, Pim A. de Jong, Robert J. 
Fleck, Francesco Fraioli, Pilar Garcia-Peña, Silvia Gartner, Edward Y. Lee, Anders Lindblad, 
Michael McCartin, Christian P. Mol, Giovanni Morana, Arlette E. Odink, Matteo Paoletti, 
Stephen M Stick, Francois Vermeulen. Special gratitude is also extended to Chen Yong, 
thank you for reevaluating more than a thousand chest CT scans and building the 
foundation for several of my studies. 
De medische staf van de afdeling kinderlongziekten, prof. dr. Johan de Jongste, dr. Hettie 
Janssens, dr. Marielle Pijnenburg, dr. Liesbeth Duijts, dr. Saskia ten Raa- Kwee, dr. Sanne 
Kloosterman dr. Ismee de Kleer, dr. Suzanne Terheggen, dr. Daan Caudri. Bedankt voor 
de leerzame patientenbesprekingen, pulmodagen, research  besprekingen. Dankzij 
jullie input vanuit een klinisch oogpunt heb ik de vele cijfers, metingen en resultaten 
kunnen extrapoleren naar de kliniek. Ook hebben jullie mij uit kunnen dagen met de 
kritische vragen en sterke argumenten.
Lieve Els, in 2012 deed ik een paar studenten klusjes bij je om de tijd op te vullen 
voordat ik kon beginnen met de coschappen. Jij hebt mijn leven veranderd door Harm 
te adviseren dat ik een ideale kandidaat zou zijn voor promotieonderzoek en dat hij mij 
niet mis zou moeten lopen. Als zijn rechterhand volgde Harm jouw advies blindelings 
op en ik heb de afgelopen jaren mogen inzien waar dit (volkomen terecht!) vandaan 
komt. Daarnaast ben je onmisbaar geweest in het opstarten van de normal chest CT 
studies en ben ik je hier uitermate dankbaar voor. Naast de unieke inzichten heb je ook 
werkelijk altijd de beste adviezen klaarliggen. Bedankt dat ik altijd bij je binnen mocht 
lopen en dat je altijd vertrouwen had in mijn kunnen. Je hebt me altijd bijgestaan met 
jouw ongekend probleemoplossend vermogen en dit zal mij altijd bij blijven. 
Beste Irma, je bent als secretaresse van de pulmo groep een onmisbaar deel van de 
groep. Voor mij was het altijd heel fijn dat ik altijd even bij je langs kon lopen en even 
kon spuien. Bedankt voor alle keren dat je mij in Harms drukke agenda hebt kunnen 
plannen, jouw hulp bij het afronden van de artikelen en het afronden van de promotie. 
De longfunctie analisten, Sandra, Laura, Cheyenne en Sunny. Bedankt dat ik altijd bij 
jullie binnen mocht lopen om vragen te stellen over de long functie data of gewoon 
even mocht komen kletsen voor de gezelligheid. De CF (research) verpleegkundige, 
Eveline, Annelies, Inge en Jorien. Bedankt voor het luisterend oor, steun en adviezen. 
Daarnaast was het altijd erg gezellig met jullie op de CF congressen, waar een dansje 
wagen hoort bij het onderzoek doen. Jorien, ik hoop dat je er vandaag bij zult zijn en je 
weet het, je mag altijd de spotlight van me stelen tijdens de verdediging;)
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Ik heb gedeeltelijk mijn promotie ook binnen de Radiologie mogen verwezenlijken 
en mijn dankbaarheid gaat natuurlijk ook uit iedereen die mij heeft geholpen binnen 
deze afdeling. In het bijzonder alle leden van de research commissie Radiologie en 
Nucleaire Geneeskunde, bedankt voor het waarborgen van de haalbaarheid van mijn 
promotieplanning en de waardevolle adviezen. Daarnaast zullen de vermakelijke 
radiologie PhD-diners, feesten en borrels mij altijd bij blijven. Beste Ton, als de grafisch 
ontwerper en fotograaf van de afdeling radiologie heb ook ik bij je aan mogen kloppen. 
Bedankt voor alle hulp bij het maken van de posters voor congressen de afgelopen 
jaren. Beste Mariette, in 2013 kwam jij het LungAnalysis team flink versterken. Bedankt 
voor je bijdrage aan de SCIFI CF studie, zonder alle data analyses was het niet gelukt. 
Daarnaast ook mijn dank aan de Kemner familie voor de gastplaatsing van Moose, ik 
weet zeker dat hij soms nog droomt over de vele treden en voetjes waar hij eindeloos 
mee plezier mee had. 
My fellow PhD-colleagues, Leonie, Pierluigi, Aukje, Tim, Jennifer, Hamed, Yifan and Clara. 
Since the start of my PhD we have moved to different locations and offices for seven times: 
within the Sophia, to Westzeedijk, to the Na-building and back to the Sophia and within 
the Sophia another several times. With all these relocations we could almost co-author 
a paper entitled: “Moving efficiently”. Besides the packing we did together, I am grateful 
for all the productive and valuable meetings we shared. The hard work we did during the 
long hours in the office, and more than one too many during the evenings or weekends. 
The lunches, coffee breaks, dinners and drinks were always a pleasant and much needed 
change of scenery. Research days, Conferences and Radiology events would not have 
been the same without each and every one of you. A particular memorable recollection 
I have was at the ECFS in Basel with Aukje and Jennifer where we were dubbed as 
“Harm’s Angels”. Lieve Aukje, samen in 2012 begonnen en direct een mooie vriendschap 
erbij. Het was erg fijn om samen met mijn “adoptiezusje” op de congressen te mogen 
trippelen. Bedankt voor alle adviezen, een luisterend oor en de presentaties die ik nog net 
voor het echte werk bij je mocht oefenen. Lieve Jennifer, je hebt Harms team vergezeld 
aan het eind van mijn promotie maar ik heb je gelukkig nog leren kennen in Knots 
voor een buitenlands werkbezoek. Samen met Sunny hebben we er een productieve 
werkbezoek, maar het was vooral ook erg gezellig om de stad en de verstopte barretjes 
te ontdekken. Bedankt voor jouw gezelligheid en je bruisende open persoonlijkheid. 
Dear Lizzie and Karla, without you guys the SCIFI CF visits would not have been the 
same. We have made quite some visits and I feel grateful being able to have shared 
so many new experiences together in-, and outside of the Netherlands. Thank you 
for your contributions, proof readings, support and the much needed distractions 
from time to time. America, Europe and who knows one day it will be time to explore 
Australia. Dear Giuseppe and Greta, it was short but a pleasure to have met you at 
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the end of my PhD. Thank you for the amazing many (I lost count) course Italian 
dinner and I hope to see you again in the Netherlands or Italy. Dear Gautam, thank 
you for all the USMLE documents, this might be useful for a potential future chapter. 
Alle overige promovendi van de afdeling kinderlongziekten, ook jullie erg bedankt voor 
alle leerzame research meetings, jullie feedback en de gezelligheid bij de borrels. 
De studenten die ik met plezier heb mogen begeleiden, Pauline, Merel, Michelle, 
Thomas en Niels. Bedankt voor jullie inzet en interesse in het onderzoek. Ook wil ik alle 
LungAnalysis studenten bedanken, in het bijzonder Sarina, Hadiye, Dora, Elena en Anh. 
Ik wens jullie allen veel succes met jullie verdere loopbaan. Het gezellige co-groepje 
16.30, bedankt voor de LSD’s zonder OMA’s en jullie support tijdens het afronden van 
mijn promotie.
Kenny Rubenis, bedankt voor het mooie ontwerp van dit proefschrift en de tekeningen 
die jij hebt gemaakt voor mijn publicaties. Als geen ander heb jij ingezien wat ik had 
ingebeeld en dit zo mooi uitgevoerd.
Mijn lieve vriendinnen, ik waardeer deze vriendschappen enorm en jullie zijn een 
onmisbaar deel van mijn leven. Lieve Inge, allereerst bedankt voor de mooie foto. Bij 
jou kan ik altijd terecht met al mijn verhalen en geniet ik nog meer van al jouw verhalen 
en ervaringen. Alle melige avonden waar we niet meer bij kunnen komen van de slappe 
lach zal ik nooit vergeten. Maar ook voor serieuze zaken kon ik altijd bij jou terecht, 
bedankt dat je er altijd voor me bent. Lieve Hanna en Daphna, jullie hebben me altijd 
gesteund en met de vele lekkere etentjes hebben we altijd heerlijk bij kunnen kletsen. 
Toen ik alleen in het buitenland was, of zelfs in het binnenland, waren jullie degene die 
elke avond van me wilde horen of ik wel goed terecht was gekomen. Bedankt voor jullie 
continue zorgzaamheid en het luisterend oor. En lieve Ellie, ik kom snel weer een keertje 
op je passen. Lieve Genesis, bedankt voor de gezelligheid, high tea’s en de dansjes, 
dit heeft me altijd goed gedaan om er weer tegen aan te kunnen. Lieve Poonam, de 
bezoekjes aan Den Haag hebben mij altijd goed gedaan. Mijn middelbare school 
vriendinnetjes, bedankt voor jullie vele gezelligheden en de nodige ontspanning. Wie 
had gedacht dat we zo lang vriendinnetjes zouden zijn? Met alle drukte wordt het helaas 
steeds moeilijker om af te spreken maar al onze tripjes, feestjes en festivals zullen me 
altijd bij blijven en wie weet in de toekomst een mooi bezoekje naar Japan? Lieve Claar, 
bedankt voor jouw eindeloze hoeveelheid aan steun. Onze romantische ervaringen zijn 
weer te lang geleden. We moeten dit maar snel overdoen met onze uitbreiding(en). 
Lieve Denise G, een veel langere periode dan afgesproken zit jij nu al in Sydney en heb 
ik je moeten missen. Ondanks de grote afstand voel ik de nodige support en bedankt 
voor alle adviezen, we blijven FaceTimen. Lieve Denise R, bedankt voor de nodige 
ontspanning en jouw hulp met figuren en grafieken. Bezoekjes naar Amerika waren 
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altijd leuk en het was ook zeer leerzaam om een keer over de Braves te leren, chop 
chop! Ik hoop binnenkort weer wat meer tijd te hebben zodat we weer gezellig op de 
bank met wat popcorn kunnen zitten. Lieve Mann, wat hebben we veel meegemaakt en 
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